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Résumé 
 
La protéine AID (déaminase induite par l’activation) joue un rôle central dans la 
réponse immunitaire adaptative. En désaminant des désoxycytidines en désoxyuridines au 
niveau des gènes immunoglobulines, elle initie l’hypermutation somatique (SHM), la 
conversion génique (iGC) et la commutation isotypique (CSR). Elle est essentielle à une 
réponse humorale efficace en contribuant à la maturation de l’affinité des anticorps et au 
changement de classe isotypique. Cependant, son activité mutagénique peut être oncogénique et 
causer une instabilité génomique propice au développement de cancers et de maladies 
autoimmunes. Il est donc critique de réguler AID, en particulier ses niveaux protéiques, pour 
générer une réponse immunitaire efficace tout en minimisant les risques de cancer et d’auto-
immunité. Un élément de régulation est le fait qu’AID transite du cytoplasme vers le noyau 
mais reste majoritairement cytoplasmique à l’équilibre. AID est par ailleurs plus stable dans le 
cytoplasme que dans le noyau, ce qui contribue à réduire sa présence à proximité de l’ADN. 
Le but de cette thèse était d’identifier de nouveaux partenaires et déterminants d’AID 
régulant sa stabilité et ses fonctions biologiques. Dans un premier temps, nous avons identifié 
AID comme une nouvelle protéine cliente d’HSP90. Nous avons montré qu’HSP90 interagit 
avec AID dans le cytoplasme, ce qui empêche la poly-ubiquitination d’AID et sa dégradation 
par le protéasome. En conséquence, l’inhibition d’HSP90 résulte en une diminution 
significative des niveaux endogènes d’AID et corrèle avec une réduction proportionnelle de ses 
fonctions biologiques dans la diversification des anticorps mais aussi dans l’introduction de 
mutations aberrantes. Dans un second temps, nous avons montré que l’étape initiale dans la 
stabilisation d’AID par la voie de chaperonnage d’HSP90 dépend d’HSP40 et d’HSP70. En 
particulier, la protéine DnaJa1, qui fait partie de la famille des protéines HSP40s, limite la 
stabilisation d’AID dans le cytoplasme. La farnésylation de DnaJa1 est importante pour 
l’interaction entre DnaJa1 et AID et moduler les niveaux de DnaJa1 ou son état de farnésylation 
impacte à la fois les niveaux endogènes d’AID mais aussi la diversification des anticorps. Les 
souris DNAJA1-/- présentent une réponse immunitaire compromise en cas d’immunisation, qui 
est dûe à des niveaux réduits d’AID et un défaut de commutation de classe. Dans un troisième 
temps, nous avons montré que la protéine AID est intrinsèquement plus instable que ses 
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protéines paralogues APOBEC. Nous avons identifié l’acide aspartique en seconde position 
d’AID ainsi qu’un motif semblable au PEST comme des modulateurs de la stabilité d’AID. La 
modification de ces motifs augmente la stabilité d’AID et résulte en une diversification des 
anticorps plus efficace. 
En conclusion, l’instabilité intrinsèque d’AID est un élément de régulation de la 
diversification des anticorps. Cette instabilité est en partie compensée dans le cytoplasme par 
l’action protective de la voie de chaperonnage DnaJa1-HSP90. Par ailleurs, l’utilisation 
d’inhibiteurs d’HSP90 ou de farnésyltransférases pourrait être un outil intéressant pour la 
modulation indirecte des niveaux d’AID et le traitement de lymphomes/leucémies et de 
maladies auto-immunes causés par AID. 
 
Mots-clés : Déaminase induite par l’activation (AID); hypermutation somatique; commutation 
de classe; lymphocyte B; diversification des anticorps; protéines de choc thermique (HSP40 
/HSP90); stabilité protéique; 
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Abstract 
 
Activation induced deaminase (AID) plays a central role in adaptive immunity. AID 
deaminates deoxycytidine to deoxyuridine in defined regions of the immunoglobulin (Ig) genes 
and initiates somatic hypermutation (SHM), gene conversion (iGC) and class switch 
recombination (CSR). While being essential for an effective immune response by underpinning 
antibody affinity maturation and isotype switching, the mutagenic activity of AID can also be 
oncogenic and causes genomic instability leading to the development of cancer, or exacerbate 
autoimmune diseases. Therefore, AID regulation, including the control of its protein level, is 
central to balancing effective immunity with cancer/autoimmunity. Notably, AID shuttles 
between the cytoplasm and the nucleus but is predominantly cytoplasmic at steady-state, with 
cytoplasmic AID being much more stable than nuclear AID. These regulatory steps contribute 
to limit the exposure of the genome to AID but their mechanisms are unknown. 
This thesis aimed at identifying AID partners and intrinsic determinants regulating its 
stability and modulating its biological functions. Firstly, we identified AID as a novel HSP90 
client protein. We demonstrated that HSP90 interacts with AID in the cytoplasm and prevents 
its polyubiquitination and subsequent proteasomal degradation. Consequently, HSP90 
inhibition results in a significant reduction of endogenous AID levels and correlates with a 
proportional reduction in both AID-mediated antibody diversification and off-target mutations. 
Secondly, we showed that the first step in the HSP90 molecular chaperoning pathway and 
stabilization is the interaction of AID with the HSP40 and HSP70 system. In fact, a specific 
HSP40 protein, DnaJa1, is the limiting step in cytoplasmic AID stabilization. DnaJa1 
farnesylation is required for DnaJa1-AID interaction and modulation of DnaJa1 levels or its 
farnesylation impacts endogenous AID levels and antibody diversification. In vivo, DnaJa1-
deficient mice display compromized response to immunization, resulting from reduced AID 
protein levels and isotype switching. Thirdly, we found that AID is intrinsically less stable 
than its APOBEC paralogs. We identified the AID N-terminal aspartic acid residue at position 
two and an internal PEST-like motif as destabilizing modulators of AID protein turnover. 
Disruption of these motifs increases AID protein stability and antibody diversification. 
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We conclude that AID’s intrinsic instability directly contributes to regulating antibody 
diversification. This intrinsic instability is at least partially compensated for in the cytoplasm by 
the protective action of the DnaJa1-HSP90 molecular chaperoning pathway. Pharmacologically 
targeting AID in an indirect way, by using HSP90 or farnesyltransferase inhibitors, could be 
relevant for treating some AID-associated lymphomas/leukemias and/or autoimmune diseases. 
 
Keywords : Activation-Induced Deaminase (AID); B-lymphocyte; Antibody gene 
diversification; Somatic hypermutation; Class switch recombination; Humoral immunity; 
HSP90; HSP40/DnaJa1; protein stability. 
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 CHAPTER 1: INTRODUCTION
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1.1. Antibody diversification during B cell development 
The immune system is composed of both an innate and adaptive arms that together 
protect the body from infections (bacterial, parasitic, fungal, and viral) and from the 
development of tumour cells [1]. While the innate immune system is programmed to detect 
invariant features of invading pathogens, therefore considered as non-specific, the adaptive 
immune system, which is composed of both T (Thymus-derived) and B (Bursal or Bone 
marrow–derived) lymphocytes, uses antigen (Ag)-specific receptors and is highly specific. We 
are mainly interested in B lymphocytes, which are a cell lineage characterized by the presence 
of cell surface immunoglobulin (Ig) receptors, also called antibodies, recognizing specific 
antigenic epitopes [2]. Plasma B cells can secrete antibodies to neutralize and eliminate 
invading pathogens. This antibody-mediated immune response is known as the humoral 
immune response.  
 
1.1.1. Immunoglobulin gene organization and antibody structure 
An antibody molecule is composed of four polypeptide chains: two identical heavy 
(IgH) chains and two identical light (IgL) chains that are linked through disulfide bonds [3]. 
The IgH and IgL chains contain distinct structural domains of ~110 amino acids in length. The 
IgL chain is composed of two of these domains while the IgH chain can display up to five 
different domains. The N-terminal domain of each chain is unique in that it contains three 
highly variable regions in length and sequence and is therefore designated as the variable (V) 
region. Together, the two IgH and IgL chains display six hypervariable loops, termed 
complementary determining regions (CDRs), which form a unique surface for recognition and 
binding to specific antigenic epitopes [4]. Each Ig molecule contains two identical Ag-binding 
sites. 
The C-terminal domain(s) of each IgH and IgL are constant, and those of the IgH define 
the antibody isotype. Two different C-terminal domains can be found in IgL, termed lambda (λ) 
and kappa (κ). However, each single B lymphocyte can only express one type of IgL chain. In 
humans, IgLκ and IgLλ are encoded on two different loci (chromosome 2 and 22 respectively). 
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The κ/λ ratio has a potential clinical value, as the kappa-IgL is usually preferred over lambda 
(2:1) in healthy adults [5] and an irregular ratio is an indicator of autoimmune disease, multiple 
myeloma or B-cell lymphoma [6-8].  
The class and the effector functions of an antibody molecule are defined by the 
structure of its IgH C-terminus. Five major classes of IgH exist and define nine different 
isotypes in humans: μ (IgM), δ (IgD), γ (IgG1, 2, 3 and 4), α (IgA1 and 2), and ε (IgE) (Figure 
1.1). The IgH locus is found on chromosome 14 in humans. Mice differ from humans in that 
they have only one IgA isotype and their IgG nomenclature is slightly different (IgG1, 2a, 2b 
and 3). B cells that have successfully rearranged their Ig genes (see section 1.1.2.) initially 
express membrane IgM and/or IgD. IgM molecules can be secreted as oligomers (pentamers or 
hexamers): they are formed through the generation of inter-molecular disulfide bonds and can 
be found in complex with the J chain, which is required for the secretion of IgM pentamers in 
the mucosa. IgM is the main class of Ig secreted during a primary immune response. Its 
oligomeric state confers high avidity to IgM (up to 12 antigenic binding sites) and is 
particularly important in activating the complement system. On the other hand, IgD is only 
found in a monomeric state and its functions are enigmatic. Recent evidence suggests that 
circulating IgD is important in the immune surveillance of the upper respiratory mucosa by 
modulating basophil function [9]. IgG is the most abundant class of antibodies in the serum and 
the most versatile with regards to its functions. In fact, it is the main Ig secreted during a 
secondary immune response. IgGs are found as monomers and cross easily the placenta (except 
IgG2), conferring protection to the foetus in utero. They usually display high affinity for a 
specific antigenic epitope and are primarily implicated in opsonisation, neutralization of 
pathogens and activation of the complement. Despite their close similarity in amino acid 
sequence, IgG subclasses display specific features which have been attributed to their selective 
binding to Fc receptors [10-12]. IgA plays a major role in mucosal immunity and can exist as a 
dimer in complex with the J chain, called secretory IgA (sIgA) [13]. In its polymeric form, IgA 
is the main Ig found in mucosal secretions, milk, colostrum, tears and saliva. Monomeric IgA 
(mainly IgA1) is also found in the serum. IgA, by preventing the invasion of pathogens through 
the mucosal-associated lymphoid tissues (MALT), has been intensively studied to develop 
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news of ways of vaccination. Finally, IgE is a monomeric antibody, prominently found in 
epithelia and mucosa, where it binds to specific receptors on highly potent effectors cells [14]. 
IgE is implicated in the immune response against helminths through the recruitment of 
eosinophils and monocytes. IgE antibodies can also cause an immediate hypersensitivity 
syndrome via the activation of mast cells and basophils. Therefore, IgE is a central player in 
allergic reactions such as asthma.   
 
1.1.2. V(D)J recombination 
To achieve nearly universal Ag recognition, vertebrates have developed a series of 
genetic alterations that target the Ig genes. During B cell development in the bone marrow, the 
variable region of the IgH and IgL is assembled from a large number of variable (V), diversity 
(D), and joining (J) gene segments, a process called V(D)J recombination (Figure 1.1). This 
reaction is catalyzed by the recombination-activating genes 1 and 2 (RAG1 and RAG2), which 
together form the RAG endonuclease and are sufficient in vitro [15, 16] and necessary in vivo 
[17, 18] for the cleavage step of V(D)J recombination. The joining of V, D and J segments is 
achieved through the generation of a site-specific DNA double-strand break (DSB) at the 
border of two coding segments in their flanking recombination signal sequences (RSSs). The 
RSSs contain two well-conserved DNA elements (heptamer and nonamer) separated by a 
spacer region. They are recognized by the RAG endonuclease complex that cleaves the DNA 
between the coding sequence and the RSS, thus creating DNA DSBs. V(D)J recombination is 
achieved by the repair of these DSBs through the non-homologous end-joining pathway 
(NHEJ) (reviewed in [19]).The final stage of B cell development is characterized by the 
expression of a functional Ag receptor (B cell receptor; BCR) at the B cell surface surface 
(Figure 1.2). This immature B cell only expresses surface IgM molecules and undergoes 
negative selection by testing its capacity to recognize self-molecules present in the bone 
marrow. Immature B cells activated by self-Ags are eliminated through clonal deletion. Non-
self reactive B cells can then migrate in the peripheral lymphoid organs and become mature B 
cells (Figure 1.2). V(D)J recombination generates the diversity of the primary repertoire of 
antibodies in different ways. Firstly, the large number of gene segments and their random 
joining give rise to a consequent combinatorial diversity. Secondly, additional diversity can 
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arise from nucleotidic processing of the DNA ends occurring during the recombination events 
which bring the V next to the J or D segment. This junctional diversity, combined to the 
insertion of a series of nucleotides between the D and J segments catalyzed by the terminal 
deoxynucleotide transferase (TdT), also contributes to the diversification of the antibody 
repertoire [20, 21]. Thirdly, the association of different IgH and IgL chains also contributes to 
the diversity of combinations.  
 
1.1.3. Antibody diversification during the germinal-center reaction 
Mature B cells continuously circulate through the secondary lymphoid organs and 
encounter Ags in the lymphoid follicles. The first cognate antibody-Ag recognition of naïve B 
cells is usually not of high affinity. This endows the immune system with enough flexibility to 
recognize almost any possible Ag using a large but limited primary repertoire. By contrast, high 
affinity antibody-Ag interactions are critical for neutralizing or disposing of Ags. Thus, there 
are additional mechanisms to change the antibody genes. Upon activation by a cognate Ag, 
follicular B cells initiate the germinal center (GC) reaction (Figure 1.2). This reaction is 
considered to be the starting point of a T-cell dependent humoral immune response, although 
certain reports suggest that GCs may also be formed during T-cell independent responses [22, 
23]. However, in general, non-protein Ags, including polysaccharides, glycolipids, and nucleic 
acids, induce a T-cell independent antibody response, consisting mainly in the activation of 
marginal zone B cells (MZ) and the subsequent secretion of low affinity IgM and IgG3 
antibodies [24, 25].  
Upregulation of the chemokine receptor CCR7 on activated B cells is the starting point of the 
GC reaction [26], leading to the migration of activated B cells from primary follicles to the T 
zone where they become distributed along the B/T border [27]. This facilitates the interaction 
between follicular helper T cells (TH) and B cells and results in an extensive B cell 
proliferation and the formation of GCs [28]. In fact, GCs are composed of proliferating Ag-
specific B cells, Tfh cells and specialized follicular dendritic cells [29]. The costimulatory 
molecule CD40, which is constitutively expressed at the B cell surface, and its ligand CD40L 
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(CD154), which is expressed on activated TH cells, play a crucial role in the formation of GCs 
[30, 31]. During the GC reaction, B cells undergo diversification of the genes encoding for IgH 
and IgL by the mechanisms of somatic hypermutation (SHM) and antibody class switch 
recombination (CSR), which underpin antibody affinity maturation and isotype switching. 
Furthermore, GC B cells differentiate into high-affinity antibody-secreting plasma cells as well 
as into memory B cells, which ensure a sustained immune protection and a rapid response 
against previously encountered Ags. 
 
1.1.3.1. Somatic hypermutation  
SHM consists in the introduction of point mutations in the Ig variable exon (VDJ or VJ 
region) [32-34] (Figure 1.1). The mutations introduced are predominantly single base pair 
changes, although insertions and deletions have also been reported [35]. All four bases (A, T, G 
and C) are targeted for mutation; A:T and C:G pairs are targeted with comparable frequencies, 
at least in humans and mice. Nevertheless, neither the targeting of individual bases nor the 
nature of the substitution are random: mutations at A:T pairs preferentially occur if the A is 
present in the coding strand and transition mutations (A to G or C to T) usually occur twice as 
frequently as transversions (reviewed in [36, 37]). Furthermore, a high proportion of the 
mutations occurs in the hotspot motif DGYW (where D=A/G/T, Y=C/T, W=A/T) or its reverse 
complement sequence WRCH (R=A/G, H=T/C/A) [38-40]. Finally, specific domains in the 
IgV region encoding the amino acids constituting the Ag binding sites (CDR domains) are 
more targeted than others [41].   
This mutagenic process depends on a B cell specific factor, activation-induced 
deaminase (AID), which initiates SHM by deaminating deoxycytidine into deoxyuridine in the 
IgV region [42-45] (Figure 1.3). The introduction of a uracil, which is a foreign base for DNA, 
can be processed in two ways [36, 37]. The introduced uracil can either be replicated over to 
produce C to T transitions or processed by components of the base excision repair pathway 
(BER) (Figure 1.3). The uracil can be excised by uracil-DNA glycosylase UNG, leaving an 
abasic site that is repaired in an error-prone manner through the recruitment of translesion 
polymerases [46, 47]. 
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Figure 1.1. Human IgH gene organization. The IgH locus is composed of several V, D and J 
segments that encode part of the functional IgV region of an antibody molecule after RAG-
catalyzed VDJ recombination. The IgH region is composed of several constant region (C) exon 
sets, each coding for a different isotype: Cμ (IgM), Cδ (IgD), Cγ3 (IgG3), Cγ1 (IgG1), Cγ2 
(IgG2), Cγ4 (IgG4), Cε (IgE) and Cα (IgA). Each C region is preceded by a switch region (S), 
where transcription takes place to generate AID ssDNA substrate. The AID-catalyzed dC>dU 
are processed by DNA repair enzymes resulting in DNA double-strand breaks that are 
intermediates for class switch recombination. CSR occurs between the Sμ region and a 
downstream S region (f.i. here Sγ1), which results in the switching from IgM to IgG1. The 
intervening DNA region that is eliminated upon CSR is predominantly released as a circular 
episome called a switch circle. Somatic hypermutation consists in the introduction of point 
mutations in the rearranged IgV region. Gene conversion is an alternative IgV diversification 
process that is used by birds and cattle species, consisting in the transfer of random stretches of 
adjacent pseudo-genes into the rearranged IgV region. SHM, CSR and iGC are initiated by 
AID. 
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This process produces both transition and transversion mutations. Alternatively, the U:G 
mistmatch can be recognized by components of the mismatch repair pathway (MMR), notably 
MSH2 and MSH6, that recruits the exonuclease EXO1 and DNA polymerase η, which 
preferentially generates mutations at A:T pairs (Figure 1.3). Inactivation of BER components 
(f.i. UNG [48-50] and XRCC1 [51]), of certain error prone DNA polymerases [52-56], or of 
key players in the MMR system [57-66] affect the pattern or frequency of SHM. A:T 
mutagenesis during the diversification of the IgV region also requires the ubiquitination of the 
proliferating cell nuclear antigen protein (PCNA) [67-69] and both the UNG- and the MSH2-
dependent pathways seem to depend on this intermediate [70]. Although many details are still 
unclear, SHM of the IgV region is achieved through DNA deamination, processing of the uracil 
and introduction of point mutations during the repair of abasic sites or single-stranded DNA 
tracts.  
During the GC reaction, antibody variants produced by SHM are selected for improved 
Ag recognition. This selection process underlying affinity maturation consists in a stepwise re-
entry model, where the B cell undergoing cell division and SHM in the dark zone of the GC can 
migrate to the light zone, where it interacts with Ag-presenting dendritic cells and TH cells. B 
cells expressing high-affinity antibodies at their surface are preferentially selected and can re-
enter the cycle of proliferation, mutation and subsequent selection. A large number of cells fail 
this selection, enter into apoptosis and are eliminated by a subset of macrophages that reside in 
the GCs [29] (Figure 1.2). 
 
1.1.3.2. Gene conversion 
In many farm animals, diversification of the antibody repertoire is achieved by both SHM and a 
process called IgV gene conversion (iGC). The best model to study iGC is the chicken Ig loci. 
Chicken have a single functional light chain V segment (Vλ), which recombines with a single 
Jλ segment, thus limiting the primary repertoire of antibodies generated by RAG-mediated VDJ 
recombination [71-74]. However, during B cell development in the bursa of Fabricius of avian 
species, the rearranged IgV undergoes an additional step of diversification, the iGC [71, 75]: 
during iGC, random stretches of adjacent pseudo-genes are recopied onto the rearranged IgV 
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region by homologous recombination (Figure 1.1). Indeed, the chicken Ig loci are composed of 
a large number of pseudo-gene segments that precede the rearranged IgV region [71]. In this 
case AID also contributes to the primary diversification of the antibody repertoire by initiating 
iGC (Figure 1.1) [76, 77]. Pseudo-genes that are more homologous, closer, or in the opposite 
orientation to the IgV segment, are usually preferred as donors [71, 78]. The IgV region is 
subsequently diversified by both iGC and SHM during the GC reaction in chicken [79, 80].    
iGC has been extensively studied in the chicken DT40 B cell lymphoma line, which 
continuously diversifies its Ig loci by iGC in vitro. Disruption of the AID gene (Aicda) in this 
cell line completely blocks iGC [76, 77]. Thus, although iGC and SHM are two distinct 
processes, they are both initiated through a common intermediate (i.e. AID-catalyzed 
deamination of deoxycytidine into deoxyuridine) and share similarities [81]. UNG mediates the 
major pathway to create abasic sites which in some way trigger homologous recombination [76, 
77, 81] (Figure 1.3). In contrast to SHM [49], UNG inactivation almost completely abrogates 
iGC in the DT40 cell line [82]. Completion of iGC requires the RAD51 paralogs XRCC2 and 
XRCC3 or RAD51B and BRCA2 to promote the transfer of sequence information from an 
upstream donor pseudogene to the IgV region [83, 84] (Figure 1.3). Several lines of evidence 
also suggest that the MRE11-RAD50-NBS1 complex (MRN) is implicated in iGC [85, 86]. 
Chicken B cells not only diversify their IgV region by iGC but also accumulate untemplated 
mutations during the GC reaction in peripheral lymphoid organs.  
 
1.1.3.3. Class switch recombination 
Activated B cells, which express IgM and/or IgD at their surface, also undergo class 
switch recombination (CSR) during the GC reaction. CSR consists in the exchange of the 
default Cμ constant region to another downstream constant region (γ, ε or α) and results in the 
expression of a different isotype of antibody (IgG, IgE or IgA) with different effector functions 
(Figure 1.1). AID also initiates CSR [42, 43] through deamination of deoxycytidines in switch 
regions, which are repetitive sequences preceding each constant region (except Cδ). Switch 
regions are enriched in AID hotspot motifs and are preferentially targeted by this enzyme. AID- 
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Figure 1.2. The germinal center reaction. Rearrangement of the IgV region takes place in the 
bone marrow and results in the expression of functional IgM and IgD molecules at the B cell 
surface. Low expression of AID has been reported in this compartment, which plays a role in 
central tolerance. In the peripheral lymphoid organs, antibody gene diversification in mature B 
cells takes place in the GC in the form of somatic hypermutation (SHM), which underpins 
affinity maturation, and class switch recombination (CSR), which changes the isotype of the 
antibody. Upon presentation of an Ag by specialized Ag presenting cells (APC), mature B cells 
are activated and undergo the GC reaction, controlled by follicular helper T cells (TH). B cells 
proliferate extensively and are subsequently selected for a better Ag affinity by APC. B cells 
that fail this positive selection die by apoptosis. The selected B cells can undergo additional 
rounds of diversification or differentiate into memory or plasma cells.  
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generated uracils are subsequently removed by UNG [48, 49, 87] and the apurinic/apyrimidinic 
endonucleases APE1 and APE2 [88], leading to DNA DSBs (Figure 1.3). Alternatively, uracils 
can be recognized as U:G mismatches by the MMR pathway (Figure 1.3). The MSH2/MSH6 
complex in collaboration with MLH1/PMS2 recruits the exonuclease Exo1, which can also 
generate a DSB intermediate [89]. Indeed, disruption of genes involved in BER (ung, ape1 or 
ape2) [48-50, 87, 88] or in MMR (Msh2, Msh6, Mlh1, Pms2, Exo1) [59, 63, 90-94] inhibits 
CSR. In absence of both UNG and MSH2, CSR is in fact completely abolished [95], indicated 
that both the BER and MMR pathways contribute to CSR. 
Early sensors of DNA DSBs are required to coordinate the downstream repair pathways leading 
to CSR. The MRN complex, which travels along DNA and scans for DNA breaks, is present 
within seconds at the site of DSBs [96]. As expected from its central role in sensing DNA 
damage and CSR, mutations affecting MRE11 and NBS1 cause immunodeficiency, 
chromosomal instability and a high incidence of lymphoid malignancies, which are 
characteristics of the Nijmegen breakage syndrome [97]. Patients affected by this syndrome 
exhibit reduced levels of CSR to IgA in vivo, which is recapitulated in Nbs1-haploinsufficient 
mice that display a two- to three-fold reduction in CSR in vitro [98, 99]. Once bound to the 
DSB, the MRN complex recruits the ataxia telangiectasia mutated kinase (ATM), which 
becomes activated and phosphorylates several substrates including NBS1, MRE11, 53BP1, 
MDC1 and γ-H2AX [100]. Ablation in mice of ATM, or its interactor protein ATMIN, 
compromise CSR in vitro [101-103], and results in patients in a rare immunodeficiency 
disorder as well as a predisposition to cancer (ataxia–telangiectasia syndrome) [104]. 
Moreover, mice deficient in 53BP1, H2AX, MDC1, or the ubiquitination machinery 
RNF8/RNF168, which is critical to propagate the DNA damage signal [105], display 
compromised CSR in vitro [106-110]. Interestingly, most of these sensors are abundantly 
expressed in a constitutive manner in the B cell lineage [111, 112]. This is thought to contribute 
to a repair-prone environment that renders activated B cells less susceptible to DNA damage-
induced apoptosis. The DNA DSBs are resolved by a “region-specific” recombination process 
involving the donor and acceptor S regions. It occurs through the recruitment of ubiquitous 
proteins from the classical non-homologous end-joining pathway (C-NHEJ), including  
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Figure 1.3. Differential processing of AID-catalyzed dU lesions leads to SHM, iGC or CSR. 
AID deaminates deoxycytidines in the Ig loci leading to U:G mismatches that can be either 
replicated over, processed by the uracil-DNA glycosylase (UNG) or recognized by the 
mismatch repair proteins MSH2/6. UNG or MSH2/6 cooperate with distinct sets of DNA repair 
factors that will result in mutations for SHM and IgV gene conversion or DNA double-strand 
breaks and repair for CSR. SHM can be divided into several pathways, depending on the type 
of mutations introduced. Similarly, DNA DSBs can be repaired by either the classical (C-) or 
alternative (A-) non-homologous end-joining pathways (NHEJ). Adapted from [36]. 
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Ku70/80, DNA-PKcs, XRCC4 and DNA ligase IV (Figure 1.3). Studies in mice have shown 
that Ku70 and Ku80 are essential for CSR [113, 114], while XRCC4 is important but not 
essential for CSR [115]. DNA-PKcs is also implicated in CSR [116-119], but has a redundant 
role with ATM [120]. The fact that the Ku70/80 complex is essential for CSR, but not XRCC4 
or DNA ligase IV, suggested the contribution of an alternative pathway for the resolution of the 
DSBs [115, 121-123]. In fact, Ku70 collaborates with the DNA end-processing factor CtIP, 
ATR (ATM and Rad3-related protein) and the DNA damage sensor PARP1 to promote an 
alternative end joining pathway (A-NHEJ) that makes more frequent use of microhomology at 
the ends for resolving the DSB [124-126] (Figure 1.3). The factors composing the A-NHEJ 
pathway are still under investigation. Resolution of the DSB by C-NHEJ or A-NHEJ ensures 
IgH loci functionality and allows the expression of an antibody with the same specifity but a 
new isotype with different effector functions. 
GC B cells are particularly interesting since they have to balance extensive DNA 
damage and apoptosis. B cells upregulate or express at high levels a series of proteins 
implicated in the MMR, BER and DNA damage sensing to be protected from DNA damage-
induced apoptosis [111, 127-129]. Activated GC B cells also express a transcriptional 
repressor, BCL6 [130, 131], which negatively regulates DNA damage response and check point 
genes [132-136]. Altogether, GC B cells generate an anti-apoptotic environment to favour the 
diversification of the Ig loci and limit DNA-damage induced apoptosis. Nonetheless, they 
become more susceptible to extrinsic apoptosis induced by negative selection in order to 
eliminate non-productive mutations [137].    
 
1.2. AID and its physiological functions 
1.2.1. The AID/APOBEC family 
AID is a member of a family of cytidine deaminase-related enzymes comprising 
APOBEC1, APOBEC2, the APOBEC3 group, APOBEC4 and the recently identified 
APOBEC5 (Figure 1.4) [138, 139]. The AID/APOBEC proteins have the unique capacity of 
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deaminating (deoxy)cytidine in DNA and/or RNA, thus converting it into (deoxy)uridine 
(reviewed in [140]). They also exhibit diverse physiological functions. AID and its paralogs 
APOBEC share the structural and catalytic backbone of the zinc-dependent deaminases that are 
involved in the metabolism of purines and pyrimidines (Figure 1.4). It is composed of two 
motifs H(A/V)E and PCxxC (where x is any amino acid) separated from each other by 24-36 
amino acids [140]. The histidine (H) and the two cysteines (C) coordinate a zinc atom and form 
the catalytic core of the deaminase. During the deamination reaction, the cytidine is bound in 
this pocket and a nucleophilic attack on the NH2 in its carbon 4 occurs. The nearby glutamic 
acid residue (E) serves as the proton donor while a water molecule serves as an activator in this 
reaction [141]. 
The AID/APOBEC group appeared with the vertebrate lineage and the evolution of 
adaptive immunity. AID and APOBEC2 are thought to be the ancestral members of the 
AID/APOBEC group, although the RNA-editing APOBEC1 enzyme was the first member to 
be discovered and characterized [142] (Figure 1. 4).  
APOBEC2 and APOBEC4 functions remain elusive. APOBEC4 is primarily expressed 
in testis but its function is unknown [143]. APOBEC2 has been reported to be expressed 
specifically in skeletal and cardiac muscle [144, 145], although broader analysis suggested a 
low but ubiquitous expression of APOBEC2 in human and mouse [146]. Little is known about 
APOBEC2 substrates or its physiological functions. Its deamination activity is in fact 
controversial [145, 147] and Apobec2-deficient mice display no developmental, survival or 
fertility problems [147]. There is genetic evidence supporting a role of APOBEC2 in muscular 
development [148]. Knockdown of Apobec2 in zebrafish embryos led to a dystrophy in skeletal 
musculature and impaired heart function. The chaperone UNC45B is essential for APOBEC2 
folding in zebrafish and disruption of Unc45b recapitulates the phenotype observed in 
APOBEC2-knockdown zebrafish embryos [149]. 
On the other hand, APOBEC1 mRNA editing functions are well characterized. This enzyme is 
mostly expressed in the human small intestine and in the liver in rodents [142, 150], and is the 
only known RNA-editing enzyme of the AID/APOBEC group. Functionally, APOBEC1 
generates a premature stop codon in apolipoprotein B mRNA that leads to the expression of a 
tissue-specific truncated apolipoprotein B polypeptide chain (ApoB48). Beside abnormalities in 
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lipoprotein metabolism, Apobec1-/- mice are viable and do not display any particular phenotype 
[151, 152]. Conversely, hepatic overexpression of APOBEC1 in mice and rabbits is oncogenic 
and results in liver hyperplasia and the development of hepatocellular carcinomas [153]. These 
could result from aberrant editing of hepatic mRNAs [154], but could also reflect the ability of 
APOBEC1 to mutate DNA [155]. Thus, APOBEC1 activity needs to be tightly regulated. This 
is in part achieved by the APOBEC1 complementation factor (ACF) that targets specifically 
APOBEC1 to an AU-rich motif in the apolipoprotein B mRNA and restrict deamination to a 
specific cytosine (C6666). Despite acting in the nucleus, APOBEC1 is a nucleo-cytoplasmic 
shuttling protein [156]. It contains a poorly characterized nuclear localization signal (NLS) and 
a carboxy-terminal nuclear export signal (NES) [157, 158]. Restricting nuclear access to 
APOBEC1 may be an additional way to limit its biological activity.  
The APOBEC3 subgroup plays a central role in the intrinsic immunity to retroviruses 
[159, 160], and protects against the transposition of endogenous retroelements [161-163]. 
Mouse encodes for only one APOBEC3 protein, whereas humans have at least eight different 
APOBEC3 members, named APOBEC3A to H. Ablation of APOBEC3 in mouse does not 
impact development, survival or fertility [147]. However, APOBEC3 proteins can restrict 
retroviral infection. Indeed, APOBEC3G is packaged into HIV virions and deaminates 
deoxycytidine in deoxuridine on the nascent first cDNA strand produced by the reverse 
transcriptase in the newly infected cell [159, 160]. Consequently, the viral genome is heavily 
mutated and becomes non functional. HIV encodes an accessory protein, the viral infectivity 
factor (Vif), that overcomes APOBEC3G restriction by recruiting the E3 Ub ligase Cullin5 and 
ElonginB/C proteins, thus targeting APOBEC3G for proteasomal degradation [164-166]. Anti-
retroviral functions have been attributed to several other human and primate APOBEC3 
proteins [167]. Additionally, APOBEC3G restriction may also occur through a deamination-
independent mechanism [168, 169]. APOBEC3G activity is regulated notably by post-
translational phosphorylation. Two APOBEC3G residues have been found to be 
phosphorylated in vitro and in vivo: Thr32 and Thr218 [170, 171]. These residues are 
evolutionary conserved in AID. Phosphorylation of Thr32 by protein kinase A (PKA) promotes 
APOBEC3G antiviral activity by reducing the binding of APOBEC3G to Vif and its  
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Figure 1.4. Phylogenetic organization of the zinc-dependent cytidine deaminase family. The 
AID/APOBEC subgroup shares the structure and catalytic backbone of the zinc-dependent 
deaminases. Cytidine deaminases (CDA) are not likely the ancestors of the AID/APOBEC 
subgroup because of the differences in gene organization and catalytic domain. The gene 
structure of most AID/APOBEC is reminiscent of the genetic organization of dCMP 
deaminases (DCDT) and tRNA adenosine deaminases (Tad/ADAT2). AID and APOBEC2 are 
the oldest members of the AID/APOBEC family, which exhibit diverse physiological functions. 
AID has a high similarity and a conserved 3D structure with its APOBEC paralogs. The tRNA 
adenosine deaminase ADAT1 and the mRNA adenosine deaminases (ADARs) are thought to 
originate from the Tad/ADAT2 family independently of the AID/APOBECs. Adapted from 
[140].  
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subsequent polyubiquitination and degradation [170]. On the other hand, phosphorylation at 
Thr218 inhibits APOBEC3G biological activity ex vivo by reducing its catalytic activity but its 
role and importance in vivo are unknown [171]. Furthermore, APOBEC3G proteins can be 
entrapped in high-molecular-mass ribonucleoprotein complexes found in cytoplasmic structures 
called P-bodies and stress granules [163, 172, 173], where APOBEC3G catalytic activity is 
greatly inhibited, or in low-molecular-mass complexes important for retroviral restriction [174]. 
Recently, an additional member of the AID/APOBEC subgroup, named APOBEC5, has been 
identified in non-placental animals. It has been suggested that APOBEC5 may be a functional 
homologue of the APOBEC3 proteins in non-placental animals [175]. 
Despite their great biological divergence, AID/APOBEC proteins share reasonably high 
level of primary sequence and structural similarities. The crystal and NMR structures of 
APOBEC2 and the C-terminal domain of APOBEC3G confirmed the structural conservation 
between the members of this family and revealed the active-site loops implicated in substrate 
binding [176-178]. Furthermore, APOBEC2 and APOBEC3G crystal structures suggest that 
AID/APOBEC proteins may dimerize/oligomerize, which could be relevant for their biological 
functions [179, 180]. 
 
1.2.2. AID in antibody diversification 
The AID gene Aicda is composed of 5 exons and has been found in all vertebrates. Its 
chromosomal localization is syntenically conserved at least among mammals [138]. 
Furthermore, its genomic structure is well conserved among chimpanzee, mouse, cattle, 
chicken, urodele amphibian, frog, fugu and zebrafish, particularly in the last three exons [138, 
181-185]. The full-length mammalian AID is composed of 198 amino acids but splice variants 
of AID in both normal human and mouse B cells have been described [181]. As expected from 
its central role in antibody diversification, loss of function mutations affecting AID cause an 
immunodeficiency syndrome called hyper-IgM syndrome type 2 (HIGM-2). HIGM2 is 
characterized by the absence of switched antibody isotypes, recurrent infections and lymphoid 
tissue hyperplasia [42], which is recapitulated in Aicda-/- mice [43]. Due to its close similarity 
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with APOBEC1, AID was initially hypothesized to be a RNA-editing cytidine deaminase 
(RNA-editing hypothesis) [43, 139]. Alternatively, Michael Neuberger’s group postulated a 
model where AID directly deaminates DNA [45], and several studies confirmed this DNA 
deamination model [45, 49, 50, 186-192]. 
In this thesis, we are mainly interested in the amount of AID protein necessary for an 
efficient antibody diversification. In fact, AID levels are limiting for antibody diversification as 
indicated by studies in Aicda+/- mice. AID haploinsufficient mice have ~40% of AID mRNA 
and protein levels compared to wt [193, 194] and several groups have found reduced CSR and 
SHM in Aicda+/- mice [193-196]. The decrease in CSR and SHM is roughly proportional to 
the decrease in AID levels. But in vivo, the effect is greatly compensated by selection [193, 
194]. Conversely, higher levels of AID protein translate into more CSR and SHM. Indeed, AID 
overexpression increased the rate of SHM in human B cell lines [197, 198]. Mouse models with 
modified AID expression levels also provided evidence for a rate-limiting role of AID in 
antibody diversification. First, several transgenic mice overexpressing AID have been made, 
which all show increased CSR and SHM [199-202]. The two transgenic lines in which AID 
was expressed from a ubiquitous promoter showed a significant but modest effect on antibody 
diversification [199, 200, 202]. In contrast, transgenic AID under the control of the Igκ 
enhancer, which showed maximal expression in GC B cells, displayed a very high increase in 
CSR and SHM levels [201]. Secondly, upregulation of AID expression in B cells by removing 
the negative post-transcriptional regulation of AID by microRNA miR-155, also leads to higher 
levels of CSR [203, 204] (see section 1.4.2). Nonetheless, none of these mice showed an 
increase in switched serum Ig levels. This may be regulated at another level (selection, 
homeostatic proliferation) and does not necessarily reflect the intrinsic CSR capacity of the B 
cells. Interestingly, mice in which higher levels of AID were achieved by removing the miR-
155 negative post-transcriptional regulation showed compromised affinity maturation but no 
differences in quantity or quality of SHM at the IgV region [203].  
 
1.2.3. AID expression profile  
Initially, AID was thought to be a B cell-restricted factor. In fact, high AID mRNA 
levels have been reported in the spleen, in MALT (Peyer’s patches, mesentery lymph nodes, 
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auxiliary lymph nodes) and in the chicken bursa, in line with AID functions in antibody 
diversification [76, 139, 205]. Aicda transcription is induced by cytokines and cell-cell 
interactions in the context of Ag-triggered B cell activation during the immune response 
(reviewed in [206]). Thus, Aicda is highly transcribed in GC cells but repressed in plasma and 
memory B cells [207, 208], and this correlates with measurements of AID mRNA and protein 
levels in the B cell lineage as well as with the analysis of an AID-GFP reporter mouse [139, 
207, 209, 210]. However, the original belief of AID being exclusively expressed in GC B cells 
has been now revised. 
AID is expressed outside of the B cell compartment in normal conditions. One example 
is the ovaries, in which basal AID mRNA levels are ~50-70% of those found in spleen [211, 
212]. Furthermore, Aicda is induced by estrogens which increases AID mRNA a few fold in the 
spleen but by >20-fold in the ovaries [213]. Breast tissue also expresses AID when stimulated 
with estrogens [213] and several human breast cancer cells express AID mRNA [214], but the 
basal levels in normal breast tissue have not been reported. AID expression was reported in 
other normal non-lymphoid cells, including prostate, heart and lung [211, 212, 215]. It is 
unclear whether AID expression in these tissues has any physiological role. Furthermore, 
infectious agents like Epstein-Barr virus, Abelson murine leukemia virus and Moloney murine 
leukemia virus are able to induce AID in the infected cells, which has been proposed as the 
result of an ancestral function in restricting retroelements [211, 216-219]. 
 Low AID mRNA levels have also been measured during B cell development [220, 
221]. Convincing evidence suggests that AID plays a role in B cell tolerance by eliminating 
autoreactive B cells [220, 221] but the mechanism of AID-mediated B cell tolerance is 
unknown. Genetic evidence suggested that AID expression during B cell development results in 
mutations in the IgV region [222, 223]. This is reminiscent of what is observed in sheep, 
rabbits, and cattle, where SHM or iGC contribute to the diversity of the primary antibody 
repertoire [224-226], and could be an evolutionary relic or may contribute to tolerance by 
mutating autoreactive clones, thus changing their specificity. Similarly, extremely low levels of 
AID mRNA (~1/10 of AID mRNA levels in immature B cells) have been measured in a subset 
of CD4+ T cells [227], but the biological significance of AID expression in T cells in unclear. 
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SHM on the T-cell antigen receptor loci was reported [228], however, it is difficult to imagine that 
the 103-104-fold lower levels of AID expressed in immature B and T cells when compared to 
GC B cells [221] could contribute to SHM, given the relative proportionality between AID 
protein levels and SHM in GC B cells. 
AID has also been detected in cell types such as oocytes, spermatocytes, primordial 
germ cells (PGCs) or embryonic stem cells [211-213, 229-232]. As mentioned, oocytes express 
AID mRNA to comparable levels as B cells [211, 212]. AID mRNA is very low in testis [207, 
211, 212] but AID protein has been detected by IF in spermatocytes [230], which would 
suggest higher levels. The timing of AID expression in PGCs is controversial, although there is 
agreement that AID mRNA levels are substantially lower than in B cells (5-10%) [212, 229, 
232]. Similarly, AID mRNA levels in stem cells are ~5-10% of those found in B cells [212, 
231]. Furthermore, AID is expressed during early development in Danio rerio [233], Xenopus 
laevis [234] and Pleurodeles waltl [183], which could suggest a role of AID during cellular 
differentiation and development. 
 
1.2.4. AID demethylation activity 
  Evidence is accumulating to suggest that AID could be part of a mechanism to 
demethylate methylated cytidine (5-mC) at CpG sites in the genome, thereby influencing gene 
expression [212, 231, 232]. In fact, AID and its paralogs APOBEC can convert 5-mC to 
thymidine with similar efficiency in vitro [212, 235]. Functionally, cytosine methylation is a 
major covalent DNA modification in mammals and plays important roles in transcriptional 
regulation [236]. Its main function is to stabilize or lock-in transcriptional silencing. It 
participates in tissue-specific gene expression, gene imprinting, nuclear reprogramming, X 
chromosome inactivation, but also in the suppression of retrotransposons. DNA methylation 
patterns are established early during cell development and maintained in adult somatic cells. 
Nevertheless, changes in methylation pattern occur during mammalian development and cell 
differentiation, as reported in mice where significant waves of demethylation/remethylation 
occur in germ lines and early embryos [237]. Genome-wide demethylation has also been 
observed in PGCs around embryonic days 11.5-12.5, followed by a gamete-specific 
methylation [238-240].  
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Consistent with a role of AID in epigenetic reprograming during development, AID 
mRNA has been detected in cell types such as oocytes, spermatocytes, PGCs or embryonic 
stem cells [211-213, 229-232]. In interspecies heterokaryons of mouse embryonic stem cells 
and human fibroblasts, AID downregulation results in a hypermethylated state of oct4 and 
nanog promoters [231]. Furthermore, genetic evidence supports a role for AID in 
demethylating the genome of PGCs. AID-deficient PGCs are up to three times more methylated 
than their wt counterparts. In Danio rerio, AID downregulation results in hypermethylation of 
the neurod2 promoter in embryos and a severe defect in neurogenesis [233]. Mechanistically, 
AID may collaborate with a group of proteins previously implicated in demethylation, Gadd45 
and the T:G glycosylate MBD4, to target specific genomic regions for demethylation [241]. But 
the amount of AID required for its proposed role in epigenetic programming seem to be 
considerably lower than that required for antibody diversification. Furthermore, the absence of 
any additional phenotype in AID-deficient humans and mice, beside a severe 
immunodeficiency syndrome, tends to favor a model where AID is redundant with other 
APOBEC deaminases in demethylation.  
 
1.3. Pathological consequences of AID 
Due to AID mutagenic activity, secondary antibody diversification is accompanied by a 
higher incidence of potentially transforming genomic lesions. The fact that AID is limiting for 
antibody diversification may be a consequence to its pathological side effects. Mice 
overexpressing AID have demonstrated its oncogenic capacity. Ubiquitous transgenic 
overexpression of AID leads to the development of T cell lymphomas and lung adenomas and 
adenocarcinomas, but not B cell malignancies [202]. In accordance with its role in central and 
peripheral tolerance, AID levels also influence antibody-mediated autoimmune diseases [195, 
242-244]. 
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1.3.1. Off-targets mutations 
AID can introduce mutations outside of the Ig loci. Several genes such as Bcl6, Cd95, 
Pim1, Pax5, RhoH, Cd79a, and Cd79b, have been reported to be hypermutated in post-GC B 
cells from healthy human donors, although at a significantly lower frequency than the IgV 
region [245-250]. In vitro-stimulated human primary B cells or human B cell lines displayed 
mutations in non-Ig genes, including Bcl6 and c-myc [251, 252]. AID is directly responsible for 
these mutations [253] (Figure 1.5). In fact, overexpression of AID in B and non-B cell lines 
results in off-target mutations in Aicda and a GFP reporter genes [254, 255], and as indicated 
before, AID-transgenic mice develop T-cell lymphomas characterized by the presence of point 
mutations in the T cell receptor, c-myc, and Pim1 genes [202, 256]. Indeed, increased levels of 
AID in B cells lead to a higher mutation rate in some non-Ig targets [201, 203, 257], although 
this does not always have oncogenic consequences in vivo [200, 204].  
Extensive sequencing of the GC-B cell genome demonstrated that AID is mistargeted to 
a larger extent than initially hypothesized [253]. AID is recruited to 5910 genes in activated B 
cells and mutates ~25% of the genes transcribed in GC-B cells [257]. AID preferentially targets 
actively transcribed genes where RNA polII and trimethylated histone H3 Lys4 (H3K4me3) are 
present and AID occupancy correlates with the localization of transcription elongation factor 
SPT5 [257]. Nonetheless, only a reduced number of genes (~23) displayed a high rate of 
mutations ressembling Ig SHM. Bcl6 is the primary AID off-target in activated B cells with a 
rate of mutation about 25-fold lower than the IgV region [253, 257]. Interestingly, some genes, 
such as c-myc or Pim1, which are frequently hit by AID in Ung-/- Msh2-/- B cells, display a 
significantly lower rate of mutations in wt B cells [253]. These results indicate that AID off-
target activity is in some cases counteracted by faithful repair to prevent the accumulation of 
mutations. Still, more than 50% of the GC-derived diffuse large B cell lymphomas (DLBCL) 
display aberrant hypermutation in Bcl6, Pim, Btg1, RhoH, and Pax5 [258]. Moreover, AID can 
be a disease progression factor by accelerating leukemia clonal evolution in Ph+ ALL 
(Philadelphia chromosome-positive B cell acute lymphoblastic leukemia) [259] and by 
mutating the BCR-ABL1 oncogene in CML (chronic myelogenous leukemia) and ALL [129, 
259, 260], thus underpinning resistance to the therapeutic drug imatinib [129].  
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1.3.2. Chromosomal translocations 
AID oncogenicity is probably in large part a consequence of its capacity to produce 
DNA breaks, thus initiating chromosomal translocations at a number of locations in normal B 
cells [261-265] (Figure 1.5). In fact, a recurrent hallmark in B cell lineage tumors is the 
presence of chromosomal translocations involving Ig loci and another partner. AID initiates 
DSBs in the IgH loci that lead to chromosomal translocations in activated B cells, and 
artifically increased levels of AID in B cells lead to a large increase in the frequency of IgH-
cMyc translocations [201, 204], a characteristic of Burkitt’s lymphomas. In addition, 
endogenous AID levels contribute to chromosomal translocations of multiple partners with the 
Ig locus, such as the IgH-Igβ [266] or IgH-Pax5 [264, 265], a hallmark of lymphoplasmacytic 
lymphoma. It can even occur between two non-Ig genes [201, 264, 265]. Indeed, most of the 
translocations occurring in a p53-deficient background involve c-Myc and miR-142 [201], a 
molecular hallmark of acute prolymphocytic leukemia [267]. Normally, apoptotic control 
eliminates cells with AID-induced translocations [261] and prevents B cell lymphomas in the 
AID-Igκ transgenic model [201]. In absence of p53, AID-Igκ induced B cell lymphomas with 
high frequency, even outpacing the T cell lymphomas that usually kill p53-deficient mice 
[201]. Curiously, GC B cells have reduced levels of p53 to allow for the necessary DNA 
damage that accompanies antibody gene diversification [134] so there are probably other 
mechanisms to prevent AID-initiated lymphomagenesis. For instance, AID-catalyzed lesions 
are more frequent in the absence of a number of DNA repair pathways, even with normal 
endogenous AID levels [253, 257, 268].  
It does not seem that AID overexpression is necessary for lymphomagenesis, as 
demonstrated in the Balb/Bcl-xL mouse model of plasmacytoma. In this model, AID is required 
for most pristane-induced plasmacytomas, where it underpins the oncogenic IgH-cMyc 
translocation [34, 39]. AID haploinsufficient mice show reduced incidence of lymphoma 
compared to Aicda+/+ but still significantly higher than the Aicda-/- [193], demonstrating that 
50% lower than normal levels of AID can be oncogenic in combination with another 
predisposing condition. Similarly, AID haploinsufficient B cells still display IgH-cMyc 
chromosomal translocations, albeit at a reduced frequency compared to wt [193, 194].  
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Figure 1.5. AID-mediated off-target mutations and chromosomal translocations. Although 
AID preferentially acts at the Ig loci, other genes (f.i. c-myc, p53, BCR-Abl, etc) can be 
targeted at a lower but significant frequency, leading to oncogenic mutations and chromosomal 
translocations. The DNA double-stranded break (DSB) generated after AID deamination and 
processing can be resolved through the joining of switch regions in the Ig loci but can also lead 
to the joining of the Ig locus with a non-Ig gene (illustrated here with c-myc), resulting in a 
chromosomal translocation.  
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Altogether, AID levels are critical in modulating the extent of off-target mutations and 
chromosomal translocations. Still, these are inherent to AID activity and contribute to cancer 
development. 
 
1.3.3. AID expression in B-derived cancer cells 
AID expression has been reported in several B lymphoid malignancies and endogenous 
levels of AID initiate B cell transformation, albeit infrequently. AID expression outside the 
GCs, f.i. in interfollicular large B lymphocytes, may give rise to precursors of mature B-cell 
malignancies [269]. Interestingly, the etiological role of AID in B cell lymphomas originating 
from GC B cells was demonstrated using the IµHABCL6 transgenic oncogene model, which 
deregulates BCL6 in B cells and results in mature B cell lymphomas. In an AID-deficient 
background, these transgenic mice did not develop mature B cell lymphomas [258]. 
IµHABCL6 lymphomas are akin to human DLBCL, which shows the highest prevalence of 
AID expression [210, 270-273], strongly suggesting an etiological role for endogenous AID in 
this lymphoma. In general, DLBCL but also follicular lymphoma samples show similar or 
lower AID levels than GC B cells [210, 270-272]. Near to normal AID levels are also 
expressed in Ph+ ALL and CML [129, 259, 260]. In these cases, BCR-ABL1 oncogene itself 
could be involved in inducing Aicda. Chronic lymphocytic leukemia is another B cell 
malignancy expressing variable levels of AID due to population heterogeneity where a defined 
subpopulation of cells can express most of the AID mRNA [274, 275]. The presence of this 
subpopulation correlates with a worsa prognosis but AID mRNA levels in these cells are not 
higher than in normal B cells [274, 275]. 
 
1.3.4. Ectopic expression of AID: link with inflammation 
AID expression is induced in several malignant epithelial cells including colonic 
epithelium [276], hepatocytes [277, 278], biliary cells [279] and gastric cells [280]. This 
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ectopic AID expression is usually associated to chronic inflammation, and there is often an 
underlying infection such as with hepatitis C virus [277, 281], Helicobacter pylori [280, 282], 
or human immunodeficiency virus [218, 283]. It is likely that NF-κβ is involved, given that it is 
an important transcription factor in B and other cells for Aicda induction [277, 280, 284] (see 
section 1.4.1). Solid tumors originating from epithelial cells are usually associated with genetic 
alterations in p53, which appears to be an early event during tumorigenesis. Genetic evidence 
supports a role for AID in the pathogenesis of inflammation-associated carcinogenesis. As 
mentioned previously, AID overexpressing mice develop T cell lymphomas but also lung 
adenomas and hepatocellular carcinomas [202]. Disruption of Aicda in the IL-10−/− mouse 
model, which recapitulates human inflammatory bowel disease (IBD), reduces the frequency of 
mutations in p53 and correlates with a reduced incidence of colon cancer. Thus, AID may play 
a central role in chronic inflammation-associated cancers by mutating non-Ig genes. 
 
1.3.5. AID and autoimmunity 
AID also influences antibody-mediated autoimmune diseases. AID is important in 
determining the severity of the pathology as demonstrated in mouse models of lupus and 
arthritis in which AID deficiency, or even haploinsufficiency, results in a more moderate 
disease [195, 242-244]. In keeping with this, increased levels of AID correlate with higher 
levels of autoantibodies in the MRL/faslpr/lpr and BXD2 mouse models of lupus and rheumatoid 
arthritis (RA), respectively [242, 285-287]. Interestingly, AID-deficient mice also have 
autoimmune disorders albeit of a different nature [288]. This fits well with the predisposition to 
autoimmune disorders noted in AID-deficient human patients [289]. The recent finding that low 
AID expression levels during B cell development play a role in establishing B cell tolerance 
could explain these findings [220, 221]. Although, like in cancer, there are predisposing 
conditions beyond AID for developing autoimmunity, here again AID levels are important in 
balancing an efficient immune response with disease. Several autoimmune diseases, including 
rheumatoid arthritis and lupus, feature chronically inflamed tissues, where ectopic GC-like 
structures are present [290]. These structures express high levels of AID and can produce 
autoantibodies in a RA-SCID mouse chimera model [291]. It is therefore unclear whether high 
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AID expression plays an etiological role in the development of autoimmune diseases, or 
whether it is a consequence of the chronic inflammation associated with these diseases and thus 
a disease progression factor.   
 
1.3.6. AID and allergies 
AID is required for switching to the IgE isotype, which is the main antibody isotype 
involved in atopic allergy. Local expression of AID and antibody diversification was reported 
in the nasal musoca of rhinitis patients [292], in the bronchial mucosa of asthma patients [293], 
and within the oesophageal mucosa of chronic oesophagitis patients [294], which could be 
driven by the local presence of the allergen [295]. Furthermore, gene expression pattern 
analysis from patients affected by chronic rhinosinusitis with nasal polyps suggests a central 
role of AID in the etiology of this disease [296]. However, there is no direct genetic evidence 
for a link between abnormal AID expression and the development of allergies.  
 
1.4. AID regulation 
The data summarized above illustrates how the optimal expression levels of AID in GC 
B cells reflect a compromise between being able to mount an effective adaptive immune 
response and delaying the onset of cancer or autoimmune diseases. A strikingly complex 
network of regulatory mechanisms exist to ensure that the optimal amount of biologically 
active AID protein gets to the Ig locus much more preferentially than to any other genomic 
location. Any alteration in the performance of these mechanisms could predispose to 
immunodeficiency, autoimmunity, or B cell lymphomas. This thesis studies aspect of AID post-
translational regulation. These will be introduced in greater details than the transcriptional 
regulation of AID.  
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1.4.1. Transcription regulation and cell-type specific expression 
A combination of promoter, enhancers and silencers, which are located within four 
evolutionary-conserved regulatory regions, determines AID expression in GC B cells of the 
spleen and MALT (Peyer’s patches, tonsils, lymph nodes) [206, 297]. These regulatory 
elements are found within 9kb upstream of the first exon and 25kb downstream of the last exon 
of the AID gene. The 5’ most region of the Aicda locus contains binding motifs for NF-κβ, 
STAT6, C/EBP and SMAD3/4 proteins. This region is responsive to cytokines, co-stimulatory 
molecules, and stimulation through the NF-κβ pathway [297]. The second region, located 1kb 
upstream of the transcription start site (TSS), contains a ubiquitously active promoter and 
binding sites for NF-κβ, STAT6, SP proteins, and HOXC4-OCT [284, 298-300]. It may also 
contain a PAX5-binding site but its location is controversial [299, 300]. The third portion is 
located in the intronic region between exons 1 and 2 of Aicda and contains sites for NF-κB, E 
proteins (E-box) and PAX5 [297, 299-301]. Regions 1 and 3 cooperate to restrict AID 
expression to Ag-activated GC B cells. Finally, the fourth regulator region is located about 6kb 
in mouse and 25kb in human downstream of exon 5. It plays an enhancer role and is required 
for normal AID expression [207].  
AID expression is also controlled by ubiquitous silencer proteins. For instance, region 1 
contains binding motifs for c-MYB and E2F proteins, which can function as transcriptional 
repressors [297]. Furthermore, the inhibitor of differentiation (Id) proteins ID1, ID2 and ID3 
repress Aicda transcription by binding to PAX5 and other stimulatory factors and preventing 
their association to DNA [299, 301]. Indirect repressors such as the transcription factor Blimp-1 
or the DSBs-initiated ATM/LKB1 signaling pathway, which inhibits the transcription factor 
CRTC2, can also limit AID expression to the GC compartment [208, 302].  
 
1.4.2. Post-transcriptional regulation 
AID is post-transcriptionally regulated by micro-RNAs (miR). miR are short (20-23 
nucleotides), noncoding RNAs that bind to complementary sequences in mRNAs and are key 
post-transcriptional regulators of gene expression. They are part of an active RNA-induced 
silencing complex (RISC) that contains the RNase III-type endonuclease Dicer and the 
29 
 
 
 
Argonaute proteins (Ago), which are important for mRNA silencing. The latter occurs either by 
mRNA degradation or by preventing mRNA from being translated. MiR-155 and miR-181b 
bind to conserved sites in the 3’untranslated region of AID mRNA and regulate its levels. This 
results in lower AID protein levels and reduced antibody diversification [203, 204, 303]. The 
different miR-155 and -181b expression patterns suggest two ways of regulating and restricting 
AID mRNA expression. MiR-155 is induced along with AID after B cell activation, and is 
expressed in GC B cells [203]. On the other hand, miR-181b is highly expressed in 
unstimulated B cells, decreases after B-cell activation and reaches its normal levels 3 days post-
stimulation [303]. Therefore, miR-181b may restrict AID expression to the GC B cell 
compartment while miR-155 may limit AID levels during antibody diversification.  
 
1.4.3. Post-translational modifications 
AID activity is modulated at the post-translational level by phosphorylation. Five AID 
residues, for the most part conserved throughout evolution, have been found to be 
phosphorylated in B cells: Ser3, Thr27, Ser38, Thr140 and Tyr184 [196, 304-308]. The 
biological significance of Tyr184 remains unknown. On the other hand, phosphorylation of 
Thr27 inhibits AID deamination and CSR in vitro, suggesting it modulates AID specific 
activity [304, 305, 309] but whether this is used in vivo to regulate AID is unknown. 
Phosphorylation at Ser3 reduces AID biological activity ex vivo but does not impact its 
catalytic activity and again its role and importance in vivo are unknown [306]. Phosphorylation 
at Ser3 is controlled by the serine/threonine phosphatase PP2A in vitro. Conversely, 
phosphorylation of Ser38 and Thr140 are not essential for AID catalytic activity in vitro but 
both significantly increase AID biological activity in vivo [196, 304, 307, 310, 311]. Ser38 is 
phosphorylated by PKA in the chromatin, which allows AID interaction with RPA and greatly 
facilitates CSR and SHM [196, 304, 305, 307, 311, 312]. The effect of mutating Ser38 and 
Thr140 in vivo was much more pronounced when combined with AID haploinsufficiency [196, 
310], thus suggesting that even if important, these modifications are not limiting for AID 
activity.  
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1.4.4. AID Subcellular localization  
AID nuclear exclusion is an additional step of regulating its mutagenic activity. AID is 
predominantly cytoplasmic at steady-state, as first reported for AID-GFP in Ramos B cells 
[313] and confirmed by subcellular fractionation and immunohistochemistry in primary B cells 
[87, 209, 210]. In fact, AID subcellular localization is dynamic and reflects the equilibrium 
between active nuclear import [314, 315], active nuclear export [314, 316, 317], and 
cytoplasmic retention  (see annexe 1 for ref.[315]). The deletion or mutation of the C-terminal 
10 amino acids of AID led to its nuclear accumulation, thus identifying this region as a nuclear 
export signal (NES). This demonstrated that AID is a nuclear-cytoplasmic shuttling protein 
[316, 318, 319]. This leucine-rich NES is a typical recognition motif for the CRM1 exportin, as 
was demonstrated by using the CRM1-specific inhibitor leptomycin B [316, 319] and by 
coimmunoprecipitation [315, 320]. 
The mechanism by which AID gains access to the nucleus is still unclear. Due to its 
small size (24 kDa), AID could in principle diffuse passively through the nuclear pores. 
However, it is actively imported into the nucleus, as demonstrated by its capacity to confer 
nuclear localization to large proteins, which requires energy [315]. The nuclear localization 
signal (NLS) of AID has not been completely defined. AID N-terminal region (roughly 
residues 5-50) contains multiple basic residues, a characteristic of many NLS, and it is clearly a 
major part of it [315, 319]. However, it is not by itself sufficient to mediate nuclear import of 
heterologous proteins, which actually requires the first 181 out of the 198 AID amino acids 
[315]. So, there are other residues elsewhere in the protein that form part of and/or are critical 
in displaying the NLS, which prompted the suggestion that AID has a conformational NLS 
[315]. The factors mediating AID nuclear import are even less defined. AID binds in vitro to 
several importin-αs, which are dedicated nuclear import factors, but their functionality in AID 
import has only been indirectly inferred [315]. AID also interacts with CTNNBL1, a nuclear 
protein presumed to work in mRNA splicing, which binds to NLS through an armadillo-like 
domain [321, 322]. Nuclear accumulation of an AID variant with mutated NES is partially 
compromised in DT40 CTNNBL1-/- cells, suggesting a role for CTNNBL1 in AID nuclear 
import [322]. Still, CH12 CTNNBL1-/- cells did not show any reduction in CSR, demonstrating 
that it is at least redundant with another mechanism for importing AID into the nucleus [323]. 
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Since CTNNBL1 interacts with importin-αs [322], they could be part of the same pathway. 
GANP, a protein associated with the RNA shuttling machinery and induced in GC B cells, has 
also been proposed to mediate active nuclear import of AID [324]. 
AID seems to be actively imported into the nucleus to counteract cytoplasmic retention, 
which prevents its diffusion [315]. Indeed, a motif in AID C-terminal region, overlapping with 
but distinct from the NES, is able to limit the passive diffusion of GFP into the nucleus [315]. 
Separation of function mutations exist to corroborate that these two signals are distinct and 
mediate different protein-protein interactions [315]. The translation factor eEF1α could 
participate in retention at least in part since it is stoichiometrically associated with AID in the 
cytoplasm and mutating the proposed AID cytoplasmic retention motif can disrupt this 
interaction [315, 325].  
Any modification in the balance of forces determining AID subcellular distribution 
should impact antibody diversification. Whether this is regulated (f.i. to increase diversification 
after some signaling event, at a particular cell cycle stage [326]), or whether the proportion of 
AID in the nucleus is constant at all times [206, 327], is unresolved. Drastic alterations or 
truncation of AID NES abolish CSR, most likely because this region also contains a domain 
mediating interactions required for CSR [316, 319, 328, 329]. Nevertheless, the relocalization 
of AID into the nucleus by mutating or deleting the NES increases SHM and immunoglobulin 
gene conversion [319, 328, 329]. This could partially be explained by a higher catalytic activity 
of nuclear AID variants [316, 328, 330], although these latter are less expressed [316, 329, 
331]. Nevertheless, mutating the C-terminal cytoplasmic retention signal of AID led also to 
faster nuclear import and higher SHM and CSR [315, 329]. Therefore, nuclear exclusion limits 
the biological activity of AID.  
 
1.4.5. AID stability 
The stability of AID is directly linked to its subcellular localization. Cytoplasmic AID 
is much more stable than nuclear AID [331]. The ~8 h half-life of AID in B cells represents in 
fact a rough average of its ~2.5 h nuclear and 18-20 h cytoplasmic half-life [331]. Indeed, 
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inhibition of AID nuclear export with leptomycin B and mutation or deletion of the NES, as 
well as disruption of AID cytoplasmic retention, increase the nuclear fraction of AID and 
correlate with a decrease in its half-life [315, 325, 329, 331, 332]. On the other hand, restricting 
AID to the cytoplasm resulted in increased AID half-life [315, 331]. The mechanistic 
explanations for this difference in stability are unclear.  
Inside the nucleus, AID seems to be constantly targeted to the proteasome by ubiquitin 
(Ub)-dependent and -independent pathways [331, 333]. Proteasomal inhibition suffices to 
detect an important increase in polyubiquitinated nuclear AID [331]. The Ub ligases modifying 
nuclear AID are unknown. The murine double minute 2 (MDM2) E3 ubiquitin ligase interacts 
with AID and could be one of them [334]. However, DT40 cells deficient in or overexpressing 
MDM2 show very modest increase and decrease in Ig gene conversion, respectively [334]. 
Thus, MDM2 is either redundant with some other Ub ligase or not relevant for AID. 
Interestingly, AID with no internal lysine residues is still significantly polyubiquitinated [331], 
suggesting either N-terminal ligation or a non-canonical pathway of polyubiquitination for 
AID. A proportion of AID interacts with and is targeted for degradation by the nuclear protein 
REG-γ, which brings proteins for proteasomal degradation in Ub- and ATP-independent 
fashion [333] (see section 1.6.1 and figure 1.8). In fact, REG-γ deficiency results in higher AID 
steady-state levels, increased nuclear AID stability, and increased CSR in mice, demonstrating 
the physiological role of this protein in reducing nuclear AID levels [333]. Thus, modulating 
AID stability seems to be one more way of limiting AID expression and yet another mechanism 
restraining antibody diversification. It remains unclear whether cytoplasmic AID is protected 
from this active degradation process. 
 
1.4.6. Targeting specificity to the Ig loci 
AID gets to the Ig locus much more preferentially than to any other genomic location. 
The reasons for this preferential targeting are still unclear. AID activity is highly dependent on 
transcription in vitro and in vivo, which transiently exposes unpaired bases in the transcription 
bubble [186-192, 254, 255, 335-340]. However, transcription alone cannot account for the 
preferential targeting of AID to the Ig loci. Indeed, AID contains a domain (residues 113-123) 
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that contributes to the preferential deamination at WRCH motifs, which are highly enriched in 
the switch and the IgV regions and therefore function as mutational hot-spots [341, 342]. AID 
equally deaminates both the transcribed and non-transcribed strands [343], due to its interaction 
with the RNA exosome complex [344]. Given the abundance of actively transcribed genes 
containing RGYW/WRCY motifs, the substrate specificity of AID cannot fully explain the 
preferential targeting to the Ig loci. 
Epigenetic modifications of histones, which control the chromatin architecture, may 
contribute in defining a window where AID can be preferentially recruited. Histone 
modifications are associated with CSR and SHM, although the nature of these modifications 
may differ between CSR and SHM [345-350]. They may play a role in AID targeting by 
modulating the structure of the chromatin and/or providing binding motifs for factors 
implicated in antibody diversification. Indeed, a proportion of nuclear AID interacts with 
KRAB domain-associated protein 1 (KAP1) and the heterochromatin protein 1 (HP1) and is 
targeted to H3K9me3 (trimethylated histone H3 at lysine 9) present at the Sμ region [351]. 
KAP1 deficiency results in impaired binding of AID to the Su region and reduced CSR in mice 
[351]. Still, KAP1 is dispensable for SHM and therefore cannot account alone for the specific 
targeting of AID to the Ig loci. 
Genetic evidence supports a contribution of the transcription machinery in AID 
targeting. The most promising targeting factor is the transcription elongation factor SPT5, 
which associates with stalled RNA polIIand recruits AID near the transcription start site [352]. 
In fact, RNA polII behaves differently in the Ig loci than in other genes and appears to stall and 
accumulate due to the high frequency of R-loops in that region [345, 353]. AID occupancy at 
transcribed regions depends on SPT5 and RNA polII. Problematically, SPT5 occupancy 
correlated with both the Ig loci and off-targets genes. Selective recruitment of AID to the 
variable and switch regions may in part depend on the polypyrimidine tract binding protein 2 
(PTBP2) and the 14-3-3 scaffold proteins. Normally, PTBP2 inhibits RNA splicing by binding 
to the polypyridimidine RNA tracts. In B cells, PTBP2, which preferentially binds RNA 
transcribed from the Sμ region, interacts with AID and promotes its specific recruitment to Sμ 
and Sγ1 regions [354]. On the other hand, the 14-3-3 scaffold proteins can bind dsDNA regions 
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that contain AID hotspot motifs and associate with transcribed switch regions in activated B 
cells [355]. They interact directly with AID through its C-terminus and may contribute to the 
preferential recruitment of AID to switch regions.     
As mentioned previously, PKA is present in switch regions in an AID-independent 
fashion but can interact with AID in the Ig loci, thus phosphorylating and enabling the local 
association of AID with the single-stranded binding protein RPA [311, 312]. In fact, RPA plays 
a role in SHM, CSR and iGC [196, 304, 305, 310, 312]. Nonetheless, neither PKA nor RPA are 
required for physically recruiting AID to DNA [311]. In conclusion, the preferential targeting 
of AID to the Ig loci results from the contribution of several elements including AID’s intrinsic 
substrate specificity, AID’s association with the transcription machinery, epigenetic 
modifications, and local post-translational modifications of AID. 
 
1.4.7. AID co-factors 
It is clear that AID interacts with co-factors critical for either SHM or CSR. 
Deletion/mutation of the amino-terminal domain of AID abolishes SHM without drastically 
affecting CSR [356]. On the other hand, deletion/mutation of AID C-terminal NES leads to 
defective CSR but retains SHM [357-359]. Nonetheless, the nature of the interactions mediated 
by AID’s N- and C-terminal domains and their functional importance remain to be determined. 
Beside the 14-3-3 adaptor proteins that recruit AID to the switch regions, AID C-terminus 
binds to the Ub ligase MDM2 [334] and DNA-PKcs [360], but the functional relevance of these 
interactions are unclear.     
In this thesis, we will show that AID interacts with several members of the HSP90 
molecular chaperoning pathway. Therefore, we will introduce the important points of this 
pathway that are relevant to our work. 
 
1.5. The HSP90 molecular chaperoning pathway 
 AID is predominantly cytoplasmic at steady-state and requires nuclear translocation 
for proper activity [361]. Consistent with the fact that cytoplasmic AID is more stable than its 
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nuclear counterpart, it was suggested that AID is protected and/or retained in the cytoplasm by 
specific chaperones [362]. Indeed, the heat shock 70-kDa protein HSC70 was 
coimmunoprecipitated with AID from HeLa cell extract [360], but the functional relevance of 
this interaction in B cells remains unclear. HSC70 is a ubiquitous molecular chaperone, which 
is mainly implicated in the folding of nascent proteins and the refolding of denatured 
proteins.Two major forms of this chaperone have been identified: the constitutive form, named 
HSC70, and the stress- and heat shock-induced form, HSP70. Both are often considered to have 
similar cellular functions. Indeed, HSC70/HSP70 play a central role in protein triage and 
controls the balance between (re)folding and degradation of denaturated proteins (reviewed in 
[363]). HSC70 is also part of the HSP90 molecular chaperoning pathway, which includes the 
HSP40 and HSP90 chaperones, as well as additional cofactors. These heat shock proteins 
(HSPs) are highly conserved throughout evolution and their role extends beyond de novo 
protein folding and protection in stressful situations. In fact, HSP90 participates in the 
stabilization and the activation of a large range of proteins, referred to as HSP90 clients, rather 
than interacting with unfolded proteins to facilitate their (re)folding. The best characterized 
HSP90 clients are involved in cell signalling and transcriptional regulation (i.e. kinases and 
steroid hormone receptors) [364-366], but recent proteomic and genetic studies suggest that the 
HSP90 molecular chaperoning pathway may be implicated in broader cellular processes [367-
369].  
 
1.5.1. HSP90 
HSP90 is highly conserved throughout evolution and is present in four different 
isoforms in humans [370]: two cytosolic (HSP90α and β), one mitochondrial (TRAP1), and one 
in the endoplasmic reticulum (GRP94). HSP90 functions as a flexible dimer and each monomer 
is constituted of three domains: an N-terminal domain which possesses an ATP-binding pocket 
and catalyzes ATP hydrolysis; a flexible and highly charged linker sequence which connects 
the N-terminal domain to the middle (M) region; and a C-terminal dimerization domain [370]. 
Genetic evidence indicates that the M region plays a key role in the binding of many HSP90 
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clients. It also modulates ATP hydrolysis [371, 372]. HSP90 interacts with the co-chaperone 
AHA1 (activator of HSP90 ATPase homologue 1), that promotes the association of the N- and 
the M-domains, thus accelerating the ATP-hydrolysis rate [373, 374] (see section 1.5.3.). The 
ability of HSP90 to recognize and stabilize a large repertoire of clients depends on its intrinsic 
flexibility and on highly dynamic conformational shifts catalyzed by ATP hydrolysis. These 
structural rearrangements are essential for client maturation and are modulated by certain co-
chaperones, including AHA-1 and p23 (reviewed in [375]).  
Little is known about the molecular basis of HSP90 client recognition. All the known 
HSP90 clients are different in structure and even close variants of the same protein do not 
necessarily depend on HSP90 stabilization in the same way. The two SRC kinase variants, the 
cellular form (c-SRC) and the viral form (v-SRC), are the perfect example. Although both are 
almost identical (95%), v-SRC requires HSP90 stabilization while c-SRC is largely 
independent of this chaperone [376-378]. This may partially be explained by the differential 
intrinsic instability of the two forms, with v-SRC being highly instable. But it remains unclear 
whether the requirement for the HSP90 chaperoning pathway is dictated by a specific motif or 
general biophysical properties of the client.  
 
1.5.2. HSP40/DnaJ proteins 
The specific recognition of client proteins for stabilization by the HSP90 pathway may 
be controlled by the HSP40/DnaJ proteins. In fact, they are the most diverse family of co-
chaperones and consist of 41 members in humans, while there are only 11 different HSC70 
isoforms and 4 different HSP90 isoforms. The canonical role of HSP40/DnaJ proteins is to 
present clients to HSC70 and stimulate HSC70 ATP hydrolysis [379]. This latter process is 
dependent on a highly conserved 70 amino acid J-domain, which is the defining feature of all 
HSP40/DnaJ proteins [380, 381]. Indeed, the J domain contains a histidine–proline–aspartic 
acid (HPD) motif that is essential for the stimulation of ATP hydrolysis by HSC70 [382]. 
HSP40/DnaJ proteins are structurally divided into three subclasses based on the presence or 
absence of conserved domains: type I (DnaJa/DjA), type II (DnaJb/DjB), and type III 
(DnaJc/DjC) [379] (Figure 1.6). In this thesis, we are primarily interested in type I HSP40/DnaJ 
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proteins (DnaJa1–4), which are orthologues of E. coli DnaJ and yeast YDJ1. DnaJa1, -a2 and –
a4 are cytoplasmic proteins, while DnaJa3 is found in the mitochondria (reviewed in [383]), 
and cytosolic DnaJa1 and –a2 are ubiquitously expressed [384]. Besides the conserved J 
domain, HSP40/DnaJ may contain a Gly/Phe-rich (G/F) linker and a C-terminal substrate-
binding region (Figure 1.6). The G/F rich region contributes to the interaction with HSC70 but 
is not involved in stimulating the ATPase activity of HSC70 [385-390] (Figure 1.6). The C-
terminal substrate-binding region can be subdivided into a hydrophobic pocket that can confer 
substrate binding specificity (CTDI), a cysteine-rich region, also known as the zinc finger 
(CTDII), and a dimerization domain, at least for type I-DnaJ proteins [391, 392] (Figure 1.6). 
Substrate specificity of type I and II-DnaJ proteins is considered to be dependent on their C-
terminal domain [393-395]. In fact, type I-DnaJs and their yeast ortholog YDJ1 are farnesylated 
at their C-terminus [396, 397]. Farnesylation is a posttranslational modification catalyzed by a 
farnesyltransferase (FTase), which consists in the addition of a 15-carbon isoprenoid group 
(farnesyl group) at the carboxyl terminus of a protein containing a CAAX motif (C=cysteine, 
A=aliphatic, and X=any amino acid) (reviewed in [398]). FTase, which catalyzes the formation 
of a thioether bond between the farnesyl group and the thiol group of cysteine, is a heterodimer 
but its substrate specifity is unclear. In fact, ~300 proteins terminate with a CAAX motif in the 
human proteome, but only a small fraction is actually post-translationally modified [398]. 
Nevertheless, farnesylation plays an important role in membrane association and protein-
protein interaction of a number of proteins. In the case of type-I DnaJ proteins, farnesylation 
largely contributes to protein-protein interactions [399] and is functionally important for the 
interaction between YDJ1 and HSP90 clients [400, 401]. The diversity of HSP40/DnaJ proteins 
and their implications in a large range of biological functions suggest a functional 
specialization and the recognition of a specific subset of substrates (see section 1.5.4.).     
 
1.5.3. Stabilization of HSP90 client proteins: the maturation process 
HSP90 and its co-chaperones HSP40/DnaJ and HSC70 interact with clients in an 
ordered ATP-dependent pathway. This maturation process has been extensively characterized  
38 
 
 
 
 
 
 
 
 
Figure 1.6. HSP40/DnaJ proteins. Schematic structure of the three types of J-proteins 
indicating their different domains (except for type IIIs, which do not share a common 
organization). They all share a highly conserved J domain, which is important of the ATPase 
activity of HSC70. Type I- and type II-HSP40/DnaJ proteins contain a glycine/phenylalamine-
rich domain (G/F), which is involved in the binding to HSC70. The C-terminal domain of 
HSP40/DnaJ protein varies largely depending on the subtype. Carboxyl-terminal domain I 
(CTDI) can confer substrate specificity; CTDII contains a zing-finger domain, and CTDIII 
encompasses a dimerization domain. CAAX indicates the farnesylation motif present in type I 
J-proteins.  
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in the context of steroid hormone receptors, and consists in the initial recognition of the newly 
synthesized or misfolded client by HSP40/DnaJ and HSC70/HSP70 [363, 402] (Figure 1.7). 
When bound to ATP, HSC70 has a low affinity for client proteins. Stimulation of HSC70 
ATPase activity by the J-domain of HSP40/DnaJ increases the affinity of HSC70 for its 
substrate and promotes the formation of a stable HSC70-client complex [402]. HSC70 
 
1.5.4. Limiting step of the HSP90 chaperoning pathway 
Consistent with the view that the HSP90 molecular chaperoning pathway stabilizes a 
functions as a monomer but can be associated with several co-chaperones beside HSP40/DnaJ 
proteins. Transfer of the client from HSC70 to HSP90 is mediated by HOP/STI, which 
simultaneously binds HSC70 and HSP90 through two distinct tetratricopeptide repeat (TPR) 
domains [403] (Figure 1.7). It remains unclear how the client is transferred from HSC70 to 
HSP90. For the progression of the maturation cycle, HSC70 and HOP/STI are replaced by 
other TPR-containing co-chaperones including p23 [404-406]. This latter step promotes ATP-
binding and the formation of a closed conformation of HSP90 with its client (Figure 1.7). The 
closed conformation of HSP90 maintains its client in a metastable state (Figure 1.7; reviewed in 
[407]). ATP hydrolysis results in the reopening of HSP90 and the dissociation of the client 
from HSP90. The client can then undergo additional maturation until it reaches a stable 
conformation (Figure 1.7). In the context of the steroid hormone receptors, hormone binding 
leads to a conformation change in the receptor [407]. Chaperone components are released and 
the steroid hormone receptor bound to its specific hormone can be translocated to the nucleus to 
perform as a transcription factor. Similarly, post-translational modifications (f.i. 
phosphorylation, acetylation or s-nitrosylation) of both HSP90 and its clients influence their 
association [375, 408, 409].broad range of proteins, HSP90 is implicated in several cellular 
processes, f.i. protein activation, translocation across membranes, and quality control in the 
endoplasmic reticulum or immunogenic peptide processing. HSP90 is very abundant, 
representing up to 2% of the cytosolic proteins, and is required for cellular viability in 
eukaryotes [410, 411]. This chaperone rarely functions alone and requires the help of other co-
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chaperones. For instance, HSP40/DnaJ proteins are less abundant and limiting in the 
chaperoning pathway. Although dnaJ and the HSP70 orthologue dnaK genes are both 
transcribed from the same strong promoter in E. coli, DnaJ proteins are 10 times less abundant 
than DnaKs [412]. Similarly, YDJ1 (HSP40/DnaJ orthologue) is estimated to be present in 
yeast at a 1:2:4 ratio relative to SSA1 (HSP70 orthologue) and HSP82 (HSP90 orthologue), 
respectively [413]. HSP40/DnaJ proteins are also functionally limiting in mammalian systems 
[390, 414, 415]. HSP40/DnaJ binding to the client is not only the first step in the maturation 
cycle; it is also the only co-chaperone that binds intrinsically to these clients without assistance 
of other co-factors [416-418]. Since HSP40/DnaJ proteins are the largest and most diverse 
family of co-chaperones, they could be indirect regulators of the HSP90 molecular chaperoning 
pathway by selecting specific client proteins. In line with this, in vitro studies indicate a certain 
level of functional specialization for HSP40/DnaJ proteins, despite some redundancy [416, 419-
423]. In vivo, all the HSP40/DnaJ-deficient mice show different phenotypes. DNAJA1-/- mice 
have a defect in spermatogenesis with aberrant androgen receptor signalling [424]. DNAJA3 
deficiency results in embryonic lethality [425] and heart-specific DNAJA3 deletion causes 
dilated cardiomyopathy [426]. DNAJB1 disruption compromises thermotolerance in mice 
[427]. DNAJB6-deficient mice are embryonic lethal and show defects in placental development 
[428]. DNAJC3-/- mice develop diabetes [429]. Finally, DNAJC5 deficiency results in 
progressive neurodegeneration [430]. These genetic evidences suggest substrate specialization 
of HSP40/DnaJ proteins. But the identity of these in vivo substrates and the mechanistic details 
beyond their specific recognition by DnaJ proteins are largely unknown. 
 
1.5.5. Pharmacological interventions 
The HSP90 pathway is not only involved in normal cellular processes but can also 
contribute to the development of cancer by stabilizing oncogenic proteins. Indeed, several 
HSP90 clients are implicated in cellular proliferation (f.i. HER-2, RAF-1, CDK4) [431-433], in 
immortalization (telomerase TERT) [434, 435], or in the prevention of apoptosis (AKT) [436], 
and the list is expanding. HSP90 also stabilizes specific B cells transcription factor such as 
BCL6 [437], which is oncogenic in DLBCL. Moreover, HSP90 stabilizes the constitutively  
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Figure 1.7. The HSP90 maturation process: pharmacological intervention. HSP90 modulates 
the function of proteins by stabilizing a meta-stable intermediate. HSP40/DnaJ protein initiates 
this maturation pathway by recognizing the client protein. Subsequently, HSP40/DnaJ transfers 
the substrate to HSC70 and stimulates HSC70 ATPase activity. HSC70 can associate with 
HSP90 via the co-chaperone HOP. The client protein is stabilized in a metastable complex with 
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HSP90. p23 locks HSP90 in a closed conformation until AHA-1 stimulates HSP90 ATPase 
activity. This results in the release of the client protein. This latter can be stabilized by post-
translational modifications or the presence of its substrate (f.i. steroid hormone), becomes 
activated, or undergoes an additional round of maturation. HSP90 chaperone activity depends 
on ATP hydrolysis, which can be inhibited by the drug geldanamycin (GA) and its derivatives 
17-AAG, leading to polyubiquitination and degradation of its clients. 
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active tyrosine kinase BCR-ABL in CML [438, 439]. Mutations in BCR-ABL that can arise 
during treatment with tyrosine kinase inhibitors (f.i. imatinib) result in a stronger dependence 
toward HSP90 [440]. In fact, HSP90 has been proposed to act as a capacitor in cancer by 
stabilizing mutated proteins that otherwise would not be functional [441, 442]. 
Increased expression of one or more HSP proteins is also a common feature of both 
solid tumors and haematological malignancies [408, 409]. Thus, targeting HSP90 for cancer 
therapy has been an expanding area of research and HSP90 is now considered to be a bona fide 
anti-cancer drug target. The N-terminal ATP-binding pocket of HSP90 can also bind natural 
products such as geldanamycin (GA) and radicicol [443] (Figure 1.7). These compounds 
interact with greater affinity with HSP90 N-terminus than ATP and prevent the chaperone from 
cycling between its open and closed states. Synthetic GA derivatives such as 17-AAG have 
been developed and are currently in clinical trials [444]. HSP90 inhibition results in the 
recruitment of E3 Ub ligases such as CHIP (carboxy-terminus of HSP70-interacting protein) 
[445-447]. HSP90 clients are therefore destabilized by polyubiquitination and targeting for 
proteasomal degradation (Figure 1.7). It is unlikely that CHIP is the only E3 Ub ligase involved 
in the degradation of HSP90 clients [447, 448]. Genetic evidence suggests that Cullin5 may be 
one alternative E3 ligase [449].  
The identification of a specific substrate for a given HSP40/DnaJ protein may also be a 
promising avenue of research in targeting this pathway for therapy. Unfortunately, there is 
limited information on the expression and function of most HSP40/DnaJ in cancer [379, 450], 
and very few specific substrates are known. Of note, there are currently 8 different 
HSP40/DnaJ proteins that have been implicated in the development of cancer and metastasis 
[379], but how mechanistically they play a role in influencing cancer properties is unknown. 
DnaJa1, a type-I HSP40/DnaJ protein, is an interesting example. Modulation of DnaJa1 levels 
in a human glioblastoma cell line modulates its resistance to radiation [451]. As mentioned 
previously, DnaJa1 is farnesylated at its C-terminus, which is important for its association with 
client proteins. Use of farnesyltransferase inhibitors (FTI) that are currently in clinical trials led 
to the accumulation of non-farnesylated DnaJa1 and correlated with increased radiosensitivity 
[451]. Although FTI may affect other farnesylated proteins, the use of these drugs may be an 
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interesting tool to target substrates recognized by a farnesylated HSP40/DnaJ proteins. 
 
1.6. Instrinsic motifs dictating protein turnover 
The differential stability between cytoplasmic and nuclear AID may also result from its 
intrinsic biochemical properties or the presence of degradation motifs in AID that may be more 
relevant in one subcellular compartment than another. AID is targeted by both an Ub-dependent 
and independent degradation pathway in the nucleus [331, 333], and one could speculate that 
specific motifs may direct AID to one or the other pathway.  
 
1.6.1. Ubiquitin-dependent and –independent degradation pathways 
The proteasome performs the majority of the proteolysis in higher eukaryotic cells and 
therefore plays a central role in protein homeostasis. It is found in both the cytoplasm and the 
nucleus and contributes in the destruction of abnormal/unwanted proteins but also to the 
maturation of polypeptide precursors [452, 453]. It is also involved in the generation of 
peptides presented by MHC class I molecules, which is crucial for initiating an immune 
response. The proteasome is composed of a proteolytic core, the 20S proteasome, which is 
highly conserved throughout evolution [452]. The 20S proteasome has a typical barrel-shape 
that results from the assembly of 28 subunits in 4 heptameric rings [454, 455]. The two inner 
rings form the catalytic sites while the outer rings associate with a variety of regulatory 
complexes. Substrates access the central catalytic sites through axial ports at the end of the 20S 
proteasome [456]. But these pores are closed in absence of the regulatory complexes. Three 
activators of the 20S proteasome have been characterized: the 19S regulatory complex (PA700) 
[457-460], the 11S activating complex (REG activator PA28) [461, 462], and the proteasome 
activator P200 [463]. Two inhibitory proteins, PI31 [464] and Pr39 [465], have also been 
described. Their mechanism of action is still under investigation but it is clear that the 19S 
complex is necessary for the processing of ubiquitinated proteins, although it has also been 
implicated in a Ub-independent pathway [466]. The 20S proteasome can associate with two 
19S regulatory complexes to form the 26S proteasome [467] (Figure 1.8A), which is directly  
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Figure 1.8. The ubiquitin-dependent and -independent proteasome system. (A) Conjugation 
of ubiquitin (Ub) is catalyzed by the RING/U-box or the HECT E3 ligase. Ub is activated in an 
ATP-dependent manner by the Ub-activating enzyme, E1. The activated Ub is subsequently 
transferred to the Ub-conjugating enzyme E2. In the case of a RING/U-box E3 ligase, Ub-
charged E2 binds to E3 and transfers the activated Ub moiety directly to the substrate that is 
also bound to E3. For the HECT E3 ligase, the Ub is transferred from E2 to a cysteine residue 
in E3 and then to the substrate .The conjugated substrate is degraded into short peptides by the 
26S proteasome, composed of the core 20S proteasome and the 19S activator subunits. (B) 
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Alternatively, a substrate can be directly recognized by the REG complex (also called 
PA28/11S), which acts as an activator of the 20S proteasome and can initiates the degradation 
of intact proteins through an Ub- and ATP-independent pathway. 
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involved in the degradation of ubiquinated proteins. Nevertheless, this complex is not 
necessarily the most abundant proteasomal complex in the cell. It is also unclear what the 
subcellular distribution of all these complexes is and how they manifest substrate specificity. 
The Ub-dependent proteasome degradation pathway requires the initial conjugation of 
single or polymeric Ub moieties to the substrate. This most often occurs through the formation 
of an isopeptide bond between the C-terminal group of Ub and the ε-amino group of an internal 
lysine residue. Ubiquitination can also occur at alternative sites, including the N-terminal group 
of a protein [468-470] or unconventional non-lysine residues (cysteine, serine or threonine) 
[471-475]. Importantly, this process is reversible through the action of deubiquitylases (DUB) 
[476]. Protein ubiquitination is carried out by an enzymatic cascade, where Ub is first activated 
by a Ub-activating enzyme (E1) in an ATP-dependent manner (Figure 1.8A) [453, 470]. A 
thioester bound is formed between the C-terminus of Ub and a cysteine residue in E1. 
Activated Ub is subsequently transferred to a Ub-conjugating enzyme (E2/UBC). Despite 
partial redundancy, E2 can confer some specificity to substrate ubiquitination. However, in 
most cases, the E3 Ub ligase provides the layer of specificity for a substrate. HECT E3 ligases 
form a thioester bond with activated Ub before transferring it to the substrate [477]. On the 
other hand, RING/U-box E3 ligases facilitate the transfer of the Ub moiety from the E2 to the 
substrate [478]. Ub moieties can then bind efficiently and specifically to the 19S regulatory 
complex, thus targeting the protein substrate for degradation. 
 Interestingly, there are a number of proteins that can be degraded in a Ub-independent 
(Figure 1.8B) manner but still require the proteasome, including ornithine decarboxylase 
(ODC) [479, 480], cyclin-dependent kinase inhibitor p21 [481, 482], or c-JUN [483]. The fact 
that p21 or c-Fos can be degraded by both a Ub-dependent and –independent pathways [476] 
suggest that both pathways can contribute to the protein turnover of a specific substrate and 
may be selected depending on the context or subcellular localization. However, it remains 
unclear what are the intrinsic protein determinants that dictate this choice. Absence of an Ub 
acceptor NH2 group on the substrate may be an obvious element, although proteins that have 
lysine redisues, including AID [484], are also subjected to this pathway (reviewed in [476]). 
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Furthermore, the proteasomal subunits involved in this pathway are still controversial. The REG 
complex (11S/PA28), which is an ATP- and Ub-independent proteasome activator, strongly 
enhances the catalytic activity of the proteasome in vitro [485]. In particular, REGγ resides 
primarily in the nucleus and can directly interact with intact protein substrates for targeting to the 
20S proteasome in an ATP- and Ub-independent manner [452] (Figure 1.8B). But the determinants 
implicated in the recruitment of REG-γ are unclear. In vitro studies have shown that proteins 
containing intrinsically unstructured regions undergo degradation by the 20S proteasome. In 
fact, up to 20% of all cellular proteins can be degraded or cleaved at unstructured domains by a 
Ub-independent 20S-dependent proteasomal pathway [476, 486-488]. However, the REGγ-20S 
proteasome seems to be highly selective and its recruitment may require additional structural or 
sequence motifs for substrate degradation [489, 490] .  
1.6.2. The N-end rule 
Although the general steps implicated in protein turnover are defined, it is less clear 
what are the actual signals dictating protein stability and whether they influence an Ub-
dependent or –independent proteasomal targeting. Several biochemical and biophysical 
properties of proteins have been described as determinants of protein turnover, including 
molecular weight [491], isoelectric point [492, 493], hydrophobicity [494, 495], and the 
presence of certain motifs [496-499]. The simplest degradation motif, the N-degron, has been 
extensively studied and illustrates that the nature of a protein’s N-terminal amino acid 
determines its half-life [499, 500]. Newly synthesized proteins contain an N-terminal 
methionine which is considered as a stabilizing residue according to the N-end rule, but 
proteins can be enzymatically modified at their N-terminus to reveal a primary, secondary or 
tertiary destabilizing residue depending on the number of steps required before 
polyubiquitination [500]. 
 There are two cytosolic methionine aminopeptidases in mammals, MetAP1 and 
MetAP2, which remove the initial methionine, thus exposing the secondary residue of a 
protein. Interestingly, MetAP2 is highly expressed in GC B cells and its inhibition led to 
suppression of T-cell dependent Ag-specific antibody response by disrupting GC formation 
[501, 502]. Indeed, N-terminal cleavage is quite a common post-translational modification that 
can affect between 55 and 70% of the proteins depending on the organism and the subcellular 
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compartment [503]. Processed proteins that contain an N-terminal cysteine residue are 
subsequently modified by an arginyl-tRNA protein transferase (ATE1) to introduce an arginine, 
which targets it to the N-end rule pathway. ATE1 can actually modify several proteins without 
necessarily creating a N-degron, suggesting that multiple determinants could influence the half-
life of a protein. In fact, high-throughput analysis suggested that the half-life of a protein is 
influenced by multiple factors (f.i. structural disorder) in vivo [504]. 
 
1.6.3. PEST and other degradation motifs 
Other degrons predisposing a protein to increased instability have been identified, 
including the PEST motifs (P=proline, E=glutamic acid, S=serine, T=threonine) [498, 505]. 
These regions are enriched in proline, aspartic/glutamic acid, serine and threonine, and are 
generally flanked by positive residues. They have been predicted to be solvent-exposed regions, 
which would make them more susceptible to proteolysis [505]. In fact, PEST motifs are 
abundant in intrinsically unstructured proteins [506, 507]. Most of the proteins containing a 
PEST motif are short-lived [508-511], which could result from the contribution of both the Ub-
dependent and independent proteasomal degradation pathway [512]. However, whether PEST 
motifs interact with specific E3 Ub ligases or substrate recognition proteins for the Ub-
independent proteasome is unknown. 
 Beside PEST motifs, additional degrons have been characterized such as the APC/C-
dependent D- and KEN boxes [497, 513-516] and the TrCP recognition box (DSGXXS) [470, 
517-519]. These motifs seem to be present in more defined and smaller subsets of proteins. The 
D- and KEN boxes are recognized by the anaphase-promoting complex/cyclosome (APC/C), an 
E3 Ub ligase involved in the polyubiquitination of regulatory proteins such as securin, cyclin A 
and geminin [520]. Proteasomal degradation of these proteins through the action of APC/C is 
important for cell-cycle progression. On the other hand, the DSGXXS motif is recognized by β-
transducin repeats-containing proteins (β-TrCP), which serve as a substrate recognition for the 
SCFβ-TrCP E3 Ub ligases [521]. This motif is mainly found in phosphorylated proteins and plays 
a role in the regulation of cell division and signal transduction. For instance, the regulatory 
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protein Iκβ and the E-cadherin-associated β-catenin protein contain such a motif and can be 
targeted to the proteasome through the action of the β-TrCP-SCFβ-TrCP complex. The D/Ken box 
and the β-TrCP motifs are highly dependent on Ub for their substrate degradation, which makes 
them improbable candidates for targeting to the other pathway.  
In summary, the rate of degradation of a protein results from the combination of 
multiple factors, including the presence of one or several degradation motifs as well as intrinsic 
domains of disorders. Whether these degradation motifs may influence the targeting of a 
substrate to the Ub-dependent or –independent proteasome remains unclear.        
 
1.7. Rationale of the research 
Given that AID is limiting for antibody diversification, and that ectopic and normal 
expression of AID results in off-target mutations which contribute to cancer/autoimmune 
diseases, it is critical to precisely define the post-translational regulations that determine the 
optimal levels of AID. Since AID is found at steady-state in the cytoplasm, where it is more 
stable than in the nucleus, we asked whether cytoplasmic AID could be protected by binding to 
specific factors in this compartment. A pull-down assay, using AID as bait, revealed 
interactions with several molecular chaperones, including DnaJa1, HSC70 and HSP90. Our 
hypothesis is that the HSP90 molecular chaperoning pathway protects AID from degradation in 
the cytoplasm. We first investigated the role of HSP90 in cytoplasmic AID stabilization and its 
biological importance in antibody diversification (Chapter 2). Analysis of the role of DnaJa1 
revealed a limiting step in the stabilization of cytoplasmic AID by the HSP90 molecular 
chaperoning pathway (Chapter 3).  This may influence the optimal levels of AID required for 
antibody diversification. Finally, we investigated whether AID stability is only linked to its 
subcellular localization or whether there is a direct contribution of intrinsic protein motifs to 
AID stability, in the context of the regulation of antibody diversification (Chapter 4). 
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2.1. Authors contribution 
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the AID-FLAG/HA purification and provided with useful advice. Dr Alain Lamarre provided 
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contributed in the conception of the project, the design of experiments and provided useful 
advice. Dr Javier M. Di Noia conceived the project and wrote the paper. All authors discussed 
and interpreted the data and contributed to the final manuscript. 
 
2.2. Abstract 
Activation-induced deaminase (AID) is the mutator enzyme that initiates somatic 
hypermutation and isotype switching of the antibody genes in B lymphocytes. Undesired 
byproducts of AID function are oncogenic mutations. AID expression levels seem to correlate 
with the extent of its physiological and pathological functions. In this study, we identify AID as 
a novel HSP90 (heat shock protein 90 kD) client. We find that cytoplasmic AID is in a dynamic 
equilibrium regulated by HSP90. HSP90 stabilizes cytoplasmic AID, as specific HSP90 
inhibition leads to cytoplasmic polyubiquitination and proteasomal degradation of AID. 
Consequently, HSP90 inhibition results in a proportional reduction in antibody gene 
diversification and off-target mutation. This evolutionarily conserved regulatory mechanism 
determines the functional steady-state levels of AID in normal B cells and B cell lymphoma 
lines. Thus, HSP90 assists AID-mediated antibody diversification by stabilizing AID. HSP90 
inhibition provides the first pharmacological means to down-regulate AID expression and 
activity, which could be relevant for therapy of some lymphomas and leukemias. 
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2.3. Introduction 
Antibody genes are first rearranged by V(D)J recombination during B lymphocyte 
development and then further diversified in the periphery after encountering cognate Ag. The 
latter is achieved by the mechanism of somatic hypermutation (SHM), which introduces 
random mutations over the exon that encodes the antibody variable region. Coupled to 
phenotypic selection during the GC reaction, SHM results in the overall maturation of the 
antibody response. SHM is initiated by activation-induced deaminase (AID), which deaminates 
dC to dU in the Ig loci. Processing of the dU by specific DNA repair enzymes produces the full 
spectrum of SHM (Di Noia and Neuberger, 2007; Peled et al., 2008). In addition, AID also 
targets the DNA immediately preceding the constant exons that encode for the different 
antibody isotypes in the IgH locus. Processing of the dU in these switch regions leads to the 
DNA breaks necessary for class switch recombination (CSR; Stavnezer et al., 2008). 
AID being a mutator enzyme sufficient to cause cancer in transgenic models (Okazaki 
et al., 2003; Pasqualucci et al., 2008), there has been a well-deserved emphasis in studying its 
regulation. Gene expression regulation is an important step during normal B cell development, 
with AID being mostly restricted to GC B cells (Muramatsu et al., 1999; Crouch et al., 2007). 
However, AID can normally be expressed outside of the B cell compartment, the exact 
physiological relevance of which is still unclear, although it may influence the expression of 
many genes by affecting DNA methylation (Morgan et al., 2004; Macduff et al., 2009; Pauklin 
et al., 2009; Bhutani et al., 2010; Popp et al., 2010). Importantly, there is ample evidence that 
AID is expressed in a variety of human lymphomas (Greeve et al., 2003; Pasqualucci et al., 
2004) and leukemias (Albesiano et al., 2003; Feldhahn et al., 2007; Klemm et al., 
2009; Palacios et al., 2010). In fact, AID plays a role in malignant transformation by initiating 
DNA double-strand breaks at various non-Ig loci, most prominently c-Myc, which in murine 
experimental plasmacytoma, and therefore most likely also in human Burkitt’s lymphoma, 
leads to the hallmark oncogenic c-Myc–IgH chromosomal translocation (Ramiro et al., 
2004, 2006; Robbiani et al., 2008,2009). A role for AID in the etiology of diffuse large B cell 
lymphoma is also very likely (Pasqualucci et al., 2001, 2004, 2008). In chronic myeloid 
leukemia (CML), AID mutates the BCR-ABL1 oncogene, leading to resistance to the tyrosine 
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kinase inhibitor imatinib, the main therapeutic drug (Klemm et al., 2009). Moreover, AID 
expression in nonlymphoid tumors has also been shown (Endo et al., 2008). Therefore, it is 
important to understand AID posttranslational regulation, which may differ between normal 
and transformed cells and have important and varied implications in the several cell types that 
can express AID. 
Multiple mechanisms seem to contribute to restrain AID protein. Subcellular 
localization is an important step in regulating AID that also impinges on its stability because 
AID has a significantly shorter half-life in the nucleus than in the cytoplasm (Aoufouchi et al., 
2008). In steady-state, the bulk of AID is cytoplasmic as a result of the integration of three 
mechanisms: nuclear import (Patenaude et al., 2009), nuclear export (Ito et al., 2004; McBride 
et al., 2004), and cytoplasmic retention (Patenaude et al., 2009). However, it is unknown 
whether AID stability is regulated in the cytoplasm. Several studies, including the analysis of 
AID-haploinsufficient mice (Sernández et al., 2008;Takizawa et al., 2008) or mice with altered 
AID levels resulting from manipulating microRNA regulation (de Yébenes et al., 2008; Dorsett 
et al., 2008; Teng et al., 2008) or enforcing transgenic overexpression (Robbiani et al., 2009), 
have suggested that AID protein levels are limiting for and correlate with the efficiency of 
antibody diversification but also B cell lymphomagenesis. Therefore, any mechanism 
impinging on the overall AID steady-state levels is important for balancing an efficient humoral 
immune response with the associated risk of B cell transformation. 
We report the physical and functional interaction of AID with the HSP90 (heat shock 
protein 90 kD) molecular chaperone pathway. HSP90 is thought to be more selective of its 
range of substrates than other chaperones, playing a prominent role in the structural 
stabilization and functional modulation of many of its client proteins, rather than in their initial 
folding (Pratt and Toft, 2003; Whitesell and Lindquist, 2005; Pearl and Prodromou, 
2006; Picard, 2006; Wandinger et al., 2008). Indeed, the interaction with HSP90 prevents 
proteasomal degradation of AID in the cytoplasm, thereby determining the steady-state levels 
of functional AID. 
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2.4. Results 
2.4.1. AID specifically interacts with HSP90 
Immunopurification of AID-Flag/HA from cell extracts of Ramos B cells produced a 
complex but reproducible pattern of copurifying proteins (Fig. 2.1 A). Of note, we used a stable 
cell line expressing only 2.5-fold the amount of endogenous AID (Fig. S2.1 A). After 
identification of the associated proteins by mass spectrometry, we noticed the presence of 
several members of the HSP90 molecular chaperone pathway (Whitesell and Lindquist, 2005), 
including the two major isoforms of HSP90 (α and β), the HSP90 cochaperone AHA-1, 
HSP70/HSC70, and one HSP40 cochaperone (DnaJa1), as well as several proteasome subunits 
(Table 2.1). The HSP90, HSP70, and HSP40 proteins are known to cooperate in a 
multichaperone system (Picard, 2006; Wandinger et al., 2008). Given the importance of HSP90 
in regulating the function of many signal transduction and nucleocytoplasmic shuttling 
proteins, we decided to further explore this interaction. We confirmed the binding of AID to 
endogenous HSP90 by coimmunoprecipitation of AID-GFP from stably expressing Ramos 
cells (Fig. 2.1 B). We also confirmed that AID coimmunoprecipitated similarly with tagged 
versions of HSP90-α and HSP90-β (Fig. 2.1 C). Both isoforms are constitutively expressed in 
the B cell lines we used, although HSP90-β is the predominant form in resting primary mouse 
B cells, with HSP90-α increasing after cytokine activation (Fig. S2.1, B and C). These results 
are in keeping with various studies indicating that mitogenic and cytokine stimuli up-regulate 
HSP90-α, whereas HSP90-β is constitutively expressed (Hansen et al., 1991; Metz et al., 
1996; Csermely et al., 1998;Sreedhar et al., 2004). HSP90-α and HSP90-β share ∼90% 
similarity, and although they may have some nonoverlapping roles, for most functions, they are 
largely equivalent (Csermely et al., 1998; Sreedhar et al., 2004). 
We then characterized the interaction between HSP90 and AID. Notably, the AID 
paralogue proteins APOBEC1, APOBEC2 (A2), and APOBEC3G, which share ∼50–60% 
similarity with AID (Conticello et al., 2005), did not coimmunoprecipitate with Myc–HSP90-β 
(Fig. 2.1 D). This is consistent with a recent study showing that zebra fish A2 interacts with the  
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Figure 2.1. AID interacts with HSP90. (A) Ramos B cells stably expressing AID-Flag/HA 
were subjected to consecutive immunoprecipitation with anti-Flag and anti-HA. Precipitated 
material was eluted with the specific peptides and separated by SDS-PAGE. Proteins were 
identified by mass spectrometry of tryptic peptides. The proteins relevant to this work are 
indicated next to the bands from where they were identified. One of two independent 
experiments is shown. MMM, molecular mass marker. (B) GFP and AID-GFP were 
immunoprecipitated from extracts of stably expressing Ramos cells and analyzed by Western 
blot (WB) to detect coimmunoprecipitated endogenous HSP90. One of three independent 
experiments is shown. (C) APOBEC2 (A2)-GFP and AID-GFP were immunoprecipitated with 
anti-GFP from transiently expressing HEK293T cells cotransfected with Flag–HSP90-α and/or 
Myc–HSP90-β. Immunoprecipitates (IP) were probed with anti-Flag and anti-Myc in Western 
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blots. The filters were then probed with anti-HSP90, which recognizes both isoforms, to verify 
that the overall HSP90 level was similar after transfection. Anti-GFP confirmed similar 
immunoprecipitation of the bait. One of two independent experiments is shown. (D) Lysates 
from HEK293T cells cotransfected with Myc–HSP90-β and Flag-tagged versions of AID or the 
indicated APOBECs or vector alone (V) were immunoprecipitated using anti-Flag and 
analyzed by Western blot with anti-Myc to verify the presence of HSP90-β and anti-Flag to 
confirm the immunoprecipitation of the baits. One of four independent experiments is shown. 
(E) Lysates from HEK293T cells cotransfected with Myc–HSP90-β and either vector only (V) 
or Flag-tagged AID, A2, or AID-A2 chimeras (#1–5, described below in schematic form) were 
immunoprecipitated with anti-Flag. Immunoprecipitates were analyzed by Western blot using 
anti-Myc and anti-Flag antibodies. One of three independent experiments is shown. In 
schematics, horizontal green lines between dashed lines identify the fragments of AID replaced 
by the homologous region of A2 in each construct. Based on experimental A2 (Prochnow et al., 
2007) and predicted AID (Patenaude et al., 2009) secondary structures, blue rectangles 
indicate α helixes, and red arrows indicate β sheets. Where indicated, aliquots (5%) of the 
whole cell lysates were probed to control for expression. 
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Table 2.1. Proteins copurifying with AID-Flag-HA from Ramos B cells identified by mass 
spectrometry 
HUGO name Mascot 
Scorea 
Coverage 
(%) 
Description 
HSP90AB1* 2178 44 Heat shock 90 kDa protein 1, beta 
 300 8  
HSP90AA1* 1668 35 Heat shock 90 kDa protein 1, alpha 
 151 6  
HSPA8 1338 39 Heat shock 70 kDa protein 8 isoform 1 
HSPA6 327 8 Heat shock 70 kDa protein B 
AHSA1* 81 3 AHA1, Activator of heat shock 90kDa  
 27 9 protein ATPase homolog 1 
DNAJA1 212 26 HSP40 homolog, subfamily A, member 1 
PSMD2 242 14 Proteasome 26S non-ATPase subunit 2 
PSMD1 105 2 Proteasome 26S non-ATPase subunit 1 
PSMD6* 105 5 Proteasome 26S non-ATPase subunit 6 
 46 6  
PSMC2 75 3 Proteasome 26S ATPase subunit 2 
* Proteins identified in two independent experiments. 
A threshold Mascot score of 50 was used as cut-off, indicating a 95% confidence of being a true 
identification. For AHSA1 in the second experiment the MS profile was manually examined to 
confirm the reliability of the observation. 
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chaperone Unc45b but not with HSP90-α (Etard et al., 2010). The region of AID interacting 
with HSP90-β could be  mapped  to the  N-terminal half of the molecule by using AID-A2 
chimeric proteins (Fig. 2.1 E). An AID mutant showing impaired oligomerization (Patenaude et 
al., 2009) was still recognized by HSP90 (Fig. S2.1D). Phosphorylation can modulate client 
binding to HSP90 (Dickey et al., 2007), but the known protein kinase A (PKA) sites within the 
N-terminal region of AID, Thr27, and Ser38, were not essential for the interaction (Fig. S2.1 
D). These results suggest that HSP90 specifically binds to AID by its N-terminal region in an 
oligomerization- and phosphorylation-independent fashion. 
 
2.4.2. HSP90 maintains the steady-state level of AID 
The chaperone activity of HSP90 depends on an ATP hydrolysis cycle, which is 
inhibited by geldanamycin (GA) and its derivatives, like 17-allylamino-17-
demethoxygeldanamycin (17-AAG; Prodromou et al., 1997; Stebbins et al., 1997; Panaretou et 
al., 1998; Young and Hartl, 2000). Treating Ramos cells with GA prevented the interaction of 
AID-GFP with HSP90, as indicated by the lack of coimmunoprecipitation (Fig. 2.2 A). More 
importantly, treatment of human, chicken, and mouse B cell lymphoma lines with GA caused a 
clear reduction in the levels of endogenous AID at 12 and 24 h. We probed for the known 
HSP90 client kinase LCK, which was also reduced, as positive control (Giannini and 
Bijlmakers, 2004). Other enzymes involved in antibody diversification, including UNG (uracil-
DNA N-glycosylase) and MSH6, were not sensitive to HSP90 inhibition (Fig. 2.2 B). Finally, 
endogenous AID in stimulated human primary B cells from multiple donors was also sensitive 
to HSP90 inhibition (Fig. 2.2 C), confirming that the functional interaction between AID and 
HSP90 is physiologically relevant. 
To use a more sensitive assay to monitor AID decay at shorter times and to be able to 
compare AID variants, we established stable Ramos transfectants expressing various AID-GFP 
constructs from a heterologous promoter. The levels of AID-GFP could thus be monitored over 
time and accurately quantified by flow cytometry. We confirmed that AID-GFP but not GFP 
was destabilized upon HSP90 inhibition in these cell lines with kinetics consistent to that                                                             
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Figure 2.2. HSP90 actively maintains the steady-state levels of AID. (A) Ramos cells stably 
expressing AID-GFP or GFP alone were treated with 2 µM GA (+) or DMSO (−) for 2 h. Anti-
GFP immunoprecipitates (IP) were fractionated on SDS-PAGE, and blots were probed with 
anti-HSP90 and anti-GFP. Aliquots (5%) of the whole cell lysates were probed to control for 
HSP90 expression. One of two independent experiments is shown. (B) Human Ramos, mouse 
CH12F3-2 (pretreated for 16 h with IL-4, TGF-β1, and anti-CD40 to induce AID expression), 
and chicken DT40 B cell lines were treated with 2 µM GA (+) or DMSO (−) and harvested at 
the indicated time points after GA. The expression level of the indicated proteins was analyzed 
by Western blot (WB) in total or nuclear (where indicated) extracts. Identical effect was 
observed with 17-AAG in all cell lines (not depicted). Representative panels from one of two or 
three independent experiments (depending on the antibody) are shown. (C) Resting B cells 
purified from blood of three donors were activated with IL-4 and anti-CD40 and 4 d later 
treated and analyzed as in B except that the HSP90 inhibitor 17-AAG (+) was used instead of 
GA. (D) Ramos cells stably expressing GFP, AID-GFP, or chimeras AID-A2 #1 or #2 were 
treated in triplicate with 2 µM GA or DMSO. The GFP mean fluorescence intensity (MFI) was 
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monitored by flow cytometry and normalized to t0 = 100%. MFI ± SD is plotted over time. One 
of three independent experiments is shown (**, P < 0.01). (E) AID-GFP was monitored as in D 
except that Ramos cells were pretreated with 100 ng/ml CHX for 30 min before HSP90 
inhibition. One of five independent experiments is shown (**, P < 0.01). (F) Purified naive B 
cells from Aicda−/− mice were activated and retrovirally transduced with mouse AID-GFP or 
GFP control. Cells were analyzed as in D 2 d after transduction. One of three independent 
experiments is shown (**, P < 0.01) 
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observed for endogenous AID (Fig. 2.2 D). This indicated a direct action on AID protein rather 
than on Aicda transcription, which was confirmed by Northern blot of Aicda in Ramos cells 
(unpublished data). As would be expected, the AID-A2 chimeras that did not interact with 
HSP90 were insensitive to GA treatment (Fig. 2.2 D). Treatments inhibiting or exacerbating 
PKA activity had no effect on the sensitivity of AID-GFP to GA, further suggesting that these 
two pathways are not connected (Fig. S2.2). We then measured the decay kinetics of AID-GFP 
after pretreating the cells with cycloheximide (CHX) so as to follow the pool of AID that had 
already been synthesized and not the nascent AID that might be more sensitive to folding 
requirements. CHX caused the expected decay of AID-GFP (compare control DMSO-treated 
AID-GFP levels in Fig. 2.2, D vs. E), which was clearly accelerated by GA (Fig. 2.2 E), 
indicating a role for HSP90 in stabilizing fully synthesized AID. We confirmed that both mouse 
and human AID-GFP were similarly sensitive to HSP90 inhibition when expressed in AID-
deficient mouse primary splenic B cells (Fig. 2.2 F and not depicted), thus ruling out any effect 
of the transformed cell environment of Ramos on our observations. We conclude that 
functional HSP90 is necessary to stabilize and maintain the steady-state levels of AID in vivo 
in primary as well as in transformed cells. 
 
2.4.3. HSP90 protects cytoplasmic AID from being degraded 
Binding to HSP90 can regulate protein subcellular localization (DeFranco, 1999;Galigniana et 
al., 2004). Indeed, our results could be explained by increased AID nuclear import after HSP90 
inhibition and therefore AID destabilization in the nucleus (Aoufouchi et al., 2008). However, 
we did not observe any changes in AID localization after HSP90 inhibition, even when 
combined with a proteasome inhibitor to prevent degradation of nuclear AID (Fig. S2.3). So, 
we compared the effects on AID-GFP of inhibiting HSP90 versus inhibiting nuclear export 
with leptomycin B (LMB), which enriches AID-GFP in the nucleus (Ito et al., 2004; McBride 
et al., 2004), in the stable Ramos transfectants. The kinetics of AID-GFP decay after GA or 
LMB treatment were different (Fig. 2.3 A). Combined GA and LMB treatment showed an 
apparently additive effect (Fig. 2.3 A). Similar results were obtained using DT40 and HeLa 
cells stably expressing AID-GFP (Fig. S2.4). The lack of detectable nuclear translocation of 
AID after HSP90 inhibition, together with the different decay kinetics after GA and LMB, 
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raised the possibility that AID degradation after each of these treatments happened in different 
compartments and therefore would involve different pathways. To test this, we used Ramos 
cells expressing GFP-AID because the N-terminal GFP fusion blocks nuclear import of AID 
(Patenaude et al., 2009) but not its binding to HSP90 (Fig. S2.1E). Consistently, with its 
exclusively cytoplasmic localization, GFP-AID did not respond to LMB, but it was still 
sensitive to GA (Fig. 2.3 B). HSP90 clients are in dynamic equilibrium with proteasomal 
degradation (Pearl and Prodromou, 2006). Indeed, the proteasome inhibitor MG132 prevented 
the HSP90 inhibition–induced degradation of AID-GFP as well as of endogenous AID in 
Ramos and DT40 cells (Fig. 2.3, C and D; and Fig. S2.4 A). We obtained identical results using 
lactacystin, another proteasome inhibitor (unpublished data). A reproducible ∼3.5-fold increase 
in AID polyubiquitylation was observed in Ramos and primary mouse B cells after combined 
HSP90 and proteasome inhibition versus inhibiting only the proteasome (Fig. 2.3 E). This was 
not particular to B cells because it was also true for AID-GFP in stably transfected HeLa cells 
(unpublished data). These experiments show that HSP90 stabilizes cytoplasmic AID by 
protecting it from proteasomal degradation. 
The E3 Ub ligase CHIP (C terminus of HSC70-interacting protein) is physically 
associated with HSP90 and triages many HSP90 clients (McDonough and Patterson, 2003). Of 
note, CHIP is constitutively expressed in Ramos and induced upon activation in primary mouse 
B cells (Fig. S2.1, B and C). Furthermore, CHIP coimmunoprecipitated with AID-GFP from 
extracts of stably transfected HeLa cells (Fig. 2.4 A). The interaction was only apparent when 
the cells were pretreated with a proteasome inhibitor, which allows the accumulation of this 
rapid turn over interaction (Li et al., 2004). We reasoned that if HSP90 was normally 
stabilizing AID in B cells, the overexpression of CHIP could reduce AID levels by shifting the 
equilibrium of the pathway from stabilization to degradation. Indeed, all subclones from three 
independent transfectants of Ramos B cells overexpressing Myc-CHIP showed a significantly 
reduced steady-state level of AID (Fig. 2.4, B and C) but not of ATM (ataxia telangiectasia 
mutated), which is not an HSP90 client. Altogether, these results indicate that cytoplasmic AID  
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Figure 2.3. Cytoplasmic ubiquitination and proteasomal degradation of AID after HSP90 
inhibition. (A) Ramos cells stably expressing AID-GFP were treated in triplicate with DMSO, 
2 µM GA, and/or 50 ng/ml LMB, and the GFP signal was monitored over time by flow 
cytometry. The MFI normalized to t0 = 100% ± SD is plotted for each treatment (**, P < 0.01). 
One of five independent experiments is shown. (B) Ramos cells stably expressing GFP-AID, 
which is completely impaired for nuclear import (Patenaude et al., 2009), were analyzed as in 
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A. One of three independent experiments is shown. (C) Ramos cells stably expressing AID-GFP 
were pretreated or not for 30 min with 10 µM MG132 before adding DMSO or 2 µM 17-AAG 
and analyzed as in A (**, P < 0.01). One of five independent experiments is shown. (D) Human 
Ramos and chicken DT40 B cell lines were treated with 2 µM GA. Where indicated, 10 µM 
MG132 was added only during the last 12 h of incubation to avoid excessive cell death. Cells 
were harvested at different time points, lysed, and analyzed by Western blot (WB). One of two 
independent experiments is shown for each cell line. (E) Ramos B cells stably expressing 
human AID-GFP or primary mouse B cells transduced with mouse AID-GFP were pretreated 
with 10 µM MG132 for 30 min before a d ditio n o r n o t of 2 µM GA for 5  h .  Anti-GFP 
immunoprecipitates (IP) were analyzed by Western blot using anti-ubiquitin (Ub) and anti-
GFP. Polyubiquitinated AID was quantified by densitometry, and the relative means ± SD were 
plotted for three independent experiments for each cell type. 
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Figure 2.4. The HSP90-associated E3 ubiquitin ligase CHIP can destabilize AID. (A) HeLa 
cells stably expressing AID-GFP were transfected with Myc-CHIP and 48 h later treated for 5 
h with DMSO (−), 2 µM GA, 50 ng/ml LMB, and/or 10 µM MG132 (30 -min pretreatment) in 
the indicated combinations. Anti-GFP immunoprecipitates (IP) were analyzed by Western blot 
(WB) with anti-GFP and anti-Myc. Aliquots (5%) of the total cell lysates were used to control 
for Myc-CHIP expression. One of two independent experiments is shown. (B) Endogenous AID 
was analyzed by Western blot in single cell subclones from untransfected control or three 
independent Myc-CHIP Ramos transfectants (CL11, CL24, and CL25) after expansion. ATM 
was used as an HSP90-independent control, antiactin as loading control, and anti-Myc to 
confirm the expression of CHIP. Three representative subclones from each transfectant are 
shown. The vertical black line indicates that intervening lanes have been spliced out. (C) AID 
protein levels in all control or Myc-CHIP Ramos subclones (distinguished by different symbols) 
were estimated from nonsaturated Western blots. The signal was normalized to each 
corresponding actin signal obtained from equivalent exposures and plotted. Median values are 
indicated (**, P < 0.01).  
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requires constant stabilization by HSP90 and that altering the balance of this reaction, either by 
inhibiting HSP90 or favoring the degradative side of this pathway through CHIP 
overexpression, leads to greatly diminished AID protein levels through proteasomal 
degradation in the cytoplasm. 
 
2.4.4. Inhibition of HSP90 results in reduced antibody diversification 
We first used the chicken B cell lymphoma line DT40 to monitor AID-dependent 
antibody diversification by gene conversion. The frequency of Ig gene conversion is estimated 
by using a DT40 line with a frameshift mutation in the IgVλ gene that prevents surface IgM 
expression. Some gene conversion events correct this frameshift, restoring IgM expression. The 
median percentage of IgM+ cells generated during expansion of several initially 
IgM− populations is proportional to the rate of Ig gene conversion (Arakawa et al., 2002). The 
problem is that HSP90 is essential for eukaryotic cells (Borkovich et al., 1989;Cutforth and 
Rubin, 1994), which precludes its genetic ablation or complete inhibition. However, we 
observed that AID decay after HSP90 inhibition was dose dependent (Fig. S2.4 C for GA and 
not depicted for 17-AAG). We used 17-AAG for these assays because we found it to be less 
toxic than GA for lymphocytes (unpublished data). Low doses of 17-AAG had minimal impact 
on DT40 cell growth but still caused a robust decrease in AID protein levels (Fig. 2.5 A). This 
partial reduction in AID levels was proportional to a reduction in Ig gene conversion (Fig. 2.5 
A). In similar experiments using a DT40 line that diversifies the IgVλ by SHM (Arakawa et al., 
2004), we could also confirm a reduction in SHM (this time by monitoring the appearance of 
sIgM-loss cells from originally sIgM+populations but also by direct IgVλ sequencing) that was 
proportional to the decrease in AID protein levels (Fig. 2.5, B and C). We then analyzed the 
effect of HSP90 inhibition on CSR by using the mouse CH12F3-2 cell line, which efficiently 
switches from IgM to IgA after cytokine stimulation (Nakamura et al., 1996). Because these 
assays take place over a few days, we used CFSE staining to monitor cell proliferation. Thus, 
we could compare the efficiency of switching between cells that have undergone the same      
number of cell divisions, accounting for any cell growth defect that continuous exposure to 17-
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AAG could cause. There was a clear and dose-dependent reduction in CSR caused by 17-AAG, 
overall and for each cell division tested (Fig. 2.5 D). Alternatively, we performed a 12-h 
treatment with higher doses of 17-AAG, after which the drug was removed (Fig. 2.6 A). A 
drastic reduction in CSR to IgA was observed when the CH12F3-2 cells were treated with 17-
AAG at day 1 after stimulation, coincident with the time when the peak of AID protein was 
observed (Fig. 2.6, B and C). As would be expected, 17-AAG treatment at day 2 had a less but 
still statistically significant effect on CSR. Importantly, we obtained identical results in 
switching assays using normal mouse splenic B cells (Fig. 2.6 D). A drastic decrease of CSR to 
IgG1 was observed when cells were treated with 17-AAG at day 1 after stimulation. This 
higher dose of 17-AAG delayed growth of primary B cells, but the effect on CSR was 
nevertheless very clear when comparing the efficiency of switching per cell division. Again, 
treating the cells at day 2 after stimulation caused a smaller but statistically significant effect. 
As expected, treating the cells at day 3 had no effect on the efficiency of CSR measured at day 
4 (unpublished data). We conclude that cytoplasmic AID degradation after HSP90 inhibition 
has a direct and proportional effect on all antibody diversification mechanisms. 
 
2.4.5. HSP90 inhibition prevents off-target mutation by AID 
We assayed AID off-target mutation using the recently described role of AID in 
generating resistance of the oncogenic kinase BCR-ABL1 to the drug imatinib in CML cells 
(Klemm et al., 2009). We transduced the BCR-ABL1+ K562 cell line with AID-ires-GFP or 
GFP control retroviruses and, for each construct, prepared mixed populations with uninfected 
(GFP−) cells at a defined ratio. Mutations in BCR-ABL1 that confer resistance are selected by 
culturing the cells in the presence of imatinib. This is readily observed by flow cytometry as an 
increased ratio of GFP+/GFP− cells over time. Indeed, we observed a higher proportion of 
GFP+ cells within 2–3 wk only in AID-expressing cells that were growing in the presence of 
imatinib (Fig. 2.7 A). This was AID dependent as it was not observed in GFP control cultures, 
and the imatinib-resistant cells appeared earlier in cultures expressing higher levels of AID 
(Fig. 2.7, A and B). More relevant to our purpose, the AID-dependent change in the 
69 
 
 
 
 
Figure 2.5. Reduced antibody diversification in chicken and mouse B cells chronically 
treated with HSP90 inhibitors. (A) The rate of Ig gene conversion in DT40 cells was estimated 
from the proportion of sIgM-gain cells arising from sIgM− populations after 3 wk of expansion 
in the presence of DMSO (Ctrl) or two different concentrations of 17-AAG. The proportion of 
sIgM+ cells for each population and the median values are indicated (left). The level of AID 
protein was quantified by densitometry from nonsaturated Western blots for each population at 
the end of the experiment and normalized to actin levels. Mean ± SD values for all populations 
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grown in each condition are plotted (middle). The effect of 17-AAG on DT40 growth was 
monitored by calculating the total number of cells in a culture originating from 105 cells 
(right). Mean ± SD of triplicate cultures are plotted over time. (B) SHM was monitored in 
analogous experiments to A except that a sIgM+ ψV− AIDR DT40 cell line, which cannot 
undergo gene conversion and instead uses SHM to diversify the Ig genes, was used. IgM-loss 
cells arise as a consequence of SHM with a certain frequency, and so the proportion of sIgM-
loss cells arising over time provides an estimate of SHM rate (Arakawa et al., 2004). (C) DNA 
was extracted from control or 0.1 µM 17-AAG–treated unsorted cultures from B after equal 
expansion. The IgVλ was PCR amplified and sequenced. The fraction of sequences containing 
the indicated number of mutations is plotted in the pie chart with the number of sequences 
analyzed indicated in the center. The calculated mutation frequency (mutations/base pair) is 
indicated under each pie chart. (D) CH12F3-2 mouse B cells stimulated with IL-4, TGF-β1, 
and agonist anti-CD40 were cultured with DMSO (Ctrl) or the indicated concentrations of 17-
AAG. The cells were stained with CFSE before activation to follow cell divisions. 
Representative plots of the proportion of IgA+ cells in each population after 3 d (left) and 
CFSE profiles (middle) are shown. For each cell division, the proportion of sIgA+ cells was 
calculated, and the results from four independent experiments are summarized in the plot as the 
mean ± SD values (right). In all panels: *, P < 0.05; **, P < 0.01. 
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Figure 2.6. Acute inhibition of HSP90 impairs CSR in mouse B cells. (A) Scheme of the 
experimental strategy fort treatment of CH12F3-2 B cells or primary naive mouse splenic B 
cells. D, day; FC, flow cytometry. (B) Kinetics of AID protein expression in CH12F3-2 mouse 
B cells determined by Western blot (WB) at different times after stimulation. One of two 
independent experiments is shown. (C) CH12F3-2 B cells were stained with CFSE and 
stimulated with IL-4, TGF-β1, and anti-CD40 to switch to IgA. Either at day 1 or 2 after 
activation, the cells were treated for 12 h with 2 µM 17-AAG and then returned to normal 
medium. The proportion of sIgA+ cells per cell division determined by flow cytometry is plotted 
under each cell division in the corresponding CFSE plot for a representative experiment (left). 
The mean proportions of sIgA+ cells for each cell division ± SD from four independent 
experiments are plotted (right; **, P < 0.01). (D) Purified mouse naive splenic B cells were 
loaded with CFSE and stimulated with IL-4 and LPS to induce switching to IgG1. Either at day 
1 or 2 after activation, the cells were treated with 17-AAG and then returned to normal 
medium. The proportion of sIgG1+ cells per cell division was determined and presented as in 
C. Data from one representative mouse are shown (left), and pooled data from five mice are 
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plotted (right). To be able to compare all the mice accounting for the inter assay variability, 
data points were normalized with the percentage of IgG1+ cells in cell division 3 of the control 
set as 1 (*, P < 0.05; **, P < 0.01). Ctrl, control. 
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GFP+/GFP− ratio was fully prevented by a very low dose of 17-AAG (Fig. 2.7 A). Treatment 
with this dose of 17-AAG visibly reduced AID but not BCR-ABL1 protein levels by day 7 
(Fig. 2.7 C). We confirmed that 17-AAG prevented the AID-mediated increase in imatinib 
IC50 (Fig. 2.7 D). We also directly checked for mutations by sequencing BCR-ABL1. An 
increase in point mutations (many of them known to induce imatinib resistance; Klemm et al., 
2009) could be detected in AID-expressing K562 cells growing in imatinib. In contrast, the 
mutation level in AID-expressing cultures that were jointly treated with imatinib and 17-AAG 
was indistinguishable from the GFP control (Fig. 2.7 E and Table 2.2). 
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Figure 2.7. HSP90 inhibition reduces AID off-target mutations. (A) BCR-ABL1+ K562 cells 
were transduced with GFP control (insets) or AID-ires-GFP retroviral vectors. Mixed 
populations of transduced (GFP+) and uninfected (GFP−) cells were cultured in the presence of 
DMSO, 2 µM imatinib, 2 µM imatinib plus 0.1 µM 17-AAG, or 0.1 µM 17-AAG, and the 
proportion of GFP+ cells was determined periodically by flow cytometry. Data are plotted as 
the mean GFP+/GFP− ratio from triplicate populations ± SD, relative to the initial ratio set as 
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1. Two independent experiments are shown differing only in AID protein level expression from 
having or not a consensus Kozak sequence before the AID start codon. (B) Western blot (WB) 
of parental K562 cells (−) and sorted GFP + populations transduced with pMX-AID-ires-GFP 
vectors differing only in the presence of the Kozak sequence. AID was detected using anti-AID, 
and antiactin was used as loading control. (C) Sorted GFP+ cells transduced or not with pMX-
KozakAID-ires-GFP vectors as in A were cultured with 0.1 µM 17-AAG for the indicated times. 
The levels of the indicated proteins were analyzed by Western blot in total extracts using anti-
AID and anti-ABL1. One of two independent experiments is shown. (D) GFP+ K562 
populations were sorted after expansion from A. Cell viability after culture for 2 d with 
different concentrations of imatinib was determined using an MTS reduction colorimetric 
assay. The relative mean OD at 490 nm ± SEM of duplicate wells (untreated cells = 100%) is 
plotted for each concentration for cell populations transduced with pMXs-KozakAID-ires-GFP 
that had been treated in A with DMSO, imatinib, imatinib plus 0.1 µM 17-AAG, or 17-AAG. 
The parental K562 cells were included in this assay. One of two independent experiments is 
shown. (E) BCR-ABL1 (exon 13 of BCR and exon 9 of ABL1) was PCR amplified from cells 
expressing GFP control or AID-ires-GFP and expanded under the indicated conditions. 
Mutations, determined relative to the consensus of all sequences, are indicated on schemes of 
the ∼700-bp ABL1 region that was directly sequenced from the PCR product. Thin vertical 
bars represent mutations at A:T bp, whereas thick bars represent mutations at C:G pairs. 
Mutations previously described to confer imatinib resistance (Branford and Hughes, 2006) are 
identified by an asterisk and indicated below the sequence stack.  
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Table 2.2. BCR-ABL1 mutations in K562 cells  
 
  
The BCR-ABL1 kinase domain (exon 13 of BCR and exon 9 of ABL1) was PCR amplified 
from single cell clones and a fragment of ~700 bp in the ABL1 domain was directly sequenced. 
The number to the left of the mutation indicates the mutated position respect to the ABL1 open 
reading frame. The mutated base is indicated underlined within the affected codon. Mutations 
at C:G pairs and amino acid substitutions previously described to confer clinical imatinib 
resistance are highlighted in bold. 
  
Construct 
transduced Treatment 
BCR-ABL1 sequence 
analysis 
Number of 
clones/total 
Amino 
acid 
change 
GFP Imatinib Unmutated 6/8 No changes 
  894 CTA to CTG  1/8 Silent 
  1062 CTA to CTG  1/8 Silent 
AID-ires-GFP Control Unmutated 7/9 No changes 
  894 CTA to CTG  1/9 Silent 
  1062 CTA to CTG  1/9 Silent 
AID-ires-GFP Imatinib Unmutated 2/10 No changes 
  894 CTA to CTG  3/10 Silent 
  944 ACT to ATT 4/10 T315I 
  1062 CTA to CTG  2/10 Silent 
  1334/1335 CGT to CTG 1/10 R445L 
  1356 CTA to CTG  2/10 Silent 
  1375 GAG to AAG 3/10 E459K 
AID-ires-GFP Imatinib + 17-AAG Unmutated 6/9 
No 
changes 
  894 CTA to CTG  1/9 Silent 
  1062 CTA to CTG  2/9 Silent 
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2.5. Discussion 
We identify and characterize herein the constitutive stabilization of AID by the HSP90 
chaperone pathway. Our results show that HSP90 largely determines the overall steady-state 
levels of functional AID protein. Although HSP90 may also contribute to the biogenesis of 
AID, its key function appears to be the stabilization of the protein. This is well in accordance 
with the major role of HSP90 in protecting the functional competence of many of its clients, 
beyond simply assisting with their de novo folding (Jakob et al., 1995; Nathan et al., 
1997; Whitesell and Lindquist, 2005; Pearl and Prodromou, 2006;Picard, 2006; Wandinger et 
al., 2008). This is a new mechanism positively regulating AID-mediated antibody 
diversification that seems evolutionarily conserved, as we find it in chicken, mouse, and human 
B cells. 
The molecular details of AID stabilization in the cytoplasm are likely incomplete 
because many proteins modulate the HSP90 pathway (Young et al., 2004; Wandinger et al., 
2008). However, our experimental evidence, together with the identification of members of the 
HSP90 chaperone pathway that consistently copurified with AID (Table 2.1), suggests a 
working model in which AID would be regulated similarly to the steroid hormone receptors 
(Picard, 2006). These receptors first form an early complex with the HSP70/HSP40 
chaperone/cochaperone, to which HSP90 and other factors are then recruited. Consecutive 
cycles of chaperoning are in dynamic equilibrium with proteasomal degradation unless the 
receptor is stabilized by ligand binding and translocates to the nucleus (Whitesell and 
Lindquist, 2005; Picard, 2006). Consistent with this model, we found HSPA8, the major 
constitutively expressed form of HSP70, among the AID-Flag/HA–interacting partners in 
Ramos B cells. The same isoform has been found using tagged AID expressed in HEK293 cells 
(Wu et al., 2005). HSP40 proteins are the first agents in the HSP70/HSP90 chaperone pathway 
(Kimura et al., 1995; Hernández et al., 2002). We identified and have confirmed the functional 
interaction of AID with a defined subset of HSP40 proteins, which will be reported elsewhere 
(unpublished data). AID stabilization requires the ATP hydrolysis cycle of HSP90, and the 
cochaperone AHA-1, which stimulates the ATPase activity of HSP90 (Panaretou et al., 
2002; Lotz et al., 2003), also copurified with AID. As is the case for steroid hormone receptors, 
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we show that cytoplasmic AID exists in a dynamic equilibrium between stabilization and 
proteasomal degradation. Indeed, inhibiting HSP90 or overexpressing the HSP90-associated 
ubiquitin ligase CHIP (Connell et al., 2001; McDonough and Patterson, 2003) can shift the 
balance toward AID degradation. Stabilization seems to be the predominant pathway because 
simultaneous inhibition of the proteasome and HSP90 leads to the accumulation of much higher 
levels of polyubiquitinated AID than only proteasome inhibition. However, it remains possible 
that the destabilizing side of this pathway contributes to limit AID levels, which we are 
exploring. It is interesting that AID seems to be uniquely dependent on HSP90 when compared 
with its paralogue proteins, the APOBEC family. The intrinsic instability of uncomplexed AID 
probably helps to limit its mutagenic potential. This fits nicely with a study showing that the 
half-life of AID is highly reduced in the nucleus compared with the cytoplasm (Aoufouchi et 
al., 2008). We speculate that AID, just as the steroid hormone receptors (Whitesell and 
Lindquist, 2005; Picard, 2006), might undergo some conformational change to dissociate from 
HSP90. An attractive possibility is that oligomerization stabilizes AID, thus emancipating it 
from HSP90. In line with this, the HSP90-interacting domain of AID comprises most of its 
proposed dimerization interface (Prochnow et al., 2007; Patenaude et al., 2009), and an 
oligomerization-deficient AID mutant can still bind to HSP90. We have proposed that 
dimerization/oligomerization of AID is important for its cytoplasmic retention and nuclear 
import (Patenaude et al., 2009). However, at variance with the estrogen receptor, HSP90 does 
not seem to play a major role in AID cytoplasmic retention. We must hypothesize that AID 
forms part of another cytoplasmic complex that fulfills this role. This HSP90-independent 
fraction of AID might explain the slower kinetics of AID degradation in Ramos cells after 
HSP90 inhibition compared with other HSP90 clients such as LCK (Giannini and Bijlmakers, 
2004). 
The interaction of AID with HSP90 has major functional consequences. HSP90 
stabilizes many proteins, and part of the effect observed on antibody diversification after 
inhibiting HSP90 could formally be indirect. However, there is a negative dose–response 
relationship between AID protein levels and HSP90 inhibition, which correlates with a 
proportional decrease in antibody diversification. This observation argues for a direct effect. 
Furthermore, HSP90 inhibition affected all AID-dependent pathways: SHM, CSR, and Ig gene 
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conversion as well as off-target mutation. All of these pathways are initiated by DNA 
deamination by AID followed by uracil processing by either UNG or MSH2/MSH6, which 
were not affected by HSP90 inhibition. Downstream from there, these pathways diverge (i.e., 
translesion synthesis for mutations, homologous recombination for gene conversion, and 
nonhomologous end joining for CSR), so a direct effect on AID is much more likely than an 
independent effect on each of these pathways. By stabilizing the bulk of AID, the HSP90 
pathway determines the availability of functional AID. Indeed, AID-catalyzed DNA 
deamination at the Ig loci was directly proportional to the overall level of AID protein 
remaining after HSP90 inhibition. This is in agreement with the previously reported AID dose 
effect on the efficiency of antibody diversification (de Yébenes et al., 2008; Dorsett et al., 
2008; Sernández et al., 2008; Takizawa et al., 2008; Teng et al., 2008). Together with our 
findings, these observations suggest that the ratio of nuclear to cytoplasmic AID is constant. 
Thus, decreasing the overall level of AID would lead to a proportional decrease in the nuclear 
fraction and biological activity of AID. Otherwise, if AID were particularly abundant in the 
nucleus at any stage, a 50% decrease in total AID protein caused by partial HSP90 inhibition 
(or by haploinsufficiency) would not necessarily lead to a proportional decrease in antibody 
diversification. Our work highlights the intimate relationship between the mechanisms of AID 
subcellular localization and protein stability (Aoufouchi et al., 2008; Patenaude et al., 2009). 
Finally, the HSP90-mediated mechanism stabilizing AID is operative in lymphoma-
derived cell lines as well as in cells with ectopic overexpression of AID. The relative HSP90 
dependence of AID in transformed versus normal cells remains to be studied. Nevertheless, our 
findings offer the first possibility of pharmacologically manipulating AID protein levels to 
prevent off-target mutation. We provide proof of principle that this is possible in a CML cell 
line model. A very low dose of HSP90 inhibitor completely abrogated BCR-ABL1 mutations 
and imatinib resistance. AID-generated lesions in non-Ig genes are widespread but much less 
frequent than at the Ig genes (Liu et al., 2008;Robbiani et al., 2009). Indeed, the AID-generated 
breaks in c-Myc seem to be limiting for the oncogenic c-Myc–IgH chromosomal translocations 
(Robbiani et al., 2008, 2009). Therefore, it might be possible that very low doses of HSP90 
inhibitors have a disproportionate effect on the frequency of oncogenic lesions versus antibody 
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diversification. It would be worth exploring whether the HSP90 inhibitors that are currently 
being tested in the clinic could be useful in treating those cancers in which AID contributes to 
disease progression (Matsumoto et al., 2007; Pasqualucci et al., 2008;Klemm et al., 2009).
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2.6. Materials and methods 
2.6.1. DNA constructs 
The pEGFP-N3–based (Takara Bio Inc.) expression vectors for human AID-GFP, AID 
FYRN-GFP, AID-Flag/HA, APOBEC2, and AID-APOBEC2 chimeras have been described 
previously (Patenaude et al., 2009). Rat APOBEC1 and human APOBEC3G cloned in pEGFP-
C3 as well as human AID T27A/T38A, which was subcloned into pEGFP-N3, were gifts from 
S. Conticello (Istituto Toscano Tumori, Florence, Italy; Conticello et al., 2008). To construct 
N-terminally Flag-tagged versions of APOBEC1, APOBEC2, and APOBEC3G, enhanced GFP 
(EGFP) was excised NheI–XhoI from pEGFP-C3 and replaced by the annealed 
oligonucleotides AO1 and AO2. To construct C-terminally Flag-tagged versions of some of the 
proteins, EGFP was excised EcoRI–NotI from pEGFP-N3 and replaced by the annealed 
oligonucleotides OJ215 and OJ216. AID was subcloned as an NheI–NotI fragment under the 
weaker EF1-α promoter in pEF. AID-APOBEC2 chimeras #1 and #2 were excised from 
pTrc99a (Patenaude et al., 2009) by partial digestion with NotI and EcoRI and subcloned into 
the pMXs retroviral vector. Untagged hAID in pMXs-ires-GFP has been described previously 
(Patenaude et al., 2009). Mouse AID (from R. Harris, University of Minnesota, Minneapolis, 
MN) was subcloned EcoRI and NotI into pMXs. Flag-human HSP90-α was inserted as a KpnI–
NotI fragment into pcDNA3.1. Myc-human HSP90-β in pCMV-3Tag2 was a gift of J.-.P 
Gratton (Institut de Recherches Cliniques de Montréal, Montréal, Québec, Canada). Construct 
names throughout the manuscript indicate the actual order of the fragments in fusion proteins. 
 
2.6.2. Reagents and antibodies. 
Stock aliquots of 2 mM GA, 2 mM 17-AAG, 5 mM H-89, and 25 mM forskolin (LC 
Laboratories) as well as 50 mM IBMX (3-isobutyl-1-methylxanthine; Sigma-Aldrich) were 
made in DMSO. Stocks of 5 mM MG132 (EMD) and 25 µg/ml LMB (LC Laboratories) were 
made in ethanol. CHX (Sigma-Aldrich) was freshly prepared before each experiment 100 
mg/ml in ethanol. Stock of 2 mM imatinib (Gleevec; Novartis) in PBS was a gift of T. Moroy 
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and C. Khandanpur (Institut de Recherches Cliniques de Montréal). All drugs were stored at 
−20°C protected from light. Antibodies and dilutions used were as follows: 1:3,000 anti–
EGFP–horseradish peroxidase (HRP; Miltenyi Biotec), 1:3,000 anti–Myc-HRP (Miltenyi 
Biotec), 1:3,000 anti–Flag-HRP (Sigma-Aldrich), 1:3,000 anti-HSP90 (sees both isoforms; 
BD), 1:1,000 anti–HSP90-α and 1:1,000 anti–HSP90-β (StressMarq), 1:1,000 anti-AID (Cell 
Signaling Technology) for human and chicken AID and 1:500 anti-mAID (a gift from F. Alt, 
Harvard University, Boston, MA) for mouse AID, 1:3,000 antiactin (Sigma-Aldrich), 1:1,000 
anti-monoubiquitinated and -polyubiquitinated conjugates antibody (Enzo Life Sciences, Inc.) 
for endogenous ubiquitin, 1:1,000 mAb anti-CHIP (Sigma-Aldrich), 1:2,000 anti-UNG2 
(specific for nuclear isoform; Abcam), 1:2,500 anti-MSH6 (Bethyl Laboratories, Inc.), 1:5,000 
anti-PCNA (PC-10; Abcam), 1:1,000 anti–DNA-PK (Santa Cruz Biotechnology, Inc.), 1:1,000 
anti-LCK (gift of A. Veillette, Institut de Recherches Cliniques de Montréal), and 1:1,000 anti–
c-abl (EMD). Secondary antibodies were used according to the species of the primary antibody: 
1:5,000 goat anti–mouse-HRP and 1:10,000 anti–rabbit-HRP (Dako) and 1:5,000 goat anti–rat-
HRP (Millipore). 
 
2.6.3. Mice and cell lines. 
HeLa cells stably expressing AID-GFP were generated by transfecting with pEF-AID-
EGFP and selecting with 2.5 µg/ml puromycin. Ramos cell lines stably expressing GFP, AID-
GFP, and AID-Flag/HA have been described previously (Patenaude et al., 2009). Ramos cells 
expressing Myc-CHIP were generated by transfecting with pcDNA3.1 Myc-CHIP (a gift of L. 
Petrucelli, Mayo Clinic, Jacksonville, FL) and selecting with G418. Subclones from three 
independent Myc-CHIP Ramos transfectants and controls were obtained by single cell 
deposition. Populations of Ramos cells stably expressing chimeras AID-A2 #1 or #2 and DT40 
cells stably expressing GFP or AID-GFP as well as the CML cell line K562 (a gift of T. 
Moroy) stably expressing AID-ires-GFP or GFP control were obtained by retroviral delivery of 
these genes cloned in pMXs vectors. The supernatant of HEK293T cells cotransfected with 
pMX and vectors expressing MLV Gag-Pol and VSV-G envelope (3:1:1 ratio) was used to 
infect 106 cells by spin-infection at 600g for 1 h at room temperature in the presence of 16 
µg/ml polybrene and 20 mM Hepes. Infected cells were sorted to obtain GFP+ homogeneous 
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populations. Primary B cells from Aicda−/−  mice (obtained from T. Honjo, Kyoto University, 
Sakyo-ku, Kyoto, Japan) were prepared and infected as described previously (Patenaude et al., 
2009). Experiments using mice followed the guidelines of the Canadian Council on Animal 
Care and were approved by the Animal Protection Committee at the Institut de Recherches 
Cliniques de Montréal. Primary human B cells were purified from PBMC obtained by Ficoll 
gradient centrifugation of voluntary donor blood samples. Resting B cells were isolated using a 
B cell isolation kit (Miltenyi Biotech) and activated with 5 ng/ml recombinant hIL-4 
(PeproTech) and 5 µg/ml recombinant human sCD40L. Work with human samples was 
performed according to the guidelines of the Institut de Recherches Cliniques de Montréal and 
Institut National de la Recherche Scientifique–Insitut Armand-Frappier Ethics Committees for 
Research with Human Samples. 
 
2.6.4. Identification of AID-interacting proteins. 
5 × 109 Ramos B cells expressing AID-Flag/HA or empty vector were pelleted, 
incubated on ice for 10 min, and resuspended in hypotonic buffer I (1 mM Tris-HCl, pH 7.3, 10 
mM KCl, 1.5 mM MgCl2, and β-mercaptoethanol). Cells were centrifuged at 2,500 rpm for 10 
min at 4°C and lysed by adding hypotonic buffer II (1 mM Tris-HCl, pH 7.3, 10 mM KCl, 1.5 
mM MgCl2,  1 mM tricho statin A,  5 0 µM β-mercaptoethanol, 0.5 mM PMSF, and protease 
inhibitors [Sigma-Aldrich]). The lysate was centrifuged at 3,900 rpm for 15 min at 4°C, and the 
supernatant was recentrifuged at 35,000 rpm for 1 h and dialyzed against 20 mM Tris-HCl, pH 
7.3, 20% glycerol, 100 mM KCl, 50 µM β-mercaptoethanol, and 0.5 mM PMSF. The dialyzed 
lysate was incubated with anti-Flag M2 affinity gel (Sigma-Aldrich) overnight at 4°C and then 
extensively washed and eluted using 3× Flag peptide (Sigma-Aldrich). The eluate was 
incubated with anti-HA beads (Santa Cruz Biotechnology, Inc.) overnight at 4°C and then 
washed and eluted using HA peptides (PEP-101P; Covance). Protein was concentrated using 
StrataClean Resin (Agilent Technologies) before loading on a 4–12% gradient gel (Invitrogen) 
for SDS-PAGE. The gel was silver stained, each lane was divided into 20 slices, and the slices 
were submitted for tryptic digestion and peptide identification by mass spectrometry to the 
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Institut de Recherches Cliniques de Montréal Proteomics service using a linear quadrupole IT 
Orbitrap hybrid mass spectrometer (Thermo Fisher Scientific). Peak generation and protein 
identification were performed using the MASCOT software package (Perkins et al., 1999) 
 
2.6.5. Coimmunoprecipitation and Western blot. 
HEK293T cells cotransfected at a 1:1 ratio with GFP and Myc or Flag-tagged proteins 
were homogenized in lysis buffer (20 mM Tris, pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM 
EDTA, 1% Triton X-100, and 20 mM NaF) 48 h after transfection and immunoprecipitated 
with anti-Flag M2 affinity gel as described previously (Patenaude et al., 2009). 
Immunoprecipitation of GFP-tagged proteins were performed using the μMACS GFP Isolation 
kit (Miltenyi Biotech) according to the manufacturer’s instructions. Where indicated, cells were 
treated with 10 µM MG132 for 30 min and/or 2 µM GA or DMSO for 5 h before lysis. The 
eluates and lysates were analyzed by Western blot developed with SuperSignal West Pico 
Chemiluminescent substrate (Thermo Fisher Scientific). 
 
2.6.6. AID stability assays. 
The GFP signal of cell lines expressing AID-GFP variants was measured by flow 
cytometry at various time points after the indicated treatments. Dead cells were excluded by 
propidium iodide staining. For endogenous AID, 5 × 106 Ramos, DT40, or K562 cells in 5 ml 
of culture medium were treated with GA or 17-AAG, and aliquots of 1.5–2 × 106cells were 
harvested at various time points. Alternatively, 2 × 106 CH12F3-2 cells (a gift of T. Honjo 
through A. Martin [University of Toronto, Toronto, Ontario, Canada]; Nakamura et al., 1996) 
were stimulated with 2 ng/ml recombinant human TGF-β1 (R&D Systems), 20 ng/ml 
recombinant murine IL-4 (PeproTech), and 5 µg/ml functional grade purified anti–mouse CD40 
(BD) for 16 h before GA treatment. Human primary B cells at 2 × 106/ml were treated with 2 
µM 17-AAG 72 h after activation, and aliquots of 106 cells were harvested at various time 
points. Cells were washed once with PBS and lysed in SDS-PAGE sample buffer. Lysates were 
analyzed by Western blotting. 
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2.6.7. Monitoring antibody diversification. 
AID-mediated Ig gene conversion was estimated in DT40 cre1 cells by scoring the 
frequency of sIgM-gain phenotype, which is directly proportional to the frequency of repair of 
a frameshift in the IgVλ by gene conversion (Arakawa et al., 2002). DT40 sIgM− cell 
populations were FACS sorted, and confluent cultures were grown in 24-well plates with 
HSP90 inhibitors. This method was favored over using single cell clones because of the effect 
of HSP90 inhibition on single cells growth. Cells were grown for 3 wk at 41°C in the presence 
of the inhibitors, and the surface IgM phenotype was measured by flow cytometry as described 
previously (Di Noia and Neuberger, 2004). AID-mediated SHM was monitored using the 
sIgM+ DT40 line ψV− AIDR, in which the IgV pseudogenes have been ablated (gift of H. 
Arakawa and J.-M. Buerstedde, Institute for Molecular Radiobiology, Neuherberg, 
Germany; Arakawa et al., 2004). IgM+ cell populations were FACS sorted and expanded for 3 
wk in 24-well plates, and the IgM phenotype was analyzed by flow cytometry. Mutations were 
scored as described previously (Di Noia and Neuberger, 2004) in Vλ sequences PCR amplified 
from unsorted populations after expansion. To analyze CSR, CH12F3-2 cells were 
preincubated with CFSE (Invitrogen) according to manufacturer’s instruction before activation 
with 1 ng/ml TGF-β1, 10 ng/ml recombinant murine IL-4, and 1 µg/ml functional grade 
purified anti–mouse CD40 (BD). For chronic HSP90 inhibition, 17-AAG was added 4 h after 
activation and kept for 3 d. For acute HSP90 inhibition, 17-AAG was added to the medium for 
12 h, and then the cells were washed twice with PBS and resuspended in fresh normal medium. 
IgA expression was monitored at day 3 after stimulation using PE-conjugated anti–mouse IgA 
antibody (eBioscience). Resting B cells from AID-deficient mice were purified by MACS 
CD43 depletion (Miltenyi Biotech) from total splenic lymphocytes (Patenaude et al., 2009). 
Cells were loaded with CFSE, and 106 cells/well were seeded in 24-well plates with 25 µg/ml 
LPS (Sigma-Aldrich) and 50 ng/ml mouse IL-4. At different times after activation, 17-AAG 
was added and washed away 12 h later with PBS, and fresh culture medium was replenished. 
Isotype switching was analyzed 4 d after activation by flow cytometry after staining with anti–
IgG1-biotin (BD), followed by APC-conjugated antibiotin antibody (Miltenyi Biotech) and 
propidium iodide. 
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2.6.8. Imatinib resistance assay. 
K562 cells stably expressing AID-ires-GFP or GFP control were mixed with the 
parental cell line at a fixed ratio. The ratio of GFP+ to GFP− cells was measured by flow 
cytometry every 2 d for populations under the different treatments indicated in the figure (2 µM 
DMSO, 2 µM imatinib, and 0.1 µM 17-AAG). GFP+ cells were FACS sorted at the end of the 
experiments for the relevant conditions. Relative imatinib resistance of these populations was 
determined using Celltiter 96 Aqueous nonradioactive cell proliferation assay (Promega) 
according to manufacturer’s instruction. For mutation analysis of the BCR-ABL1 gene, single 
GFP+ CML cells expressing AID or not were sorted at the end of the treatments and expanded 
to obtain a clone in 96-well plates. RNA was extracted with TRIZOL (Invitrogen), and cDNA 
synthesis was performed using M-MULV first strand cDNA synthesis kit (New England 
Biolabs, Inc.). A 1540-bp fragment of the BCR-ABL1 cDNA was PCR amplified using specific 
primers for BCR (in exon 13) and ABL1 (in exon 9; Klemm et al., 2009) with KOD Hot Start 
Polymerase (EMD). PCR products were purified and directly sequenced using an ABL1-
specific primer. 
 
2.6.9. Statistical analysis. 
The unpaired two-tailed Student’s t test was used. 
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2.9. Supplementary material 
                     
 
Figure S2.1. Expression levels of AID, HSP90, and CHIP in various B cells and interaction 
of HSP90 with various AID variants. (A) Total extracts from parental Ramos B cells and its 
derived cell lines stably expressing AID-Flag/HA and AID-GFP were analyzed by Western blot 
(WB) with anti-AID to compare the protein level of each transgenic AID with the endogenous 
enzyme. Bands were quantified using ImageQuant, and the ratio (R) of tagged to endogenous 
AID is indicated. One of two independent experiments is shown. (B) Expression of HSP90 
isoforms and of the HSP90-associated E3 ubiquitin ligase CHIP (Fig. 2.4) in human Ramos 
and chicken DT40 B cell lines. Total cell lysate lines were analyzed by Western blot using anti–
HSP90-α, anti–HSP90- β, anti-CHIP, and antiactin. Apparent differences in expression 
between Ramos and DT40 cells most likely reflect variations in the chicken epitopes because 
anti–HSP90-α and anti-CHIP are mAbs raised against human proteins. One of two 
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independent experiments is shown. (C) Kinetics of HSP90 isoforms and CHIP expression in 
purified naive mouse B cells activated with IL-4 and LPS. Cells were harvested at different time 
points, lysed, and analyzed by Western blot using anti–HSP90-α, anti–HSP90-β, anti-CHIP, 
and antiactin. One of two independent experiments is shown. (D) AID oligomerization or 
phosphorylation is not necessary for HSP90 interaction. Interaction of HSP90 was tested by 
coimmunoprecipitations with AID mutants carrying the F46A/Y48A/R50G/N51A simultaneous 
mutations (FYRN), previously shown be defective for oligomerization (Patenaude et al., 2009), 
or the T27A and T38A phospho-null mutations (T27/38A). (E) The position of the tag on AID 
does not affect the association with HSP90-β. HEK293T cells were cotransfected with Myc–
HSP90-β and GFP-AID, AID-GFP, A2-GFP, or GFP. Anti-GFP immunoprecipitates (IP) were 
analyzed by Western blot with anti-Myc and anti-GFP. One of three independent experiments is 
shown. 
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Figure S2.2. AID dependence on HSP90 is unaffected by PKA inhibition or activation. (A 
and B) Ramos cells stably expressing AID-GFP were treated with 10 μM of PKA inhibitor H-89 
(A) or 50 μM of adenylate cyclase activator forskolin (Fsk) in combination with 100 μM of 
phosphodiesterase inhibitor IBMX to boost cAMP levels (B) before treating the cells with 2 μM 
GA or DMSO. AID-GFP was followed by flow cytometry and the MFI (normalized to the t = 0 
signal) plotted at different times for each treatment. Note that Fsk + IMBX equally increases 
the level of GFP and AID-GFP in Ramos cells. The reasons behind this increase are unknown, 
but although GFP control increases also in the presence of HSP90 inhibition, a similar 
increase in AID-GFP is totally prevented by GA, confirming the dependence of AID on HSP90. 
Mean ± SD of triplicates is plotted. One of three independent experiments is shown. Ctrl, 
control. 
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Figure S2.3. HSP90 inhibition does not affect AID compartmentalization. HeLa cells were 
transiently transfected with untagged AID and 48 h later treated as indicated (control [Ctrl] = 
DMSO, 2 μM GA, 50 ng/ml LMB, and 10 μM MG132). AID localization was monitored by 
immunofluorescence using anti-AID antibody. Treatments GA 2 h + LMB 2 h and GA + LMB 2 
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h differ in the time of addition of LMB; in the first case, cells were pretreated with GA before 
adding LMB, whereas in the latter, both drugs were added simultaneously. Simultaneous 
inhibition of HSP90 and nuclear export may have a small effect on the speed with which AID 
accumulates in the nucleus. One possibility is that a proportion of the HSP90-bound AID might 
be nuclear import competent. So, release of AID from HSP90 by GA treatment at the same time 
of nuclear export inhibition could allow nuclear import to compete with cytoplasmic AID 
degradation, leading to an apparent enrichment of AID in the nucleus. However, HSP90 on its 
own has no effect on AID subcellular distribution, indicating that it is not retaining it in the 
cytoplasm. C, cytoplasmic; N, nuclear. Bar, 10 μm 
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Figure S2.4. The effect of HSP90 inhibition on AID stability is conserved in chicken B cells 
and human non-B cells and is dose dependent. (A and B) DT40 Aicda-/- (A) and HeLa cells 
stably expressing AID-GFP (B) were treated with the indicated combinations of DMSO (Ctrl), 
2 μM GA, 50 ng/ml LMB, and/or 10 μM MG132 (30-min pretreatment). The GFP signal was 
monitored over time by flow cytometry, and the MFI was normalized to the signal at t0 = 100% 
for each treatment. Means ± SD of triplicates are plotted (**, P < 0.01). One of three 
independent experiments is shown in each case. (C) Ramos cells stably expressing AID-GFP 
were treated with DMSO (Ctrl) or the indicated concentrations of GA, and the GFP signal was 
monitored by flow cytometry. Means ± SD of triplicates are plotted. One of three independent 
experiments is shown. 
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3.2. Abstract 
The enzyme activation-induced deaminase (AID) deaminates deoxycytidine at the 
immunoglobulin genes, thereby initiating antibody affinity maturation and isotype class 
switching during immune responses. In contrast, off-target DNA damage caused by AID is 
oncogenic. Central to balancing immunity and cancer is AID regulation, including the 
mechanisms determining AID protein levels. We describe a specific functional interaction 
between AID and the HSP40 DnaJa1, which provides insight into the function of both proteins. 
Although both major cytoplasmic type I HSP40s, DnaJa1 and DnaJa2, are induced upon B-cell 
activation and interact with AID in vitro, only DnaJa1 overexpression increases AID levels and 
biological activity in cell lines. Conversely, DnaJa1, but not DnaJa2, depletion reduces AID 
levels, stability and isotype switching. In vivo, DNAJA1-deficient mice display compromised 
response to immunization, AID protein and isotype switching levels being reduced by half. 
Moreover, DnaJa1 farnesylation is required to maintain, and farnesyltransferase inhibition 
reduces, AID protein levels in B cells. Thus, DnaJa1 is a limiting factor that plays a non-
redundant role in the functional stabilization of AID. 
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3.3. Introduction 
Antibody genes  Naive B lymphocytes display the prediversified primary repertoire of 
antibodies. Antibody responses are initiated when a few of them recognize their cognate Ag 
and proliferate. To be effective, the antibodies produced by the selected B-cell clones still need 
to undergo affinity maturation to better recognize the Ag; as well as isotype switching to 
change the default IgM isotype for IgG, IgE or IgA. Antibody affinity maturation and isotype 
switching absolutely depend on activation-induced deaminase (AID) (Muramatsu et al, 2000; 
Revy et al, 2000). 
AID deaminates deoxycytidine to deoxyuridine at defined regions of the 
immunoglobulin (Ig) genes, which initiates somatic hypermutation or gene conversion, the 
molecular pathways underpinning antibody affinity maturation, as well as class switch 
recombination (CSR) (Di Noia and Neuberger, 2007; Peled et al, 2008; Stavnezer et al, 2008). 
AID deficiency compromises the antibody response resulting in a Hyper-IgM 
immunodeficiency syndrome (Revy et al, 2000). On the other hand, AID contributes to 
antibody-mediated autoimmune diseases (Zaheen and Martin, 2011) as well as to cancer 
(Okazaki et al, 2003; Pasqualucci et al, 2008). The latter ensues from AID mutating tumour 
suppressor and (proto)-oncogenes as well as from initiating chromosomal translocations as 
byproducts of CSR (Pasqualucci et al, 2001; Ramiro et al, 2004; Liu et al, 2008; Robbiani et al, 
2008; Yamane et al, 2011). A number of regulatory pathways enforcing an appropriate AID 
expression pattern, optimal AID mRNA and protein levels as well as modulating its access to 
the nucleus, favour AID physiological functions over its pathological effects (reviewed in 
Stavnezer, 2011; Storck et al, 2011). 
AID post-translational regulation is important for two reasons. First, because upwards 
and downwards variations in AID levels impact the frequency of both antibody diversification 
and pathological byproducts (Sernández et al, 2008; Teng et al, 2008; Robbiani et al, 2009; 
Orthwein et al, 2010). Second, because physiological and pathological expression of AID 
outside germinal centre B cells is well documented (Morgan et al, 2004; Pasqualucci et al, 
2004; Matsumoto et al, 2007; Macduff et al, 2009; Pauklin et al, 2009; Kuraoka et al, 2011). 
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Prominent among AID regulation are subcellular localization and protein stability, which are 
linked mechanisms that limit AID access to the genome. Indeed, AID is a nucleo-cytoplasmic 
shuttling protein but most of AID is in the cytoplasm in steady state because nuclear export 
plus cytoplasmic retention outcompete nuclear import (Brar et al, 2004; Ito et al, 2004; 
McBride et al, 2004; Patenaude et al, 2009; Patenaude and Di Noia, 2010). In turn, cytoplasmic 
AID is more stable than nuclear AID (Aoufouchi et al, 2008; Orthwein et al, 2010). We have 
shown that AID is stabilized in the cytoplasm by the chaperone HSP90, which helps explaining 
the differences in AID stability depending on its localization (Orthwein et al, 2010). We now 
describe a key role for the HSP40 DnaJa1 in determining AID protein levels and stability. 
The prototypical HSP40 is Escherichia coli DnaJ, a cochaperone of the bacterial HSP70 
DnaK (Langer et al, 1992). DnaJ is but one member of a large protein family characterized by 
the J-domain, which stimulates the ATPase activity of HSP70 as part of a chaperoning cycle 
that allows folding, conformational changes, degradation and transport across membranes 
(Walsh et al, 2004; Qiu et al, 2006; Kampinga and Craig, 2010). The human genome encodes 
for 41 J-domain proteins, which can be divided into three groups (Qiu et al, 2006; Kampinga 
and Craig, 2010). Type I J-proteins or DjAs (DnaJa1–4) are orthologues of E. coli DnaJ and 
yeast YDJ1. DjAs have an N-terminal J-domain separated by a Gly/Phe-rich linker from the C-
terminal substrate-binding region. This region contains three distinct structural domains 
revealed by the YDJ1 crystal structures (Li et al, 2003; Wu et al, 2005) (Supplementary Figure 
S3.1): CTDI, has a hydrophobic pocket that binds certain peptides found in a subset of YDJ1 
substrates; CTDII, is made of two Zn-fingers; and CTDIII, which contains most residues 
involved in DjA dimerization. Additionally, like YDJ1, cytoplasmic DjAs have a short C-
terminal extension ending in a farnesylation motive (Kanazawa et al, 1997). Type II J-proteins 
or DjBs (13 members in humans) are orthologues of yeast SIS1 and have CTDI and CTDIII 
structurally homologous to DjA's (Sha et al, 2000) but lack Zn-fingers. Type III J-proteins are 
very heterogeneous in structure, size and function sharing only the J-domain. Only DjAs and 
some DjBs behave as HSP70 cochaperones similarly to DnaJ, YDJ1 or SIS1 (Qiu et al, 2006; 
Kampinga and Craig, 2010). Some DjAs additionally work in the HSP90-mediated stabilization 
pathway (Caplan et al, 1995; Kimura et al, 1995; Hernández et al, 2002). 
The expansion and divergence of J-protein paralogs during evolution contrast with the 
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conservation of many orthologues across vertebrate species (f.i. DnaJa1 is >95% identical 
between most vertebrates). This is likely to reflect functional specialization and presumably 
some specific subset of substrates in vivo, the mechanistic details of which as well as the 
identity of the substrates are largely unknown (Kampinga and Craig, 2010). In-vitro folding 
experiments have shown some redundancy but also clear functional differences between the 
major mammalian cytosolic HSP40s (DnaJa1, DnaJa2, Dnaja4, DnaJb1) (Terada and Mori, 
2000; Bhangoo et al, 2007; Tzankov et al, 2008; Walker et al, 2010). The different phenotypes 
of mice deficient for DnaJa1 (Terada et al, 2005) and DnaJb1 (Uchiyama et al, 2006) support 
this view but have not provided yet the identity of any substrates that would depend on one 
particular HSP40. Here, we identify DnaJa1 as a specific limiting factor in determining AID 
protein levels and biological activity during the immune response in mice. 
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3.4. Results 
3.4.1. AID interacts with a subset of HSP40 cochaperones and with 
HSC70 
Several results pointed to the interaction between AID and type I HSP40/DjAs. A yeast 
two-hybrid screening using AID as bait (described in Conticello et al, 2008) yielded DnaJa2 
(Figure 3.1A). Mass spectrometry then identified DnaJa1 among the proteins copurifying with 
AID–Flag/HA through two consecutive immunopurifications using agarose-conjugated 
antibodies (Orthwein et al, 2010), which we confirmed here by coimmunoprecipitation (coIP) 
(Figure 3.1B). Finally, DnaJa1, a2 and a3 were pulled down with AID–GFP using anti-GFP-
coated magnetic beads from extracts of stably transfected Ramos B cells (Table 3.1). We 
verified the DnaJa1–AID interaction by coIP (Figure 3.1C). CoIP also confirmed the 
preferential association of AID with cytoplasmic DjAs compared with DnaJb1 and DnaJb11, 
two of the DjB members most similar to DnaJa1 (Figure 3.1D and E). We focused on DnaJa1 
and DnaJa2, which are highly induced upon B-cell activation, excluding DnaJa4, which was 
undetectable (Figure 3.1F) and DnaJa3 because it is mitochondrial (Qiu et al, 2006). DjAs have 
Zn-fingers and E. coli J-proteins non-specifically bind to DNA (Gur et al, 2005) but nuclease 
treatment confirmed that AID interaction with DjAs was not mediated by nucleic acids (Figure 
3.1G). 
We previously showed that AID interacts with HSP90 while the AID paralogs 
APOBECs do not despite being up to 60% similar to AID (Orthwein et al, 2010). Also here, 
AID but not APOBEC1, 2 or 3G, interacted with DnaJa1 and DnaJa2 by coIP (Figure 3.2A and 
B). The major cytosolic HSP70 isoform, HSC70 (encoded by HSPA8) was identified in our 
three pull-down experiments (Table 3.1). Again, HSC70 coIP with AID but not with any of the 
APOBECs from transfected cells (Figure 3.2C). Interestingly, the binding of DnaJa1 or DnaJa2 
to AID was not equivalent. We used AID–APOBEC2 chimeras, in which 30–50 amino acids 
long AID regions were replaced by the homologous APOBEC2 residues (Figure 3.2D) 
(Conticello et al, 2008), to probe the interaction between AID and DjAs. Most chimeras                                                                                      
partially or completely lost interaction with DnaJa1 while they all interacted with DnaJa2 just  
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Table 3.1. (Co)chaperones identified by mass spectrometry copurifying with tagged AID from 
Ramos B cell extracts  
HUGO 
name 
Description 
AID-
Flag/HA 
Pull down1 
AID-GFP Pull down 
Peptide 
number 
Mascot 
Score 
Coverage 
(%) 
DNAJA1 HSP40 homolog, subfamily A, 
member 1 
× 47 1232 65 
DNAJA2 HSP40 homolog, subfamily A, 
member 2 
 39 1003 60 
DNAJA3 HSP40 homolog, subfamily A, 
member 3 
 9 207 14 
HSPA8 Heat shock 70 kDa protein 8 isoform 1 × 19 517 19 
HSP90AA1 Heat shock 90 kDa protein 1, alpha × 39 1101 25 
HSP90AB1 Heat shock 90 kDa protein 1, beta × 81 2010 48 
AHSA1 AHA1, Activator of heat shock 90kDa 
protein ATPase homolog 1 
× 19 480 28 
BAG2 BCL2-associated athanogene 2 
(HSP70-cochaperone) 
 16 327 39 
TCP1 T-complex polypeptide 1 × 5 154 6 
CCT6A T-complex protein 1 subunit zeta × 1 84 3 
CCT4 T-complex protein 1 subunit delta × 3 60 7 
CCT7 T-complex protein 1 subunit eta  1 56 5 
1 Data from ref [332]. 
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Figure 3.1. AID interacts with type I J-proteins. (A) Yeast two-hybrid assay showing the 
interaction of AID with DnaJa2 (truncated clone starting at codon 198). The AID-interacting 
protein CTNNLB1, isolated in the same screening from a human spleen library (Conticello et 
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al, 2008), was used as positive control. GAL, galactose; GLU, glucose; MET, methionine. (B) 
AID–Flag/HA was sequentially immunoprecipitated using anti-Flag and then anti-HA from 
extracts of stably expressing Ramos cells and analysed by western blot after each step to detect 
endogenous DnaJa1. One of the two independent experiments is shown. (C) GFP or AID–GFP 
were immunoprecipitated from extracts of stably expressing Ramos cells and analysed as in 
(B). (D) Schematic structure of type I (DjA) and type II (DjB) J-proteins. Similarity values (%) 
for each structural domain, calculated from the alignment between DnaJa1 and DnaJb1, are 
indicated. (E) Lysates from HEK293T cells cotransfected with Flag-tagged AID or APOBEC2 
(A2) and Myc-tagged versions of the indicated DnaJ proteins were immunoprecipitated with 
anti-Flag and analysed by western blot. One of the two independent experiments is shown. (F) 
Expression of selected DnaJ proteins in total cell lysates of mouse naive primary splenic B cells 
purified by CD43 depletion (>97% CD43− B220+) either resting (0) or after 1–3 days 
stimulation with IL-4 and LPS, analysed by western blot using antibodies against DnaJa1, 
DnaJa2, DnaJa4, DnaJb1 and actin. The CD43-enriched fraction (a heterogeneous mixture 
including T, B and other leukocytes) was included as an additional control. Exposure times 
vary between panels and do not accurately reflect relative abundances. (G) AID–GFP or AID–
Flag/HA were immunoprecipitated in the presence of 1 mg/ml DNase and/or 0.5 mg/ml RNase 
using the corresponding anti-tag antibodies from lysates of HEK293T cell contransfected with 
Flag–DnaJa1 or Myc–DnaJa2, respectively, and analysed by western blot. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
 
 
 
 
 
Figure 3.2. AID but not the APOBECs interacts with DnaJa1, DnaJa2 and HSC70 in vitro. 
(A) GFP-tagged versions of AID, the indicated APOBECs or GFP control were transiently 
cotransfected with Flag–DnaJa1 into HEK293T cells and immunoprecipitated with anti-GFP. 
Immunoprecipitates were probed by western blot. (B) As in (A) but using Flag-tagged versions 
of AID and the APOBECs cotransfected with Myc–DnaJa2 and immunoprecipitated with anti-
Flag. (C) As in (B) but cotransfected with GFP–HSC70. One of the two independent 
experiments is shown for (A–C). (D) Schematic representation of AID–APOBEC2 chimeric 
proteins (AID–A2ch1–5) in which either one of the regions from A2 indicated between dotted 
lines was substituted into the homologous AID region. (E) Flag-tagged versions of AID, A2 or 
the AID-2 chimeras were immunoprecipitated using anti-Flag from HEK293T cell lysates 
cotransfected with Myc–DnaJa1 and analysed by western blot. (F) Flag-tagged versions of 
AID, A2 or the AID-2 chimeras were immunoprecipitated using anti-Flag from HEK293T cell 
lysates cotransfected with GFP–DnaJa2 and analysed by western blot. 
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 as well as AID (Figure 3.2E and F). We can conclude that there is a specific association of 
AID to DjAs and the HSP40–HSP70 chaperoning machinery, which is not detected for the 
APOBEC enzymes. 
 
3.4.2. DnaJa1 determines the protein levels and activity of AID in 
B-cell lines 
The ability of both DnaJa1 and DnaJa2 to bind to overexpressed AID may not be 
surprising since they share ~70% similarity (Supplementary Figure S3.1). Notwithstanding this, 
several reports suggest that they are not completely redundant in their functions (Terada et al, 
2005; Bhangoo et al, 2007; Tzankov et al, 2008). We thus tested whether DnaJa1 and/or 
DnaJa2 were functionally relevant for AID biology, first through overexpression. We used the 
mouse B-cell line CH12F3 in which stimulation with anti-CD40, TGF-β1 and IL-4 induces 
AID and isotype switching to IgA (Nakamura et al, 1996; Muramatsu et al, 1999). Retroviral 
delivery led to ~2-fold overexpression of DnaJa1 or DnaJa2 in CH12F3 cells (Figure 3.3A and 
B). Only DnaJa1 overexpression was associated with higher AID protein levels (~1.6-fold) and 
a significant increase in CSR (Figure 3.3B and C). We obtained similar results in the chicken 
B-cell lymphoma line DT40, which constitutively expresses AID and undergoes Ig gene 
conversion (Arakawa et al, 2002). Overexpression of DnaJa1, but not of DnaJa2, correlated 
with increased levels of endogenous AID (Figure 3.3D and E). This was accompanied by a 
similar increase in the rate of Ig gene conversion as measured by a surface IgM-gain fluctuation 
assay (Figure 3.3F). In this assay, a proportion of AID-dependent gene conversions in the DT40 
CL18 line reverses a frameshift in the IgVλ, thus rescuing IgM expression (Arakawa et al, 
2002). The median proportion of IgM+ cells arising during clonal expansion of multiple 
populations is proportional to the Ig gene conversion activity. In contrast, overexpression of 
HSC70 or HSP90 had no effect on AID or Ig gene conversion in DT40 (Figure 3.3D–F). 
We then asked whether depletion of DnaJa1 would have the predicted opposite effect to 
its overexpression. We transduced CH12F3 cells with different shRNAs targeting murine 
DnaJa1. Each of them decreased DnaJa1 protein to a different extent (from ~70 to 30% of the 
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control; Figure 3.4A and B), which was mirrored by a proportional decrease in isotype 
switching to IgA (Figure 3.4C and D). Importantly, the relative reductions in CSR and in 
DnaJa1 were linearly correlated (Figure 3.4E). Depletion of DnaJa1 reduced AID protein levels 
(Figure 3.4F) but did not affect Aicda or Iα germline transcription, nor did it impact cell growth 
kinetics or HSC70 or HSP90 levels (Supplementary Figure S3.2). In contrast, efficient 
knockdown of DnaJa2 in CH12F3 cells had no effect on CSR or AID protein levels (Figure 
3.4G–J). Finally, DnaJa2 depletion had no effect on AID half-life while DnaJa1 depletion 
reduced it by half (Figure 3.4K and L). Altogether these results suggest a non-redundant and 
limiting role for DnaJa1 in determining the levels of functional AID partaking in its 
stabilization. 
 
3.4.3. Compromised antibody immune response in DnaJa1-deficient 
mice 
The only phenotype observed so far in DNAJA1−/− mice is a defect in spermatogenesis 
likely due to abnormal androgen receptor signalling (Terada et al, 2005). Our findings 
prompted the analysis of the antibody response in these mice. Flow cytometry analysis of 
lymphocyte populations showed little difference between DNAJA1−/− and control mice 
lymphocyte populations. The only statistically significant changes were a 10% decrease in the 
proportion of follicular B cells and an ~2-fold increase in marginal zone B cells in the spleen 
(Supplementary Figure S3.3). In contrast, there was a consistent 50% deficiency in isotype 
switching to IgG1 in splenic naive B cells from DNAJA1−/− mice stimulated ex vivo compared 
with their DNAJA1+/+ or DNAJA1+/− controls (Figure 3.5A and B). The defect in CSR was also 
clear when comparing cells that have undergone the same number of cell divisions without any 
sign of increased cell death in DNAJA1−/− cells (Figure 3.5C; Supplementary Figure S3.4). In 
fact, there were no differences in proliferation, Aicda, Iμ or Iγ1 germline transcription in 
DNAJA1−/− versus control activated B cells (Supplementary Figure S3.4). Western blots 
showed a consistent 50% decrease in AID protein levels in activated B cells from each 
DNAJA1−/− mouse compared with their littermate controls (Figure 3.5D). DnaJa1-deficient 
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Figure 3.3. DnaJa1 overexpression increases AID levels and antibody gene diversification. 
(A) CH12F3 mouse B cells transduced with pMX-ires–GFP vector either empty (GFP) or 
encoding untagged DnaJa1 or DnaJa2 were sorted for GFP-expressing cells, lysed and 
analysed by western blot using anti-DnaJa1 or anti-DnaJa2 and anti-PCNA as loading control. 
P, parental cells. (B) Endogenous AID from transduced and parental CH12F3 cells was 
analysed by western blot using the indicated antibodies before (−) and 24 h after ( +) 
stimulation with agonist anti-CD40, IL-4 and TGF-β1 (CIT). (C) Proportion of IgA+ CH12F3 
cells at day 3 post-CIT. The mean proportion of IgA+ cells determined by flow cytometry±s.d. 
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from six independent stimulations is plotted for each population relative to the GFP controls 
set as 100%. (D) Endogenous AID was analysed by western blot using anti-AID on cell lysates 
from two representative, independently derived stable DT40 cell clones transfected with empty 
vector (Ctrl) or plasmids encoding myc–DnaJa1, myc–Dnaja2, myc–HSP90 or GFP–HSC70. 
Specific antibodies against each protein detected the transfected (triangles) and endogenous 
(circles) proteins. PCNA was used as loading control. (E) Endogenous AID levels quantified by 
densitometry from unsaturated western blots similar to those shown in (D) and normalized to 
the corresponding PCNA level. The mean value for AID in control samples set as 1 was used to 
normalize all values in each experiment. Data expressed as mean values±s.d. of multiple 
subclones for each construct are plotted (myc–DnaJa1 n=15 and myc–DnaJa2 n=21 versus 
controls n=18; myc–HSP90β n=11 versus controls n=11; GFP–HSC70 n=12 versus controls 
n=12). (F) Ig gene conversion frequency in transfected DT40 cells was estimated as the median 
proportion of IgM+ cells arising from multiple IgM− subclones after 4 weeks of clonal 
expansion. The proportion of sIgM+ for each subclone and median values are plotted. Different 
symbols indicate subclones obtained from independent transfectants. In all panels, P-values 
from unpaired, one-tailed t-test are indicated only for significant differences (P<0.05). 
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Figure 3.4. Reduced AID levels and CSR in DnaJa1-depleted CH12F3 cells. (A) CH12F3 
cells were transduced with a lentiviral vector carrying control shRNA (Ctrl) or one of five 
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different mouse DnaJa1-specific shRNAs (#1–#5), selected on puromycin and analysed by 
western blot for DnaJa1 and PCNA as loading control. Populations obtained from two 
independent infections are shown. (B) DnaJa1 protein levels were estimated by densitometry 
from western blots of three independently infected populations and normalized to each 
corresponding PCNA signal. Data expressed as mean values±s.d. for each DnaJa1 shRNA are 
plotted relative to DnaJa1 levels in control shRNA cells set as 100% (*P<0.01, **P<0.0005, 
paired one-tailed t-test). (C) Proportion of IgA+ cells at day 3 post-CIT as determined for flow 
cytometry for the same populations used for (B). Data expressed as mean values±s.d. from six 
independent inductions are plotted relative to the IgA+ proportion in control shRNA cells set as 
100% (*P<0.005, **P<0.0005 in paired one-tailed t-test). (D) Representative flow cytometry 
profiles of transduced CH12F3 stimulated with CIT for 3 days or not (no CIT) and stained with 
anti-IgA. The proportion of IgA+ cells is indicated in each histogram. (E) The mean reduction 
in CSR versus the mean reduction in DnaJa1 protein for each shRNA was plotted for two 
independent experiments (circles and squares) and analysed by linear regression. The 
correlation coefficients (R2) are indicated. (F) Western blots from two independent experiments 
measuring AID in CH12F3 cells transduced with control or DnaJa1 shRNAs, 24 h post-CIT. 
(G) CH12F3 cells transduced with control shRNA (ctrl) or one of three different mouse 
DnaJa2-specific shRNAs (#1–#3) were analysed as in (A). One of the two independent 
experiments is shown. (H) DnaJa2 protein levels were estimated and plotted as in (B). (I) The 
proportion of IgA+ cells at day 3 post-CIT in control versus DnaJa2-depleted cells was 
determined and plotted as in (C). (J) Western blot measuring AID in CH12F3 cells transduced 
with control or DnaJa2 shRNAs, 24 h post-CIT. (K) AID levels were measured by western blot 
24 h post-CIT in CH12F3 cells transduced with shRNA control, DnaJa1 shRNA#3 or DnaJa2 
shRNA#2 at 0, 4 and 8 h after treatment with 100 ng/ml CHX. PCNA is used as a loading 
control. One of the two independent experiments is shown. (L) AID protein levels after CHX 
treatment were estimated by densitometry from western blots of two independent experiments, 
normalized to each corresponding PCNA signal. Data expressed as mean values±s.e.m. for 
each time point are plotted with AID levels at t=0 h set as 100%. AID protein half-lives were 
calculated and are indicated. 
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mice had similar IgM and IgG1 serum levels than controls (Figure 3.5E). This was expected 
since the long lifespan of plasma cells and Ag-mediated selection allow substantial 
accumulation of switched Ig isotypes in the serum of AID haploinsufficient or MSH2−/− mice, 
which have defects of similar magnitude in AID levels and/or CSR as those we observe (Rada 
et al, 2004; Sernández et al, 2008; Takizawa et al, 2008). DnaJa1-deficient mice had impaired 
response to immunization with the T-cell-dependent Ag 4-hydroxy-3-nitrophenylacetyl-
conjugated chicken γ globulin (NP-CGG). There was a significant decrease in the titre of total 
as well as high affinity anti-NP IgG1 during the primary response in all six DNAJA1−/− mice 
analysed (Figure 3.5F), demonstrating a CSR defect in vivo. By the secondary response anti-NP 
titres remained lower than controls in only half of them so only a non-significant trend was 
apparent when analysing the group (Figure 3.5F). Unlike androgen signalling defects and 
slightly reduced body weight, which are only found in DNAJA1−/− males (Terada et al, 2005), 
there was no sex bias for the phenotypes reported here. We conclude that DnaJa1 deficiency 
causes a B-cell intrinsic defect in CSR, most likely by reducing AID protein levels, thus 
delaying antibody immune responses. 
 
3.4.4. DnaJa1-mediated stabilization of AID depends on its 
farnesylation 
Since we have shown that AID is an HSP90 client (Orthwein et al, 2010) and HSP40s 
partake in the HSP90 molecular chaperoning pathway (Kimura et al, 1995; Young et al, 2004), 
we sought some evidence linking DnaJa1 to HSP90, in addition to the decrease in AID stability 
observed after Dnaja1 depletion (see Figure 3.4L). Molecular details about the link between 
HSP40 and HSP90 in vivo are scarce but it has been shown that YDJ1 farnesylation is 
necessary for maintaining the protein levels of HSP90 clients in yeast (Flom et al, 2008). We 
first determined which domains of DnaJa1 mediated interaction with AID. CoIP of AID with 
DnaJa1 truncated variants showed that the CTDI, an YDJ1 substrate-binding site (Li et al, 
2003), as well as the Zn-fingers domain were dispensable for the interaction. Indeed, deletion 
of the N-terminal 160 amino acids of DnaJa1 destroys the structure of both these domains 
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(Figure 3.6A and B) but still allowed AID interaction (Figure 3.6C). Mutating the farnesyl 
group acceptor Cys (Caplan et al, 1992) abolished the interaction of DnaJa1 with AID (Figure 
3.6D). Thus, the CTDIII and farnesylation are the minimal requirements for DnaJa1 binding to 
AID. More importantly, while DnaJa1 expression was able to complement the CSR defect in 
DNAJA1−/− B cells, expression of the DnaJa1-C394S was not able to; nor was DnaJa2 further 
suggesting a specific role for DnaJa1 (Figure 3.6E–G). To confirm that the AID levels were 
dependent on farnesylated DnaJa1, we treated the Ramos human B-cell line and mouse primary 
B cells with the farnesyltransferase inhibitor FTI-277. Increasing doses of FTI-277 correlated 
with the accumulation of non-farnesylated DnaJa1 and a concomitant decrease in AID protein 
levels in both cases (Figure 3.6H) without affecting Aicda transcription (Supplementary Figure 
S3.5). Furthermore, FTI treatment was able to decrease ex-vivo isotype switching to IgG1 in 
mouse B cells (Figure 3.6I–K). Confocal microscopy of cotransfected cells showed that AID 
shuttled independently of DnaJa1 localization, which was not obviously affected by the C394S 
mutation (Figure 3.6L). In fact, DnaJa1 depletion in CH12F3 cells had no effect on AID 
localization or shuttling (Supplementary Figure S3.5).  
Taken together, these results indicate that AID biological activity levels depend on 
farnesylated DnaJa1 through a mechanism that determines AID protein levels in the cytoplasm. 
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Figure 3.5. Reduced AID protein levels and isotype switching in DNAJA1−/− mice. (A) 
Proportion of IgG1+ cells in purified splenic B cells from five DNAJA1−/− and control (+/+ or 
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+/−) mice 4 days post-IL-4 and LPS stimulation, measured by flow cytometry. Two 
independent experiments are plotted in the same graph. A line links littermate pairs, with 
females (triangles) and males (circles) distinguished. (B) The data from (A) were compiled by 
normalizing the IgG1+ B-cell proportion from each of the DNAJA1−/− mice to its paired control 
set as 100%. The mean relative CSR±s.d. value for DNAJA1−/− mice is plotted. (C) Splenic 
naive B cells from DNAJA1−/− mice and littermate controls were loaded with CFSE, activated 
with IL-4 and LPS for 4 days and the proportion of IgG1+ cells for each cell division 
determined by flow cytometry. One representative out of four mice pairs analysed is plotted. 
(D) DnaJa1, AID and PCNA protein levels were analysed by western blot in lysates from 
resting (R) or LPS + IL-4-activated (A) splenic B cells purified from three DNAJA1−/− and their 
matched control littermates (pairs separated by dashed lines). AID levels in each mouse were 
quantified by densitometry, normalized to PCNA levels and the mean±s.d. AID levels for 
DNAJA1−/− mice relative to their corresponding littermate are plotted in the right-hand panel. 
(E) Concentration of IgM and IgG1 in sera from 3- to 5-month-old DNAJA1−/− or littermate 
control mice determined by ELISA. Each dot represents an individual mouse with females 
(triangles) and males (circles) distinguished. Horizontal lines indicate median values. (F) Six 
littermate pairs of control and DNAJA1−/− mice were immunized with NP15-CGG and serum 
samples collected at day 11 post-immunization (primary response). The mice were boosted at 
day 30 and sera collected again at day 37 (secondary response). Anti-NP IgG1 titres were 
determined by ELISA using plates coated with NP26-BSA (NP26 column, total anti-NP 
antibodies) or NP4-BSA (NP4 column, high affinity anti-NP antibodies). The value for each 
mouse is indicated, distinguishing females (triangles) and males (circles) with lines indicating 
median values. In all panels, P-values from paired, one-tailed Student's t-test are indicated 
only for statistically significant differences (P<0.05). 
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Figure 3.6. DnaJa1 farnesylation is necessary to maintain AID levels and for CSR. (A) 
DnaJa1 domains illustration indicating the deletions and single point mutation variants used. 
CaaX indicates the farnesylation motif where Cys394 was mutated to Ser in DnaJa1ΔF. (B) 
Crystal structure of the yeast DnaJa1 orthologue YDJ1 substrate-binding domain using the 
same colour scheme as in (A). Residues homologous to those truncated in DnaJa1ΔN2, which 
destroy CTDI and II, are in grey. A YDJ1 substrate peptide, which cocrytstalized bound to 
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CTDI, is shown as filled model. Data are from pdb1NLT (Li et al, 2003). (C) Flag-tagged AID 
or A2 were immunoprecipitated using anti-Flag from lysates of HEK293T cells cotransfected 
with the indicated GFP-tagged DnaJa1 variants and analysed by WB. One of the two 
independent experiments is shown. (D) Similar experiment to (C) but using Myc-tagged 
DnaJa1 variants. One of the two independent experiments is shown. (E) Splenic B cells purified 
from DNAJA1+/+ and DNAJA1−/− mice activated with LPS and IL-4, transduced with 
retroviruses expressing control (GFP), DnaJa1–, DnaJa1ΔF– or DnaJa2-ires–GFP and 
analysed at day 4 post-infection by flow cytometry. Histograms show GPF-gated cells stained 
with anti-IgG1 indicating the proportion of IgG1+ cells for one representative out of three mice 
analysed. (F) Compilation of ex-vivo CSR data from three DNAJA1−/− mice complemented as 
in (E). The proportion of IgG1+ cells for the DNAJA1−/− B cells expressing each transduced 
protein is shown relative to the value obtained for the corresponding DNAJA1+/+ littermate B 
cells infected with control GFP vector, set as 100%. Paired, two-tailed t-test was used to 
evaluate significance (P<0.05). (G) Transduced splenic B cells were analysed by western blot 
with anti-DnaJa1 and anti-DnaJa2 using anti-GFP as loading control. (H) Ramos B-lymphoma 
cells and purified mouse splenic B cells were treated with the indicated concentrations of the 
farnesyltransferase inhibitor FTI-277 for 72 h and the levels of AID and farnesylated (circle) 
and non-farnesylated (triangle) DnaJa1 analysed by western blot. PCNA was used as loading 
control. (I) Experimental strategy used for assaying CSR in mouse splenic B cells after 
farnesyltransferase inhibition. D, day. (J) Relative proportion of IgG1+ cells measured by flow 
cytometry in mouse splenic B cells treated with the farnesyl transferase inhibitor FTI-277 or 
solvent control as in (I). (K) CFSE staining profile of the cells used for (I) with the proportion 
of IgG1+ cells for each cell division plotted below. (L) Hela cells cotransfected with GFP-
tagged DnaJa1 or DnaJa1ΔF and untagged AID were treated with leptomycin B or heat 
shocked for 90 min at 43°C, fixed, stained with anti-AID and anti-mouse Alexa-680 and imaged 
by confocal microscopy. Representative confocal images are shown, scale bar=10 μm. The 
cellular localization of each protein was classified and the proportion of cotransfected cells 
showing each distribution is plotted as bars with the number of cells counted indicated (n). C, 
cytoplasmic; N, nuclear. 
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3.5. Discussion 
We have previously identified AID as an HSP90 client, with this interaction being 
critical for AID stability (Orthwein et al, 2010). We now show the interaction of AID with the 
HSP40–HSC70 system and with DnaJa1 in particular. The remarkable specificity of the 
functional interaction between AID and DnaJa1 in vitro and in vivo provides insight not only 
on AID biology but also into the functional specialization of HSP40s. 
The HSP40–HSP70 system delivers a subset of its substrates to the HSP90 molecular 
chaperoning pathway for their functional stabilization (Young et al, 2004; Hartl et al, 2011). 
Indeed, AID folding and stabilization shows similarities with the stabilization cycle of steroid 
hormone receptors (Picard, 2006; Hartl et al, 2011) and our results suggest the identity and 
function of many of the molecules involved (Orthwein et al, 2010 and this work). DnaJa1 could 
act as cochaperone of HSC70 by stimulating its ATPase activity to initiate a folding cycle that 
is completed by HSP70 nucleotide exchange factors (Young et al, 2004; Kampinga and Craig, 
2010; Terada and Oike, 2010). We speculate BAG2 could be the HSC70 nucleotide exchange 
factor in this cycle since it was the only one that copurified with AID (Table 3.1). HSP40–
HSP70 and HSP90 are coupled by STI1/HOP, which has been copurified with AID (Okazaki et 
al, 2011) and may link the ternary AID–HSP40–HSP70 complex to HSP90. 
Although DnaJa1 may well be an HSC70 cochaperone during AID folding, the fact that 
different HSP40s can at least partially substitute for each other in this role (Johnson and Craig, 
2001; Cintron and Toft, 2006), combined with the non-redundant function that DnaJa1 has in 
determining AID cellular levels in vivo, suggest that DnaJa1 may have another, more specific 
function. There is considerable genetic and biochemical evidence showing that HSP40 is a 
functional component of some of the complexes during the HSP90 cycle (Caplan et al, 1995; 
Kimura et al, 1995; Dittmar et al, 1998; Kosano et al, 1998; Hernández et al, 2002; Wegele et 
al, 2006; Flom et al, 2008). Three observations suggest that DnaJa1 has a specific role in AID 
stabilization and link this activity to HSP90. First, AID is less stable in cells depleted of 
DnaJa1. Second, DnaJa1 farnesylation is required for binding to and optimal CSR activity of 
AID just as YDJ1 farnesylation is required for its interaction with HSP90 clients (Flom et al, 
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2008). Cytoplasmic type I HSP40s are isoprenylated (Caplan et al, 1992; Kanazawa et al, 
1997). Although farnesylation targets a minor proportion of YDJ1 to intracellular membranes 
(Caplan et al, 1992), this seems to be in no small part by contributing to protein–protein 
interactions (Marshall, 1993). Indeed, the farnesylated CTDIII domain of DnaJa1 mediates AID 
binding instead of the CTDI, a characterized YDJ1 substrate-binding domain (Li et al, 2003). 
Coincidently, the YDJ1 mutant found to compromise HSP90 client stability in yeast had a 
single point mutation in CTDIII (Kimura et al, 1995). Third, DNAJA1−/− mice can only make 
50% of the normal AID protein levels, indicating that no other J-protein is fully redundant with 
DnaJa1. DnaJa2 would be the obvious backup in DNAJA1−/− cells since it is very similar to 
DnaJa1, well expressed in B cells and interacts with AID in vitro. However, this is not the case 
since AID and CSR are reduced proportionally to DnaJa1 depletion in CH12F3 cells (despite 
abundant DnaJa2 expression) while DnaJa2 depletion or overexpression do not change AID 
levels, nor can DnaJa2 rescue CSR in DNAJA1−/− B cells. An analogous specificity was 
observed for the potassium channel HERG with depletion of DnaJa1, but not DnaJa2, reducing 
the intracellular trafficking of HERG (Walker et al, 2010). Interestingly, like AID, HERG 
stability depends on HSP90 (Ficker et al, 2003). It is interesting that most AID–APOBEC2 
chimeras disrupt DnaJa1 binding while they all bind to DnaJa2. One could speculate that 
DnaJa1 recognizes a certain structure, which would be easily altered in the chimeras, while 
DnaJa2 may recognize less specific hydrophobic motifs present in earlier folding intermediates. 
Our results are compatible with some specialization of DnaJa1 to work in the HSP90 pathway 
but defining this will require further work. The experiments with HERG were done in 
transfected HeLa cells and there is in fact hardly any data about protein levels of endogenous 
HSP90 clients in the absence of a particular DjA in any system. In yeast, the STE11 kinase 
levels are reduced by YDJ1 deficiency (Flom et al, 2008). In DNAJA1−/− mice, the androgen 
and glucocorticoid receptors were increased (Terada et al, 2005) while AID is reduced. This 
nicely illustrates the existence of different subpathways for folding/stabilization of HSP90 
clients. To the best of our knowledge, AID is the first HSP90 client identified in higher 
eukaryotes that requires a specific HSP40 to maintain its physiological levels in vivo. 
If DnaJa2 is not able to complement DnaJa1 deficiency and DnaJa4, the only other 
cytoplasmic DjA, is not expressed, it is interesting to speculate how the residual AID is folded 
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and stabilized in vivo in DNAJA1−/− lymphocytes. Whichever pathway forms AID in 
DNAJA1−/− B cells, it is clearly not fully redundant with DnaJa1. At least in yeast, the DjB Sis1 
can partially substitute for YDJ1 (Lu and Cyr, 1998; Johnson and Craig, 2001). Thus, a DjB 
like DnaJb1 or even DnaJa2 could substitute for DnaJa1 in early HSP70-assisted AID folding; 
and/or it could proceed via the CCT chaperonin (Young et al, 2004; Hartl et al, 2011). The end 
result is anyhow much less efficient. Therefore, we hypothesize that a later DnaJa1 role must 
exist in vivo, probably by linking AID to the HSP90 pathway, and/or helping in assembling 
some AID complexes. This role would be more specific than, and thereby limiting, compared 
with protein biogenesis. 
The fact that the response of DNAJA1−/− mice to immunization is so similar to the one 
observed in AID haploinsufficient mice (Sernández et al, 2008; Takizawa et al, 2008) suggests 
that the defect in CSR in vivo reflects the 50% reduction in AID rather than any other unknown 
defect on immune cell function. Beyond any small differences, the phenotypes of Aicda+/− and 
DNAJA1−/− mice indicate that AID can be limiting for antibody diversification and that reduced 
AID levels, no matter their cause, are detrimental for antibody responses, which could be 
exploited for therapy. We have shown that HSP90 inhibitors could be used in this way 
(Orthwein et al, 2010). DnaJa1 now offers alternative possibilities by linking AID protein 
levels to protein farnesylation. Farnesyltransferase inhibitors have promising anti-cancer 
activity but their relevant targets are incompletely understood (Sebti and Der, 2003). We show 
that it is indeed possible to reduce AID levels and function by using farnesyltransferase 
inhibitors, which could have therapeutic value to modulate AID. 
HSP40s are limiting components in chaperone networks. In E. coli, DnaJ is present in a 
1:10 ratio with respect to DnaK (HSP70) (Bardwell et al, 1986). In yeast, the relative molecular 
proportion of HSP82 (HSP90), SSA1 (HSP70) and YDJ1 can be estimated at ~4:2:1, 
respectively (Ghaemmaghami et al, 2003). HSP40s can also be functionally limiting in 
mammalian systems (Minami et al, 1996; Dittmar et al, 1998; Heldens et al, 2010). We indeed 
see a modest increase in AID levels upon DnaJa1 overexpression. We would not expect a 
dramatic increase since DnaJa1 surely has many substrates and is distributed among all of them 
and so would be any excess DnaJa1. Considering that we achieve ~2-fold increase in DnaJa1 
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levels, the fact that we can see an increase in AID levels and activity is significant and suggest 
that DnaJa1 is indeed limiting for AID folding and/or stabilization. This raises the question of 
whether DnaJa1 overexpression in certain cases, such as EBV infection (Young et al, 2008) or 
its association with antibody-mediated autoimmune diseases (Ramos et al, 2011) could 
contribute to disease by increasing AID levels. 
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3.6. Materials and methods 
3.6.1. Cell lines and drug treatments 
The Ramos Burkitt's B-cell lymphoma lines stably expressing GFP, AID–GFP or AID–
Flag/HA have been described (Patenaude et al, 2009; Orthwein et al, 2010). Chicken DT40 B-
lymphoma cells stably expressing myc–DnaJa1, myc–DnaJa2 or myc–HSP90β were obtained 
by electroporation as described (Sale et al, 2001). GFP–HSC70 was introduced by retroviral 
infection. CH12F3 mouse B cells stably expressing DnaJa1, DnaJa2, AID–GFP or empty 
vectors were generated by retroviral delivery of pMXs-ires–GFP or pMXs constructs and 
sorted for GFP-expressing cells. FTI-277 (Sigma-Aldrich) was diluted in water at 1 mM and 
stored at −20°C. Cycloheximide (CHX) (Sigma -Aldrich) was freshly prepared before each 
experiment and diluted in EtOH at 100 μg/ml. 
 
3.6.2. Identification of AID partners 
The yeast two-hybrid screening has been described (Conticello et al, 2008). Ramos B 
cells stably expressing AID–GFP were lysed on ice in 50 mM Tris–HCl pH 8, 150 mM NaCl, 
1% Triton X-100, 5 mM MgCl2, 100 μg/ml RNase, 100 μg/ml DNase and complete protease 
inhibitors cocktail (Roche) at 3 × 108 cells/ml. AID was immunoprecipitated using anti-GFP-
coated magnetic microbeads and MACS separation columns (Miltenyi Biotec) following the 
manufacturer's instructions. Eluted proteins were separated by SDS–PAGE and silver stained. 
Differential bands compared with the pattern obtained from Ramos cells expressing GFP only 
were excised and submitted to mass spectrometry for protein identification as described 
(Orthwein et al, 2010). 
 
3.6.3. DNA constructs 
AID–GFP, AID–Flag/HA, APOBECs and Myc–HSP90β expression vectors have been 
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described (Orthwein et al, 2010). Human DnaJa1 in pFlag–CMV2 was a kind gift of Dr HY 
Zoghbi (Baylor College of Medicine, Houston). Human HSC70 in pEGFP-C1 was a kind gift 
from Dr U Stochaj (McGill University, Montreal). Human DnaJa2, DnaJa4, DnaJb1 and 
DnaJb11 were obtained from the I.M.A.G.E consortium. Details on DNA constructs are 
provided in Supplementary data. 
 
3.6.4. Retroviral and lentiviral infections 
Retroviral transduction of mouse primary B cells and DT40 cells was as described 
(Patenaude et al, 2009). CH12F3 B cells were infected with retroviral particles obtained from 
the supernatant of HEK293T cell cultures cotransfected with pMXs-ires–GFP or pMXs 
constructs and vectors expressing MLV Gag-Pol and VSV-G envelope (2:1:1 ratio). Briefly, 
the retroviral supernatant was spun down at 2000 g for 90 min at 32°C in Retronectin® 
(Takara)-coated plates before adding 5 × 105 CH12F3 cells and spinning at 600 g for 30 min at 
32°C and GFP+ cells were sorted. A similar procedure was used for lentiviral infections. 
Mission® DnaJa1 and DnaJa2 shRNAs (Supplementary Table SII) cloned in pLKO.1-Puro 
(Sigma-Aldrich) were contransfected with psPAX2 (Addgene plasmid 12260, deposited by Dr 
D Trono) and pVSG-G into HEK293T cells to produce lentiviral particles. An shRNA targeting 
luciferase and cloned in pLKO.1-Puro (Addgene plasmid 1864 deposited by Dr D Sabatini) 
was used as control. Cells were selected in 0.5 μg/ml puromycin 2 days post-infection. 
 
3.6.5. IP and western blot 
Cells were homogenized in lysis buffer (20 mM Tris, pH 8.0, 137 mM NaCl, 10% 
glycerol, 2 mM EDTA, 1% Triton X-100, 20 mM NaF) 48 h after transfection and extracted on 
ice for 10 min. The lysate was clarified for 10 min at 12 000 g at 4°C and processed for western 
blot or IP. Typically, 2–5 × 106 cells were analysed by western blots to detect endogenous 
proteins. Tagged proteins were immunoprecipitated using either anti-Flag M2 affinity gel 
(Sigma-Aldrich) or MACS GFP Isolation kit (Miltenyi Biotech) according to the 
manufacturer's instructions. Eluates and lysates were analysed by western blot developed with 
SuperSignal West Pico Chemiluminescent substrate (Thermo Fisher Scientific). Antibodies 
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used are in Supplementary data. 
 
3.6.6. Monitoring of antibody diversification 
Ig gene conversion was estimated by fluctuation assay of the proportion of cells 
undergoing surface IgM− to IgM+ reversion in multiple single cell-derived populations of DT40 
cells after 3-week expansion at 41°C. IgM expression was measured by flow cytometry using 
1:200 PE- (Southern Biotech) or FITC (Bethyl)-conjugated anti-chicken IgM. IgM to IgA 
switching was assayed in CH12F3-2 cells activated for 3 days with 1 ng/ml TGF-β1, 10 ng/ml 
IL-4 and 1 μg/ml agonist anti-CD40 (BD). IgA expression was measured by flow cytometry 
using anti-mouse IgA-PE antibody (1:200; eBioscience). Ex-vivo isotype switching to IgG1 
was assayed using resting splenic B cells purified by CD43 depletion, with CFSE loading to 
monitor cell division where indicated, as described (Orthwein et al, 2010). Cells were stained 
with anti-IgG1-biotin (1:200; BD) followed by APC-conjugated anti-biotin (Miltenyi Biotech) 
and 10 μg/ml propidium iodide. For the complementation assays of DNAJA1−/− B cells using 
retroviral delivery, double infection was performed at days 2 and 3 post-stimulation and isotype 
switching analysed at day 5. 
 
3.6.7. Mice immunizations and lymphocyte populations 
DNAJA1−/− mice (Terada et al, 2005) were backbred to C57Bl/6J background for at 
least 11 generations. In all experiments, 2- to 4-month-old, sex-matched littermates were used. 
DNAJA1+/+ and DNAJA1+/− served as controls as they were indistinguishable (our results and 
Terada et al, 2005). Mice were immunized i.p. with 100 μg of NP15-CGG (Biosearch 
Technologies Inc., # N5055-5) in 100 μl PBS+100 μl of Imject Alum (Thermo Scientific) and 
boosted at day 30. Blood samples were collected at day −1 (preimmune), day 11 post -
immunization (primary response) and day 37 (secondary response). Anti-isotype-specific 
antibodies were used to capture and detect total serum IgM and IgG1 in serum by ELISA. 
Concentrations were estimated from calibration curves made with Ig isotype standards (BD 
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Pharmingen). Serum levels of total or high affinity anti-NP-specific IgG1 were determined by 
coating plates with NP26-BSA or NP4-BSA (5 μg/well), respectively. IgG1 was detected using 
biotynilated anti-mouse IgG1 (1:1000; BD Pharmingen) followed by HRP-conjugated 
streptavidin (1:5000; Thermo Scientific) and 2,2′ -Azino-bis(3-ethylbenzothiazoline-6-sulfonic 
acid) substrate, detected by absorbance at 405 nm. Arbitrary units were calculated multiplying 
OD readings for each point of a curve made of serial twofold dilutions of the serum by the 
corresponding serum dilution factor. The OD 50% was defined as the anti-NP IgG1 titre for 
each mouse and plotted divided by 100 (NP26) or 10 (NP4) to have similar graphing scales. 
Lymphocyte populations from spleen and thymus were analysed by flow cytometry as detailed 
in Supplementary data. The IRCM's and Kumamoto University's animal experimentation ethics 
committees approved all mouse work. 
 
3.6.8. IF and confocal microscopy 
HeLa cells were transiently cotransfected with AID in pCDNA3.1 and either pEGFP-
C3 DnaJa1 or DnaJa1-C394S using TransIT-LT1 (Mirus). Cells were treated 48 h post-
transfection either by heat shocking at 43°C for 90 min, or with 50 ng/ml Leptomycin B or 
EtOH solvent control for 2 h. Cells were processed for IF and confocal microscopy as 
described (Patenaude et al, 2009), except that blocking was 5% goat serum 1 mg/ml BSA in 
PBS overnight at 4°C and we used a mouse anti-AID MAb (clone, 1:500; Invitrogen) for 1 h 
followed by goat anti-mouse Alexa-680 (1:500; Invitrogen) for 30 min and imaged in an LSM 
510 microscope (Zeiss) with a HeNe 633 laser. Control and DnaJa1-depleted CH12F3 cells 
stably expressing AID–GFP or GFP and DnaJa1 were treated with 10 ng/ml Leptomycin B or 
EtOH for 2 h. Cells were plated on poly-L-Lysine-treated coverslips and processed for confocal 
microscopy. 
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3.9. Supplementary figures 
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Supplementary Figure S3.1. J-protein family structure and comparison between relevant J-
proteins. (A) Schematic structure of the three types of J-proteins indicating their different 
domains (except for type IIIs, which do not share a common organization). CaaX indicates the 
farnesylation motif present in type I J-proteins. CTD, C-terminal domain (B) Similarity 
between all the mouse type I and II J-proteins was estimated from full length protein 
alignments using ClustalX (Thompson et al, 2002) and illustrated by a neighbour-joining tree 
constructed using Seaview 4.2.8 (Gouy et al, 2010). All nodes have significant boostraps 
(>0.5). Type I HSP40s are in red. Type II HSP40s are in black with the ones used in this work 
highlighted in bold. (C) Comparison of the three dimensional structure of the yeast type I 
HSP40 YDJ1 and type II HSP40 Sis1 C-terminal region domains drawn using the same color 
coding as in (A) drawn in MacPymol using pdbs 1NLT (Li et al, 2003) and 3AGZ (Sha et al, 
2000), respectively. The dimerization domain of YDJ1 involving many interspersed 
hydrophobic residues in CTDIII was drawn from pdb 1XAO (Wu et al, 2005). (D) Protein 
alignment of mouse DnaJa1 and DnaJa2 with identities shown as grey boxes to highlight the 
extensive similarity between the two proteins. 
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Supplementary Figure S3.2. Analysis of DnaJa1- or DnaJa2-depleted CH12F3 cells. (A) IgA 
germline transcript (Iα GLT) and Aicda transcript levels were estimated by semiquantitative 
RT-PCR on serial two-fold dilution of cDNA made from CH12F3 transduced with control or 
DnaJa1 shRNA, 24h post-CIT. Gapdh was used as control; – ,reverse transcriptase was 
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omitted. (B) Growth curves of the indicated CH12F3 populations starting from 5 x 104 cells/ml 
were determined by counting live cells in a haemocytometer. Mean ± SEM of duplicate cultures 
are plotted over time. (C) The effect of DnaJa1 or DnaJa2 downregulation on the levels of 
HSP90 and HSC70 was monitored by western blot for the indicated CH12F3 populations using 
actin as loading control. 
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Supplementary Figure S3.3. Analysis of lymphocyte populations in DNAJA1-/- mice. (A) 
Mean ± SD spleen weight of three DNAJA1-/- mice normalized to their respective littermate 
controls. (B) Total number of splenocytes per spleen for three littermate mice pairs. (C) 
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Representative flow cytometry profile of splenocytes from DNAJA1-/- and littermate control 
stained for B and T cells with anti-B220-APC and anti-CD3-PercPCy5.5, respectively. (D) 
Proportion of T cells (CD3+ B220-), B cells (CD3- B220+) and their ratio in splenic 
leukocytes for 3 pairs of control and DNAJA1-/- littermates. Each female (triangles) and male 
(circles) pair is linked by a line. (E) Splenic CD4 to CD8 T cell ratio for three DNAJA1-/- mice 
calculated from flow cytometry data and plotted as mean ± SD of the value normalized to their 
littermate controls set at 2. (F) Representative flow cytometry profile of B220+ splenic B cell 
subpopulations from DNAJA1-/- and littermate control mice. Anti-CD21-FITC versus anti-
CD23-PE plot of B220+-gated cells is shown. Marginal zone (MZ) (CD21+ CD23-), follicular 
(Fo) (CD21+ CD23+) and non-follicular (NF) (CD21- CD23-) B cells are indicated. (G) 
Proportion of follicular, marginal zone and non-follicular B cells in splenic B cells calculated 
from flow cytometry data of 3 littermate pairs. (H) Relative proportion of immature and mature 
B cells in splenic B220+ cells plotted as mean ± SD of the DNAJA1-/- mice values normalized 
to their littermate controls set as 100%. (I) Total number of thymocytes per thymus for 3 mouse 
littermate pairs. (J) Representative flow cytometry profile of CD3+ thymic T cells stained with 
anti-CD4 and anti-CD8. (K) Relative proportion of thymic T cell subpopulations plotted as 
mean ± SD of three DNAJA1-/- mice normalized to their respective littermate controls set as 
100%. In all panels, paired, two-tailed t-test was used with p values indicated where the 
differences are statistically significant (p<0.05). 
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Supplementary Figure S3.4. DNAJA1-/- B cell proliferation, Aicda and IgH sterile 
transcripts. (A) Proportion of IgG1+ cells at each generation, as determined from CFSE 
staining, for four littermate pairs of DNAJA1-/- and control mice. (B) Mean proportion + SD of 
live (top panel) and dead (bottom panel) cells in each generation for the four DNAJA1-/- (white 
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bars) and the four control (black bars) mice shown in (A). The proportion of live cells was 
calculated by flow cytometry as the proportion of cells at each CFSE peak after gating cells on 
forward and side scatter and excluding dead cells by propidium iodide (PI) staining. Dead cell 
proportion was calculated by gating cells on forward and side scatter, then plotting CFSE 
versus PI and determining the proportion of PI+ cells for each generation. (C) Resting splenic 
B cells from DNAJA1-/- and littermate control mice were loaded with CFSE and analyzed at 0, 
48 and 96 h poststimulation by flow cytometry. Profiles from all time points are plotted 
superimposed in the same histogram. (D) Aicda transcript and IgM (μ) and IgG1 (γ1) germline 
transcripts (GLT) estimated by semi-quantitative RT-PCR using 2-fold serial dilutions of cDNA 
made from DNAJA1-/- and littermate control mice B cells. Gapdh was used as control; –, 
samples in which reverse transcriptase was omitted. 
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Supplementary Figure S3.5. DNAJA1-/- B cell proliferation, Aicda and IgH sterile 
transcripts. (A) Aicda transcript levels were estimated by semi-quantitative RT-PCR using 2-
fold serial dilutions of cDNA prepared from mock or FTI-277-treated Ramos and mouse 
primary B cells. (B) Control or DnaJa1-depleted CH12F3 cells expressing AID-GFP or GFP 
and DnaJa1 were treated with leptomycin B to monitor the effect of DnaJa1depletion on AID 
subcellular localization. Representative confocal images are shown, scale bar 10 μm. The 
cellular localization of each protein was classified and the proportion of cells showing each 
distribution is plotted as bars with the number of cells counted indicated (n). C, cytoplasm; N,  
nuclear. 
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3.10. Supplementary materials and methods 
3.10.1. DNA constructs.  
DnaJa1 was subcloned as a BglII-BamHI fragment into pEGFP-C1 and pcDNA3.1-myc 
by using oligonucleotides AO14 and AO6 (see oligonucleotide sequences in Supplementary 
Table SI). DnaJa1 C394S (ΔF) point mutation was introduced by Quickchange (Stratagene) 
using oligonucleotides AO58 and AO59. DnaJa1 truncations were generated by using internal 
restriction site: HindIII-BamHI fragment subcloned into pEGFP-C3 for DnaJa1ΔN1(50-397) 
and EcoRI-BamHI fragment subcloned into pEGFP-C1 for DnaJa1ΔN2(161-397). hDnaJa2 
was subcloned into pEGFP-C1 as a SalI-BamHI fragment or into pcDNA3.1-myc as BglII-
BamHI fragment. hDnaJa4 was subcloned as a BlgII-BamHI fragment, hDnaJb1 and hDnaJb11 
as BamHI-EcoRI fragments into pcDNA3.1-myc using oligonucleotides AO16-AO17, AO18-
AO19 and OJ110-OJ111 respectively. hDnaJa1 and its respective ΔF mutant were subcloned as 
a BamHI-NotI fragment into pMX-iresGFP using oligonucleotides AO66- AO67 and AO66-
AO68 respectively. hDnaJa2 was excised from pcDNA3.1-myc as a BamHI-EcoRI fragment 
and subcloned into pMX-iresGFP. GFP-HSC70 was excised as a HindIII-XhoI fragment and 
subcloned in pMXs vector. 
 
3.10.2. Antibodies used for western blot.  
Anti–EGFP–HRP (1:3,000; Miltenyi Biotec), anti– Myc-HRP (1:3,000 Miltenyi 
Biotec), anti–Flag-HRP (1:3,000 Sigma-Aldrich), anti- HSP90 (1:3,000 sees both isoforms; 
BD), anti-AID (1:1,000 Cell Signaling Technology), anti-actin (1:3,000; Sigma-Aldrich), anti-
PCNA (1:5,000 PC-10; Abcam), anti-DnaJa1 (1:3000 KA2A5; Thermo Scientific), anti-HA 
(1:3000 CAB3872; Thermo Scientific), anti-HSC70 (1:2000 SMC-106A; Stressmarq). 
Polyclonal rabbit serum recognizing mouse AID (1:500) was a kind gift from Dr J. Chaudhuri 
(Sloan-Kettering Institute, New York). Specific antibodies against DnaJa2, -a4 and –b1 have 
been described (Abdul et al, 2002; Terada & Mori, 2000). Secondary antibodies used were goat 
anti–mouse Ig-HRP and anti–rabbit Ig-HRP (1:10,000; Dako) and goat anti–rat Ig-HRP 
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(1:5,000; Millipore). 
 
3.10.3. Lymphocyte population analysis.  
Mice were euthanized, organs collected and grinded through a 70 μm cell strainer. 
Splenocytes were centrifuged at 400 x g for 10 min at RT and resuspended in 1 ml erythrocytes 
lysis buffer for 5 min at RT, washed and resuspended in PBS. Aliquots of 5 x 105 cells were 
stained for 15 min using combinations of the following antibodies (BD Pharmingen): anti-
B220APC, anti-CD3PerCCPCy5.5, anti- CD4PE, anti-CD8APC, anti-CD21FITC and anti-
CD23PE (all 1:200); anti-IgMPE and anti- IgDFITC (both 1:100). Dead cells were excluded by 
staining with 10 μg/ml propidium iodide. Data was acquired in a FACSCalibur (BD 
Biosciences) and analyzed using FlowJo (Tree Star, Inc). 
 
3.10.4. Semi-quantitative RT-PCR.  
Total RNA was extracted with TRIzol® (Invitrogen). cDNA was synthesized by 
random priming using the ProtoScript® M-MuLV Taq RTPCR kit (NEB). Mouse and human 
Aicda transcripts were amplified using oligonucleotides AO43/AO44 and OJ500/OJ538 
respectively. IgM (μ), IgA (Iα) and IgG1 (γ1) germline transcripts were amplified using 
oligonucleotides OJ530/OJ531, AO45/AO46 and AO39/AO40 respectively. Gapdh transcripts 
were amplified using oligonucleotides provided by the manufacturer. 
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conceived the project and wrote the paper. All authors discussed and interpreted the data and 
contributed to the final manuscript. 
 
4.2. Abstract 
Activation Induced Deaminase (AID) and the APOBEC proteins constitute a group of 
cytidine deaminases acting on DNA and/or RNA with diverse physiological functions. AID 
targets the immunoglobulin genes thereby initiating antibody somatic hypermutation and 
isotype class switching during immune responses. Regulation of AID protein levels is central to 
balancing efficient immunity with AID pathological roles in cancer and autoimmunity. In this 
study, we report that AID is instrinsically less stable than its APOBEC paralogs. This, at least 
partially explains why AID stability depends on constant chaperoning by the HSP90 system, 
while we find that APOBEC1, 2 and 3G are not even indirectly depending on HSP90. We 
identify AID N-terminal aspartic acid residue and an internal PEST-like motif as destabilizing 
modulators of AID protein turnover. Disruption of these motifs impacts AID levels by 
increasing its stability and concomitantly upregulates antibody diversification. Moreover, we 
find that cytoplamic polyubiquitination and proteasomal degradation of AID is not dependent 
on its internal lysine residues. Furthermore, the addition of a HA tag at the N-terminus of AID 
did not prevent its cytoplasmic protein turnover, suggesting a non-canonical way of targeting 
AID to the proteasome. Thus, we show that there is a direct contribution of AID intrinsic 
instability to regulate the efficiency of antibody diversification. 
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4.3. Introduction 
The Activation Induced Deaminase (AID)/APOBEC family comprises several members 
that act as DNA and/or RNA mutators to perform their biological roles (1). While the functions 
of APOBEC2 and APOBEC4 are still unclear, AID, which is considered to be one of the 
ancestral members of this family, plays a central role in adaptive immunity by initiating the 
diversification of the peripheral antibody repertoire during the GC reaction (2, 3). APOBEC1, 
on the other hand, edits apolipoprotein B mRNA, which generates a premature stop codon and 
leads to the expression of a tissue-specific truncated apolipoprotein B polypeptide chain (4, 5). 
Finally, the APOBEC3 subgroup is important for the innate immune response to retroviruses 
and protects against the transposition of endogenous retroelements by deaminating their cDNA 
(6). 
AID catalyzes the deamination of deoxycytidine to deoxyuridine at defined regions of 
the immunoglobulin (Ig) genes, initiates somatic hypermutation (SHM) and class switch 
recombination (CSR) (7-9). SHM entails the introduction of point mutations within the IgV 
region and underpins affinity maturation of the antibody response (8, 9). In addition, AID 
targets the DNA regions immediately preceding the constant exons that encode for the different 
antibody isotypes. Processing of the deoxyuridine leads to the generation of a double-strand 
break intermediate and results in CSR, replacing the default IgM isotype for either IgG, IgE or 
IgA (7). AID deficiency compromises the antibody response leading to a hyper-IgM 
immunodeficiency syndrome and to a susceptibility to specific autoimmune manifestations (3, 
10-12). On the other hand, AID overexpression contributes to other types of antibody-mediated 
autoimmune diseases such as lupus (13). Finally, physiologically or aberrantly expressed AID 
predisposes to cancer (14, 15) due to some off-target activity which leads to mutations in tumor 
suppressor and/or (proto)-oncogenes (16-18) and chromosomal translocations (19-23). Beyond 
its role in antibody diversification, physiological expression of AID outside the GC B cells is 
well documented but the role and the regulation of AID in these contexts are virtually unknown 
(11, 12, 24-31).  
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Ensuring that AID is expressed appropriately and in the right context is critical to favor 
its physiological functions over its pathological effects. However, the growing number of 
instances in which AID is expressed outside of the GC B cells in physiological or pathological 
conditions highlights the importance of post-transcriptional and post-translational regulation. In 
this context, regulatory pathways controling AID at the mRNA and protein levels as well as 
restricting its access to the nucleus are extremely important (32, 33). AID stability is directly 
linked to its subcellular localization. AID is a nucleo-cytoplasmic shuttling protein with 
predominantly cytoplasmic steady-state localization (34-38). AID is much more stable in the 
cytoplasm than in the nucleus (39, 40), but the molecular explanation for this differential 
stability is only partially known. We have shown that AID interacts with and is stabilized by 
the HSP90 molecular chaperoning pathway in the cytoplasm (40, 41). Nuclear AID may be 
unstable in part of a lack of chaperoning but the finding that AID is targeted for degradation by 
REGγ suggests also some active destabilization (42). It remains unclear why AID requires the 
assistance of chaperones in comparison to the APOBEC proteins, which share conserved three-
dimensional structure and much sequence similarity but do not bind the same chaperones (40, 
41). 
This study aimed at identifying putative intrinsic sequence or structure that determines 
AID stability. Although the general steps implicated in protein turnover are well characterized, 
it is unclear what are the actual signals dictating protein stability. Several biochemical and 
biophysical properties of proteins have been described as determinants of protein turnover 
including molecular weight (43), isoelectric point (44, 45), hydrophobicity (46, 47) and the 
presence of certain motifs (48-51). The presence of unstructured regions has also been 
implicated in protein stability (52, 53). In several subsets of proteins, motifs also called degrons 
that predispose a protein to increased instability have been identified including the APC/C-
dependent D- and KEN boxes (49, 54-57), the TrCP recognition box (DSGXXS) (58-61), and 
the PEST motifs (50, 62). The simpler N-degron has also been extensively described in which 
the nature of a protein N-terminal amino acid determines its half-life (51, 63). Newly 
synthesized proteins contain an N-terminal methionine which is considered as a stabilizing 
residue according to the N-end rule, but proteins can be enzymatically modified at their N-
terminus to reveal a primary, secondary or tertiary destabilizing residue depending on the 
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number of steps required before its polyubiquitination starts (63). Proteins degraded by the 
ubiquitin-proteasome pathway not only require the presence of degrons, but also the availability 
of free residues for attachment of polyubiquitin chains for targeting to the proteasomal 
degradation (64, 65).  
Here, we report that AID is intrinsically less stable than its paralogs, the APOBECs. 
This is in good part determined by the N-end rule and an internal PEST-like motif. Disruption 
of these degrons modulates AID protein turnover and directly impacts antibody diversification, 
without affecting AID subcellular localization. Strikingly cytoplasmic AID protein turnover 
and polyubiquitination state is independent of its internal lysine residues. In conclusion, we 
report for the first time a direct contribution of AID intrinsic instability in the regulation of its 
biological activity and antibody diversification, independently of its subcellular localization.  
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4.4. Experimental procedures 
4.4.1. DNA constructs 
AID-GFP, GFP-AID, AID-A2 chimeras and APOBEC constructs have been described 
previously (66). The AID Kzero mutant in which every lysines were mutated to arginines and 
fused to GFP was a kind gift of Dr Reynaud (INSERM, Paris). AID-D2A was cloned in 
pGEM-T vector as a BamHI-EcoRI fragment by using oligonucleotides OJ251 (5'-
AAGGATCCCAAATGTTCAGCCTCTT GATGAA-3') and OJ166 (5'-CGAATTCCCAAGTC 
CCAAAGTACGAAATGC-3') and subcloned into pEGFP-N3 as a BglI-EcoRI fragment. AID-
D2A-GFP fragment was subsequently subcloned into pTRC vector as a Nhe-NotI fragment or 
in pMX vector as a NotI-EcoRI fragment. The same procedure was performed with AID-D2F 
using oligonucleotides OJ252 (5'-AAGGATCCCAAATGTTCAGCCTCTTG ATGAA-3') and 
OJ166. D67A/D69A double mutation was introduced into pAID-GFP by quickchange using 
oligo-nucleotides OJ343 (5'-GCTACATCTCGGCCTGGGCCCTAGACCCTGG-3') and OJ344 
(5'-CCAGGGTCTAGGGCCCAGGCCGAGATGTAGC-3'). AID-D67/69A-GFP was 
subcloned into pTRC vector or pMX vector as previously described. 
 
4.4.2. Drug treatments 
Stock aliquots of 2 mM GA were made in DMSO. Stocks of 5 mM MG132 (EMD) and 
25 µg/ml LMB (LC Laboratories) were made in ethanol. CHX (Sigma-Aldrich) was freshly 
prepared before each experiment (100 µg/ml) in EtOH. All drugs were stored at −20°C 
protected from light. 
 
4.4.3. Confocal microscopy 
HeLa cells were transiently transfected with AID and its mutants in pEGFP-N3 using 
TransIT-LT1 (Mirus). Cells were treated 48 h post transfection with 50 ng/ml Leptomycin B or 
EtOH solvent control for 2 h. Cells were processed for confocal microscopy as described (38). 
 
4.4.4. AID stability assays 
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The GFP signal of cell lines expressing AID-GFP variants was measured by flow 
cytometry at various time points after the indicated treatments as previously described (38, 40). 
Dead cells were excluded by propidium iodide staining. 
 
4.4.5. AID mutagenic activity 
AID catalytic activity was measured by a mutation assay as previously described (67) 
using the ung-deficient E. coli strain BW310 expressing AID-GFP and derived mutants. 
 
4.4.6. Retroviral infection 
The Ramos Burkitt’s B cell lymphoma lines stably expressing AID-GFP or GFP-tagged 
APOBEC proteins were generated as previously described (38, 66). Retroviral transduction of 
mouse AID-/- primary B cells has been described (38). DT40 IgM+ ψV− AID-/- chicken B and 
Ramos B cells were infected with retroviral particles obtained from the supernatant of 
HEK293T cell cultures cotransfected with pMX and vectors expressing MLV Gag-Pol and 
VSV-G envelope (2:1:1 ratio) as previously described (38). GFP+ cells were FACS-sorted.  
 
4.4.7. Monitoring of antibody diversification 
AID-mediated somatic hypermutation was estimated by fluctuation assay of the 
proportion of cells undergoing surface IgM+ to IgM- reversion in multiple subcloned 
populations of sIgM+ ψV− AID-/- DT40 cells complemented with various GFP-tagged AID 
constructs after 4 weeks of expansion at 41°C (68). IgM expression was measured by flow 
cytometry using 1:200 PE-conjugated anti–chicken IgM (Southern Biotech). Ex vivo isotype 
switching to IgG1 was assayed using resting splenic AID-/- B cells purified by CD43 depletion 
as described (38). Cells were stained with anti–IgG1-biotin (1:200; BD) followed by APC-
conjugated anti-biotin (Miltenyi Biotech) and 10 µg/ml propidium iodide. 
 
4.4.8. Western blot 
Cells were homogenized in lysis buffer as previously indicated (40). The lysate was 
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clarified for 10 min at 12,000 x g at 4°C and processed for western blot. Typically, 2 x 106 cell 
equivalents were analyzed by western blots. Tagged proteins were immunoprecipitated using 
MACS GFP Isolation kit (Miltenyi Biotech) according to the manufacturer’s instructions. 
Eluates and lysates were analyzed by western blot developed with SuperSignal West Pico 
Chemiluminescent substrate (Thermo Fisher Scientific). Antibodies used for western blot were 
anti–EGFP–HRP (1:3,000; Miltenyi Biotec), anti-AID (1:1,000 Cell Signaling Technology), 
anti-PCNA (1:5,000 PC-10; Abcam), and anti-monoubiquitinated and -polyubiquitinated 
conjugates antibody (1:1,000; Enzo Life Sciences, Inc.). 
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4.5. Results 
4.5.1. Unlike AID, the APOBEC enzymes are independent of HSP90 
We have previously shown that AID interacts with several members of the HSP90 
molecular chaperoning pathway including the HSP40 DnaJa1, HSC70 and HSP90 (40, 69). 
None of the APOBEC1, 2 or 3G was able to bind to any of these chaperones, which is puzzling 
given the phylogenetic and high sequence and structure similarities among AID/APOBEC 
members. This could be due to a more transient interaction or an indirect dependence on 
HSP90 of the APOBECs. The AID-HSP90 interaction is functionally important to stabilize and 
maintain the steady-state levels of cytoplasmic AID and can be monitored by stably expressing 
GFP-tagged proteins in a human B cell line and measuring the mean fluorescence intensity 
(MFI) of the GFP signal over time after inhibiting HSP90 with geldanamycin (GA) (40). We 
used stable transfectants of the Ramos B cell lymphoma line because at least AID and 
APOBEC3G are endogenously expressed in B cells (2, 70). We found that, unlike AID, 
APOBEC1 (A1), APOBEC2 (A2) and APOBEC3G (A3G) levels did not change over time 
after HSP90 inhibition (Figure 4.1A). AID nuclear accumulation upon treatment with the 
CRM1 nuclear export inhibitor leptomycin B (LMB) leads to its degradation in the nucleaus 
(Figure 4.1A and 4.1B) (39, 40). A3G is exclusively cytoplasmic but A2 is distributed 
throughout the cell; A1 shuttles in and out of the nucleus and accumulates in the nucleus of 
Ramos cells after LMB treatment (Figure 4.1B). However, neither A2 nor A1 are destabilized 
by LMB treatment, in fact A1 levels increased after CRM1 inhibition (Figure 4.1A). We then 
measured the stability of AID and its paralogs by treating cells with cycloheximide (CHX) to 
block protein synthesis and followed the decay of GFP-tagged proteins in Ramos B cells 
(Figure 4.1C). AID displayed the fastest decay with a half-life of 13.6 hours; A3G 
demonstrated a longer half-life with 24 hours. As expected, HSP90 inhibition led to a 
significant decrease in AID half-life but did not affect the APOBECs (Figure 4.1C). We 
conclude that none of the APOBECs directly or indirectly requires HSP90 activity. These 
results also suggest that AID requires constant chaperoning by HSP90, a chaperone that 
stabilizes nearly-folded proteins rather than participating in protein biogenesis, because it bears  
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Figure 4.1. The protein half-life of AID is shorter than the other APOBECs. (A) GFP-tagged 
AID, APOBEC1 (A1), APOBEC2 (A2) and APOBEC3G (3G) were stably expressed in Ramos 
B cells and GFP mean fluorescence intensity (MFI) was monitored by flow cytometry at 
different times after treatment with 2µM geldanamycin (GA), 50 ng/ml leptomycin B (LMB) or 
DMSO control (Ctrl) and normalized to t0 = 100%. One of two independent experiments is 
shown. Average MFI ± SD of duplicates is plotted over time (*, p<0.05, paired two-tailed t-
test). (B) Hela cells transfected with GFP-tagged AID, A1, A2 or A3G were treated with 
leptomycin B fixed and imaged by confocal microscopy. Representative confocal images are 
shown, scale bar 10 µM. The cellular localization of each protein was classified and the 
proportion of transfected cells showing each distribution is plotted as bars with the number of 
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cells quantified indicated (n). C, cytoplasm; N, nuclear.(C) Stable transfected Ramos cells were 
treated with 100 ng/ml cycloheximide (CHX; upper panel) alone or before HSP90 inhibition 
(lower panel) and GFP-tagged protein levels were followed as in (A). One of two independent 
experiments is shown. Average MFI ± SD of duplicates is plotted over time (*, p<0.05, paired 
two-tailed t-test). The half-life of each AID/APOBEC proteins was calculated by linear 
regression. Half-life in hours ± SD is indicated.  
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intrinsic instability features that destabilize AID both in the cytoplasm as well as in the nucleus. 
 
4.5.2. Survey of putative destabilizing sequences in AID 
We asked whether there were domains in AID that could cause instability. We used 
AID-APOBEC2 chimeras, in which 30-50 amino acid-long AID regions were replaced by the 
corresponding homologous APOBEC2 residues (Figure 4.2A), to screen for regions of AID 
that could be implicated in its intrinsic instability. A caveat of this strategy is that the structure 
of AID is not known and these AID-A2 chimeric proteins could simply be unstable because 
they are not folded properly. Indeed, chimeras #3 and #4, in which amino acids 88-116 and 
118-150 of AID were respectively replaced, displayed shorter half-lives than wild-type AID 
(Figure 4.2B-C). However, chimeras #1 and #2, replacing AID N-terminal residues (19-57 or 
59-84 amino acids, respectively), showed significantly longer half-lives than AID (Figure 4.2B-
C). These could be explained by a defect in AID subcellular trafficking since we have shown 
previously that chimera #1 fails to enter the nucleus and chimera #2 has a reduced kinetic of 
nuclear import compared to AID (38). However, N-terminal GFP tagging of AID also entirely 
blocks its nuclear import (38) and still had a shorter half-life than chimera #1 (Figure 4.2B-C). 
These results suggested that the AID regions replaced in chimeras #1 and #2 contained motifs 
destabilizing AID. 
As a first approach to define AID destabilizing residues, we performed a sequence 
analysis for known destabilizing structures and motifs (degrons). Several HSP90 client proteins 
are intrinsically unstructured proteins (IUP) (71-76). Furthermore, several studies have 
highlighted the importance of unstructured regions for protein degradation by the ubiquitin-
dependent and independent proteasome (52, 64, 77, 78). We compared AID and APOBEC 
proteins for the presence of disordered regions using two different prediction algorithms  
(DisEMBLTM (79) and PONDR® (80)) which report unstructured residues based on the protein 
sequence. In both analyses, AID presented the largest proportion of disordered regions (31% 
and 18% of AID, respectively) (Table 4.1). Interestingly, several of these regions are predicted 
as hot loops (defined as loops with a high degree of mobility) and indeed coincide with 
predicted loops in the three-dimensional model of AID (Figure 4.2D). Analysis of AID protein  
 
163 
 
 
 
Table 4.1. Predicted intrinsic protein disorder and unstructured regions within human AID/ 
APOBEC proteins. 
 
HUGO 
name 
Description 
               Hot loops 
    Predicted by DisEMBLTM 
         Disordered regions 
        predicted by PONDR® 
Position (aminoacid) 
Unstructured 
coverage 
(%) 
Position 
(aminoacid) 
Unstructured 
coverage (%) 
AICDA activation-induced 
cytidine deaminase 
14-29 
38-51 
120-130 
179-198 
 
31 1-6 
13-19 
25-33 
125-128 
188-195 
 
18 
APOBEC1 apolipoprotein B mRNA 
editing enzyme, catalytic 
polypeptide 1 
1-32 
51-62 
 
19 1-14 
48-55 
 
10 
 
APOBEC2 
 
apolipoprotein B mRNA 
editing enzyme, catalytic 
polypeptide-like 2 
 
10-24 
197-207 
 
 
12 
 
10-24 
 
7 
 
APOBEC3G 
 
apolipoprotein B mRNA 
editing enzyme, catalytic 
polypeptide-like    3G 
 
1-31 
40-52 
204-214 
 
 
14 
 
1-3 
48-52 
138-147 
326-330 
373-381 
 
8 
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Figure 4.2.  N-terminal region of AID modulates its stability. (A) Schematic representation of 
AID-APOBEC2 chimeric proteins (AID-A2ch1-4) in which either one of the regions from A2 
indicated between dotted lines was substituted for the homologous AID region. (B) GFP-tagged 
AID and AID-A2 chimeras were stably expressed in Ramos B cells and GFP MFI was 
monitored as previously indicated after CHX treatment and normalized to t0 = 100%. One of 
two independent experiments is shown. Average MFI ± SD of duplicates is plotted over time (*, 
p<0.05, paired two-tailed t-test). (C) Half-life in hours ± SD of each AID and AID-A2 proteins 
calculated from linear regression projection of the data obtained in (B) is indicated. (D) 
DisEMBLTM prediction of AID hot loops are indicated in red in AID three-dimensional model 
(38). (E) Multispecies alignment of AID N-terminal region containing a conserved aspartic 
acid at position two (in red) and two conserved PEST-like motifs (highlighted in blue for the 
PEST-I (score: -10.81) and in green for the PEST-II (score: -15.23)).  
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sequence for the presence of degrons failed to identify any significant TrCP recognition box 
(81), KEN box or D-box motif usually present in cell-cycle regulated proteins (49). Unfolded 
regions have been shown to be enriched in PEST motifs, which are stretches of amino acids 
enriched in proline (P), glutamic (E) or aspartic acid (D), serine (S), and threonine (T) and are 
implicated in protein turnover of many unstable proteins (50, 62). PEST motifs are usually 
located in solvent-exposed loops or extensions that are preferentially targeted for proteolytic 
cleavage by the proteasome (82, 83). Analysis of human AID protein sequence using the 
pestfind algorithm identified two putative PEST sequences with poor scores (Figure 4.2E), 
located between amino acids 63-74 (PEST-I) and amino acids 77-92 (PEST-II). These domains 
are highly conserved in AID orthologs (Figure 4.2E), PEST-I was only absent in Xenopus AID.  
Several others destabilizing motifs have been described previously. N-terminal 
unstructured proteins are also associated with N-degrons that regulate protein stability by the 
proteasome through the N-end rule pathway (63). Some of these proteins have their N-terminal 
methionine enzymatically removed. The nature of the second N-terminal residue influences the 
stability of these proteins by making it more or less susceptible to the N-end rule pathway. 
Amino acids are divided between primary, secondary or tertiary destabilizing for this pathway. 
Interestingly, AID displays a secondary destabilizing aspartic acid residue at position two, 
which is conserved throughout evolution (Figure 4.2E). This raised the possibility that AID 
could be subjected to the N-end rule. Although none of these predictions is conclusive, they all 
prompted to the N-terminal region of AID for possible intrinsic determinants of its stability. 
 
4.5.3. Altering AID cytoplasmic stability impacts its physiological 
activity 
There is no evidence that AID N-terminus is modified but the influence of the N-
terminal residue in half-life can be tested by mutating it to a more stabilizing or destabilizing 
residue. We replaced AID D2 residue with either a more destabilizing residue, we chose 
phenylalanine (D2F), or a more stabilizing one, alanine (D2A), and analyzed their impact on 
AID stability. We first confirmed that D2A or D2F mutation did not affect AID subcellular 
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localization and shuttling, which are important for AID stability (Figure 4.3A). We also 
measured the catalytic activity of these mutants using the E.coli-based rifampicin-resistance 
assay (67). D2A catalytic activity was reduced by ~25% compared to AID and D2F was 
equally active than wild-type (Figure 4.3B). Conserved enzymatic activity and nucleo-
cytoplasmic shuttling are good indications that these single point mutants of AID do not have 
any major structural alteration. We then analyzed their half-lives in Ramos B cell. In steady-
state, D2A showed a mild but significantly longer half-life than AID while D2F was less stable 
than wild-type AID (Figure 4.3C). Interestingly, modification of the AID N-terminal residue 
impacts its stability in the cytoplasm, but not in the nucleus since both mutants show equal 
decay kinetics after LMB treatment (Figure 4.3C lower left and upper right panels). Analysis of 
AID variants expression in 293 cells by western blot correlates with stability data obtained in 
Ramos B cells : D2A showed higher steady-state levels whereas D2F was less expressed 
compared to AID (Figure 4.3D). Unlike the AID-A2 chimeras, these mutants provided useful 
enzymes to analyse the impact of AID cytoplasmic stability on its biological function. 
Therefore, we performed CSR assays on Aicda-/- mouse B cells complemented by retroviral 
delivery with GFP-tagged AID variants. D2A and D2F showed significantly reduced isotype 
switching to IgG1 (Figure 4.3E). We also assayed AID-mediated SHM in an Aicda-/- chicken 
DT40 cell line that diversifies the IgVλ by SHM (68) and can be monitored by the appearance 
of sIgM-loss cells from originally sIgM+ populations. There was also a reduction for both D2A 
and D2F mutants, although, in this case, D2A reduction was non-significantly different from 
wild-type AID (Figure 4.3F). The compromised CSR and SHM of the D2A mutant could be 
simply explained by its reduced catalytic activity. However, D2F mutant shows that the 
introduction of a primary destabilizing residue in AID N-terminus had no impact on its 
catalytic activity, therefore the decrease in CSR and SHM must be due to the change in 
stability. We conclude that AID stability in the cytoplasm is important for antibody 
diversification. 
 
4.5.4. A PEST-like motif influences AID stability and function 
Although our data suggest that the N-degron contributes to AID instability, it cannot 
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Figure 4.3. Altering AID N-terminal aspartic acid residue impacts both its stability and 
function. (A) Hela cells transfected with GFP-tagged AID mutated at position 2 either for a 
more stabilizing residue alanine (D2A), or a primary destabilizing residue phenylalanine 
(D2F) with regard to the N-end rule were treated with LMB and processed as previously 
indicated (Figure 1B). Representative confocal images are shown; scale bar 10 µM. n, number 
of cells counted indicated; C, cytoplasm; N, nuclear. (B) The catalytic activity of GFP-tagged 
AID and the indicated mutants was monitored by E. coli mutation assay. The number of 
rifampicilline-resistant colonies/109 viables colonies obtained for AID-GFP construct was set 
as 100%. Ctrl, pTRC empty vector. (C) GFP-tagged AID and its mutants D2A and D2F were 
stably expressed in Ramos B cells and analyzed as previously described. One of two 
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independent experiments is shown. Average MFI ± SD of duplicates is plotted over time (*, 
p<0.05, paired two-tailed t-test). Half-life in hours ± SD is indicated. (D) 293 retroviral 
producing cells transfected with the indicated AID-GFP contruct or GFP control in pMX were 
harvested, lyzed and the expression level of the indicated proteins was analyzed by WB using 
anti-AID antibody. GFP-tagged AID contructs migrate at an approximate size of 45 kDa. 
PCNA was used as a loading control. Expected AID-GFP band was identified by a circle. (E) B 
cells from AID-deficient mice were infected with retroviruses encoding GFP-tagged AID, the 
indicated AID-GFP variants or GFP control in pMX. The proportion of infected (GFP positive) 
cells that have switched to IgG1 was measured by flow cytometry in non-saturating conditions 
of stimulation (5 ng/mL IL-4 and 25 µg/mL LPS) and summarized in the bar graphs. Means ± 
SD values from seven independent mice for each construct are plotted relative to AID-GFP 
value set as 100%. (F) SHM was monitored in analogous experiments to (E) except that a 
sIgM+ ψV− AID-/- DT40 chicken cell line, which uses SHM to diversify the Ig genes, was used. 
IgM-loss cells arise as a consequence of SHM with a certain frequency, and so the proportion 
of sIgM-loss cells arising over time provides an estimate of SHM rate. DT40 cells infected with 
the indicated retroviral GFP-tagged AID contruct were sorted for GFP+ cells. The proportion 
of infected (GFP positive) cells that have lost IgM was measured for several subclones by flow 
cytometry and summarized in the graphs. Median values from twelve subclones for each 
construct are indicated. In all panels, p values from paired, two-tailed t-test are indicated only 
for significant differences (p<0.05). 
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Figure 4.4. Disruption of a PEST-like motif in AID results in increased stability and 
antibody diversification. (A) Detailed location in a putative AID monomer (left panel) and 
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dimer (right panel) of PEST domains present in its N-terminus. For clarity, the same colors as 
in figure 2E were used to deliminate PEST domains. The right panel shows a predicted solvent-
accessible surface of the putative PEST. (B) GFP-tagged AID and its mutant were stably 
expressed in Ramos B cells and analyzed as previously described. One of two independent 
experiments is shown. Average MFI ± SD of duplicates is plotted over time (*, p<0.05, paired 
two-tailed t-test). (C) Half-life in hours ± SD of AID and D67/69A mutant calculated from 
linear regression projection of the data obtained in (B) is indicated. (D) Hela cells transfected 
with GFP-tagged AID or its mutant D67/69A which affects the putative PEST-I domain were 
treated with LMB and processed as before as in Figure 1B. Representative confocal images are 
shown; scale bar 10 µM. n, number of cells counted indicated; C, cytoplasm; N, nuclear. (E) 
The catalytic activity of GFP-tagged AID and the indicated mutant was monitored as 
previously indicated. AID-GFP catalytic activity was set as 100%. Ctrl, pTRC empty vector. 
(F) CSR was measured as previously indicated. Means ± SD values from six independent mice 
for each construct are plotted relative to AID-GFP value set as 100%. (G) SHM was monitored 
as previously indicated. Median values from twelve subclones for each construct are 
indicated.In panels (F) and (H), p values from paired, one-tailed Student’s t-test are indicated 
only for statistically significant differences (p<0.05) 
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explain the difference in protein turnover between AID and chimeras #1 and #2, which do not 
affect AID N-terminal end. We asked whether the PEST-like motifs present in AID contribute 
to its intrinsic instability. The PEST-I domain overlapped a solvent-exposed loop in our AID 
model (Figure 4.4A), while the PEST-II domain would be less accessible for proteolytic 
cleavage in the folded protein. Despite their low score in pestfinder, two PEST-I motifs would 
be in close proximity to each other in a putative AID dimer, which might result in a stronger 
motif. Thus, we focused on the PEST-I and mutated D67 and D69 to alanines to destroy the 
PEST-I. 
D67/69A GFP-tagged mutant showed significantly increased half-life when compared 
to AID (Figure 4.4B-C). In addition, D67/69A was less responsive to GA suggesting that this 
mutant is more stable in the cytoplasm where AID stability highly depends on HSP90. 
Interestingly D67/69A mutation also increased AID half-life in the nucleus (Figure 4.4B right 
panel and 4.4C). Importantly, these differences in protein turnover could not be explained by 
any defect in subcellular localization that was equivalent for AID and D67/69A mutant in 
steady-state and after LMB treatment (Figure 4.4D). Our results suggest that the PEST-I is an 
intrinsic destabilizing motif for AID in the cytoplasm and in the nucleus. Using the E.coli 
mutation assay, the D67/69A mutant showed 60% catalytic activity compared to wild-type AID 
(Figure 4.4E). Despite this, disruption of the PEST-I led to a significant increase in CSR and 
SHM (Figure 4.4F-G). We conclude that a PEST-like motif influences AID stability in both the 
cytoplasm and in the nucleus as well as its function in antibody diversification. 
 
4.5.5. AID internal lysine residues are not required for its 
cytoplasmic polyubiquitination and degradation by the proteasome 
We have shown that cytoplasmic AID gets polyubiquinated and degraded by the 
proteasome after HSP90 inhibition (40). Others have described that nuclear AID is both 
polyubiquitinated but also targeted by an ubiquitin-independent pathway involving REGγ to the 
proteasome (39, 42). To verify whether internal AID lysine residues were required for its 
polyubiquitination and cytoplasmic degradation by the proteasome, we used a construct 
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previously described (39) in which all AID lysines were mutated to arginines (Kzero; Figure 
4.5A). AID-Kzero showed delayed degradation in the nucleus compared to AID (39), which we 
confirmed in our system using stably transfected Ramos cells treated with LMB (Figure 4.5B).  
Inversely, HSP90 inhibitor GA treatment led to a faster decay of the lysineless mutant than 
wild-type AID in our assay (Figure 4.5B). Furthermore, addition of proteasomal inhibitor 
MG132 blocked Kzero decay, confirming the requirement of the proteasome for AID Kzero 
degradation after HSP90 inhibition (Figure 4.5B). CHX treatment showed that internal lysines 
residues are structurally important for AID, since Kzero displayed a significant shorter half-life 
compared to wild-type AID (Figure 4.5C). However, only a small portion of AID or AID Kzero 
are polyubiquitinated in steady-state as observed by inhibiting the proteasome with MG132 
(Figure 4.5D). Strikingly, proteasome inhibitor combined with the HSP90 inhibitor GA led to a 
significant increase in the proportion of both AID and AID Kzero polyubiquitinated forms 
(Figure 4.5D). We therefore investigated the presence of alternative sites for AID 
polyubiquitination. Free α-NH2 terminus can serve as the conjugation site for ubiquitin by a 
poorly understood mechanism and addition of N-terminal tags has been shown to stabilize 
proteins which are N-terminally ubiquitinated including the AID paralog APOBEC3G (84-87). 
To verify whether AID α-NH2 terminus is implicated in its protein turnover in the cytoplasm, 
we added an HA tag to AID Kzero N-terminus. As shown previously, N-terminal tagging of 
AID prevents its nuclear import which explains why HA-Kzero-GFP levels were not affected 
by LMB treatment (Figure 4.5E) (38). However, HA-Kzero-GFP was still responsive to GA 
(Figure 4.5E). We therefore conclude that cytoplasmic AID degradation could occur through 
the polyubiquitination of non-lysine residues. 
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Figure 4.5. AID lysine residues are dispensable for its polyubiquitination and degradation 
after HSP90 inhibition. (A) Schematic representation of AID and the positions of its eight 
lysine residues. All lysines were mutated to arginines in the GFP-tagged Kzero construct. Data 
from (39). (B) GFP-tagged AID and its lysineless mutant (Kzero) were stably expressed in 
Ramos cells and GFP MFI was monitored after treatment with 50 ng/ml leptomycin B (LMB), 
2µM geldanamycin (GA), 10 µM MG132 or DMSO control (Ctrl) and normalized to t0 = 
100%. One of two independent experiments is shown. Average MFI ± SD of duplicates is 
plotted over time (*, p<0.05, paired two-tailed t-test). (C) Stable transfected Ramos cells were 
treated with 100 ng/ml cycloheximide (CHX; upper panel) alone or before HSP90 inhibition 
(lower panel) and GFP-tagged protein levels were followed as in (B). One of two independent 
experiments is shown. Average MFI ± SD of duplicates is plotted over time (*, p<0.05, paired 
two-tailed t-test). (D) GFP-tagged AID and its lysineless mutant Kzero were immunoprecipated 
using anti-GFP from extracts of stably expressing Ramos cells treated with 2µM Geldanamycin 
(GA) and/or 10 µM MG132 as indicated and analyzed by western blot to detect ubiquitinated 
forms of AID. Anti-GFP western blot confirmed similar immunoprecipitation levels of the bait. 
(E) A N-terminal HA tag was added to AID lysineless mutant (HA-Kzero), stably expressed in 
Ramos cells and analyzed as in (B).  (*, p<0.05, paired two-tailed t-test). 
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4.6. Discussion 
There is ample evidence correlating AID localization and its stability (38-40, 88). 
Because of this interdependence, it has been difficult to test the contribution of each one to 
regulate AID and antibody diversification. We identify here mutations that stabilize AID by 
increasing its half-life without impacting its subcellular localization. These mutations serve to 
define instrinsic destabilizing regions or motifs in AID. But more importantly, they allow to 
experimentally proving that the stability of AID in the cytoplasm and in the nucleus is limiting 
for antibody diversification. 
 
4.6.1. Instrinsic unstructured regions in AID  
Our results show that, while AID and the APOBECs show apparently similar stability, 
AID depends on the HSP90 molecular chaperoning pathway whereas the APOBECs do not. 
We hypothesize that one of the reasons for this difference could be their different content of 
unstructured regions. This is speculative in the absence of an AID three-dimensional structure 
but many HSP90 clients are considered to be instrinsically unstructured proteins such as the 
neuronal -synuclein (73, 74), the microtubule stabilizing tau protein (71, 72), the cyclin-
dependent kinase inhibitor p21(WAF1/CIP1) (75, 89) and the steroid hormone receptors (90-93). 
Unstructured regions confer useful properties to these proteins such as rapid and specific 
interaction potential without excessive binding strength at the cost of some instability, 
versatility in the nature of its partners and susceptibility to post-translational regulation (94). 
Indeed, AID interacts with multiple partners including DNA replication factor A (RPA) (95), 
chromatin-associated and transcription factors (KAP1/HP1, RNA pol II, SPT5/SPT6, RNA 
exosome) (96-100), RNA processing proteins (CTNNLB1, GANP, PTBP2) (101-103) and 
subcellular localization mediators (importin-α, CRM1, eEF1α) (38, 88). AID is also post-
translationally modified by PKA/PKC and PP2A (104-106). Association to these factors is 
either through the N-terminal or the C-terminal region of AID when it has been mapped, which 
are the regions predicted to be unstructured (Figure 4.2D and Table 4.1). A recent study 
suggests that intrinsically unstructured proteins require the chaperones for assistance in the 
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association to other proteins, rather than for folding (107). The fact that AID is present in 
different pools in the cytoplasm and the nucleus as revealed recently (88, 96), indicates that 
HSP90 stabilization could be a transitory state before moving on to another complex (i.e 
cytoplasmic retention or nuclear import complex), preventing AID from aggregating and/or 
being targeted to the ubiquitin-proteasome system due to exposed degradation motifs.    
 
4.6.2. Nature of these intrinsic determinants and their impact on 
AID stability  
In an attempt to identify the domains implicated in AID intrinsic instability, we show 
that changing the amino acid in position two of AID affects its protein stability as it would be 
predicted by the N-end rule. Although there is no direct evidence that the N-terminal 
methionine of AID is processed to reveal the destabilizing aspartic acid, this is quite a common 
N-terminal modification that can affect between 55 and 70% of the proteins depending on the 
organism and the subcellular compartment (108). Of note, others have reported a methionine 
aminopeptidase (methionine aminopeptidase 1, MetAP1) copurifying with AID (101). We 
show that replacing AID aspartic acid at position two for a more stabilizing residue (alanine) 
delays its turnover and results in higher steady-state levels. This mutation also reduces its 
catalytic activity by 25% and proportionally its ability to perform antibody diversification. 
Other stabilizing residues have been described including proline, serine, threonine, glycine and 
valine. Mutating aspartic acid to a serine may be an alternative to conserve the charged 
environment at the N-terminus of AID and should be tested to confirm the implication of the N-
end rule pathway in AID turnover. The introduction of a more destabilizing amino acid at the 
second position of AID leads to increased destabilization and reduced antibody diversification 
confirming the importance of this position for AID stability. Furthermore, it suggests a direct 
contribution of AID stability for its biological function.   
Our results show that disrupting a PEST-like motif in AID N-terminal region stabilizes 
AID both in the cytoplasm and in the nucleus. These regions enriched in proline, 
aspartic/glutamic acid, serine and threonine, are generally flanked by positive residues and have 
been predicted to be solvent-exposed regions more susceptible to proteolysis (62). In fact, 
177 
 
 
 
PEST motifs are abundant in intrinsically unstructured proteins (82, 83). Whether the PEST-I is 
an actual PEST domain or not is secondary. The identification of an additional destabilizing 
motif suggests that AID intrinsic instability results from the combination of at least two 
degradation motifs. Indeed, there is no direct correlation between the presence of any specific 
degradation signal and the in vivo half-lives of proteins (53). It is rather the combination of 
multiple factors including protein disorder and degrons that would influence the rate of a 
protein turnover (53). Our data show that a PEST-like motif by destabilizing AID influences its 
function in antibody diversification. Controlling AID protein turnover through the presence of 
destabilizing motifs could be an additional post-translation regulation to limit its biological 
function.   
 
4.6.3. AID degradation in the cytoplasm 
The turnover of most of the proteins is mediated by the ubiquitin-proteasome pathway. 
In agreement with this, we showed previously that cytoplasmic AID gets polyubiquitinated and 
degraded by the proteasome after HSP90 inhibition (40). Surprisingly, we report here that AID 
polyubiquitination is independent of its lysine residues, which are usually the typical acceptor 
of ubiquitin moieties. Lysineless ubiquitination has been reported for a small group of proteins 
including p21 (WAF1/CIP1)(86, 109), p14/19ARF (84), ERK3 (86), Id1 and Id2 (110, 111), MyoD 
(87) as well as APOBEC3G (112, 113). Instead, these proteins are polyubiquitinated at their α-
NH2 group. Addition of an N-terminal tag prevented their stabilization by an unclear 
mechanism. The high sequence and structure similarities among AID/APOBEC members 
would predict that they use similar pathway of degradation. However, attachment of an HA tag 
at AID N-terminus has no impact on its stability after HSP90 inhibition, suggesting an 
alternative way for targeting AID to the proteasome. Several viral proteins including the HIV-1 
Vpu protein and the KSHV K3 and K5 proteins utilize non-canonical ubiquitin acceptors 
(serine and threonine) to target cellular proteins for proteasomal degradation (114-118). AID 
could therefore be polyubiquitinated on serine and threonine residues. However, we cannot 
exclude that the absence of available lysines in the Kzero mutant forces the ubiquitin-
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proteasome pathway to use noncanonical residues for AID degradation. It is also possible that 
AID degradation is mediated by an ubiquitin-independent proteasomal pathway. Indeed, 
nuclear AID is actively destabilized by the ubiquitin-independent REGγ-proteasome pathway 
(42).  
In conclusion, our data suggest a direct contribution of destabilizing motifs in AID 
protein turnover and antibody diversification. They are consistent with a model in which AID 
presents unstructured regions requiring the assistance of the HSP90 molecular chaperoning 
pathway to prevent its aggregation. Therefore, limiting AID protein levels through the presence 
of destabilizing motifs is an additional way to regulate antibody diversification. 
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This thesis described the identification of new cytoplasmic partners and determinants of 
AID that modulate/affect its stability and contribute in regulating antibody diversification. We 
have found that cytoplasmic AID is stabilized by the HSP90 molecular chaperoning pathway, 
which we have described in much detail (Chapters 2 and 3). This regulatory pathway is 
important to set up the necessary AID levels for efficient antibody diversification, while 
limiting AID oncogenic potential. We were also able to initiate a study which points toward 
intrinsic destabilizing determinants in AID protein sequence that could explain the need for 
chaperoning, and toward a direct contribution of AID stability to antibody diversification 
(Chapter 4).    
 
5.1. AID association with the HSP90 molecular chaperoning 
pathway 
During the course of this thesis, Aoufouchi et al. described that AID is much more 
stable in the cytoplasm than in the nucleus [522], but the molecular explanation for this 
differential stability was unknown. We identified and functionally characterized AID as a novel 
HSP90 client [523] and we showed that AID interacts with several factors that are part of the 
HSP90 molecular chaperoning pathway, in particular the HSP40 DnaJa1, HSC70 and HSP90 
[523, 524]. AID requirement for these chaperones is evolutionary conserved, as HSP90 
inhibition or modulation of DnaJa1 levels affected both endogenous AID levels and AID-
mediated antibody diversification in chicken, mouse and human B cells [523, 524]. 
Intriguingly, none of AID paralog APOBECs, which share high sequence and structure 
similarities, were able to bind to any of these chaperones [523, 524]. APOBEC1 was reported 
to associate with a type II HSP40/DnaJ protein, DnaJb11, and downregulation of DnaJb11 
inhibited APOBEC1-mediated ApoB mRNA editing [525]. This observation was surprising at 
first since DnaJb11 is an endoplasmic reticulum (ER)-resident protein [526] while APOBEC1 
is a nucleo-cytoplasmic shuttling protein [157, 314, 527]. In fact, a truncated form of DnaJb11 
lacking its ER localization signal was used and therefore it is likely that the observated 
interaction is not physiologically relevant. However, convincing evidence showed that 
zebrafish APOBEC2 interacts with the chaperone UNC45B but not with HSP90-α [149]. 
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Disruption of unc45b in zebrafish showed the same dystrophic phenotype as downregulation of 
APOBEC2 [149]. UNC45B interacts with HSP90 [528], but our data showed that, unlike AID, 
APOBEC proteins do not depend on the HSP90 pathway for their stabilization (Chapter 4). It 
remains unclear whether any other chaperones are involved in the stabilization of APOBEC 
proteins. 
Since HSP90 stabilizes nearly-folded proteins rather than participating in protein 
biogenesis, the AID-HSP90 association could be due to the presence of intrinsically 
unstructured domains that make AID partially unfolded unless stabilized by an interacting 
partner. Indeed, early reports suggested that recombinant AID purification is quite challenging 
and only yields a low amount of active/soluble protein (~5%), with the rest being found in 
complexes that are inactive [187, 190]. In the absence of an AID crystal structure, we can only 
speculate about the position and the extent of these partially unfolded regions. The presence of 
unstructured domains in AID would fit with the fact that several intrinsically unstructured 
proteins such as α-synuclein [529, 530], tau [531, 532], p21(WAF1/CIP1) [533, 534], and the steroid 
hormone receptors [535-538], also require HSP90 assistance for their stabilization. But the 
absence of any canonical sequence or structural motif that dictate HSP90 association to its 
clients makes it difficult to identify domain(s) controlling AID-HSP90 interaction [375]. We 
mapped this interaction to AID N-terminal region spanning residues 19 to 84 [523]. This region 
contains 2-3 putative unstructured domains as predicted by two different algorithms, 
DisEMBLTM and PONDR® (Chapter 4). Together, these domains could confer to AID a 
partially unfolded face and require its binding to HSP90. Indeed, several lines of evidence 
suggest that recognition of HSP90 clients is related to their conformation and stability [375]. 
This is exemplified by the cellular and viral forms of the SRC tyrosine kinase (c- and v-SRC), 
which share high sequence similarities (~95%) but depend differently on HSP90. V-SRC is 
intrinsically unstable and associates strongly to HSP90, while c-SRC is more resistant to 
denaturating conditions in vitro and only transiently associates with this molecular chaperone 
[376-378]. Similarly, the differential dependence of AID/APOBEC on the HSP90 pathway may 
be related to their different contents in unstructured regions. Although this is a hypothesis, it is 
suggestive that replacing these regions with the homologuous APOBEC2 regions or mutating 
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them to disrupt the PEST-like motif result in less responsiveness to HSP90 inhibitors (Chapter 
4 and data not shown). Altogether, we showed that AID requires the assistance of the HSP90 
molecular chaperoning pathway. We suspect this process to be determined by AID intrinsic 
instability conferred by unstructured regions containing destabilizing motifs such as a PEST-
like motif. 
 
5.2. The role of the HSP90 pathway in AID stability and its 
interdependence with subcellular localization 
Our studies provide mechanistic insight into the link between AID subcellular 
localization and stability. Indeed, the HSP90 molecular chaperoning pathway stabilizes 
cytoplasmic AID and determines the overall AID steady-state levels [523], thus at least 
partially explaining why cytoplasmic AID is much more stable than its nuclear counterpart. 
HSP90 protects cytoplasmic AID from degradation since HSP90 inhibition resulted in the 
polyubiquitination and the proteasomal degradation of AID in the cytoplasm (Figure 5.1). This 
recapitulates the major function of HSP90 as a modulator of the stability and the functional 
maturation of its clients [375, 409, 539], such as the steroid hormone receptors [540, 541]. 
 In general, HSP90 client stabilization is initiated by the interaction with the HSP40 and 
HSP70 system [524, 540, 541] (Figure 5.1), but only a subset of HSP40-HSP70 substrates is 
delivered to HSP90 for stabilization [541, 542]. Different HSP40 proteins can have a redundant 
role in this initial substrate recognition and association with HSP70. Indeed, several HSP40s 
(f.i. DnaJa1 and –b1 for the progesterone receptor [416] , DnaJa1 and -a2 for the potassium 
channel protein HERG [420]) can bind to the same substrate in vitro [416, 421, 423, 543, 544], 
as we found to be the case for AID [524]. Nonetheless, AID specifically depends on DnaJa1 for 
its stabilization since its deficiency results in reduced endogenous AID levels and decreased 
AID half-life, accompanied by reduced biological activity [524]. The requirement of DnaJa1 
farnesylation for binding and biological activity of AID supports a non-redundant role for this 
co-chaperone in linking AID to the HSP90 pathway. This is based on a previous report showing 
that the farnesylation of DnaJa1 ortholog YDJ1 is required for its interaction with HSP90 
clients in vitro [400] and in vivo in yeast [401]. To our knowledge, AID is the first endogenous 
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HSP90 client in higher eukaryotes for which a specific HSP40 has been identified to be 
involved in its stabilization in vivo. The only other known example for an endogenous protein 
is the mitogen-activated kinase kinase kinase (MAPKKK) STE11 in yeast [400], but in this 
case the diversity of HSP40/DnaJ proteins is limited as yeast only expresses one type I- and one 
type II- cytosolic DnaJ proteins [545, 546]. 
It remains unclear whether additional HSP40 proteins are implicated in AID 
stabilization, since DNAJA1-/- mice can make up to 50% of normal AID protein levels. The 
first candidate for this DnaJa1-independent pathway would be DnaJa2, given its high similarity 
with DnaJa1 (~95%), but our data exclude this possibility [524]. In yeast, the type II HSP40 
SIS1 protein can partially substitute for the DnaJa1 ortholog YDJ1 [394, 544], which suggests 
that DnaJb1 could potentially contribute to AID stabilization in the absence of DnaJa1. 
Partially folded AID could also skip the stabilization by HSP90 altogether and become stable in 
complex with others factors such as eEF1α [325] or importins [315] (Figure 5.2). The nature of 
this DnaJa1-independent pathway for AID stabilization remains unclear and requires further 
investigations but it is clearly much less efficient than the DnaJa1-dependent pathway. 
 In any case, the cytoplasmic stabilization by the DnaJa1–HSP90 pathway is critical for 
producing the physiological maximal levels of AID. Overexpression experiments suggest that 
DnaJa1 is the limiting factor in AID stabilization [524], in line with previous studies showing 
that HSP40 co-chaperones, especially DnaJa1, are limiting components in the HSP90 molecular 
chaperoning pathway in E. coli, yeast, but also in mammalian systems [390, 412-415]. DnaJa1 
overexpression increases both AID protein levels and AID biological activity in B cell lines 
[524]. Interestingly, mice in which higher levels of AID were achieved by either 
overexpression AID through a transgene [199-202] or removing the negative post-
transcriptional regulation of AID by miR-155 [203, 204] all showed increased CSR and SHM 
in vitro but did not display increased levels of switched serum Ig. In particular, loss of AID  
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Figure 5.1. AID stabilization by the DnaJa1-HSP90 pathway and drugs that can inhibit it. 
Detailed schematic representation with each step participating in the stabilization of AID. AID 
is synthesized in the cytoplasm where unfolded AID is met by the HSP40-HSC70 system; the 
specific action of DnaJa1 allows transferring AID into the HSP90 molecular chaperoning 
stabilization cycle. AID stabilization can also occur through a DnaJa1-independent pathway, 
as DNAJA1-/- B cells still display up to 50% of normal AID levels. HSP90 inhibitors, such as 
geldanamycin (GA) and its derivative 17-AAG, prevent the ATP hydrolysis cycle of the 
chaperone. FTI, farnesyltransferase inhibitors, prevent farnesylation of DnaJa1, which is 
required for binding to and stabilization of AID. Both inhibitors lead to polyubiquitination and 
proteasomal degradation of cytoplasmic AID.  
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regulation by mi-R155 resulted in impaired affinity maturation in vivo [203]. It may be that the 
upper limit for AID physiological levels could be influenced by the increased apoptosis that 
elevated AID can bring about [547]. Thus, it is unlikely that DnaJa1 overexpression, which is 
predicted to increase steady-state AID levels in B cells, results in a more efficient antibody 
diversification. It may rather affect AID oncogenic potential as increased levels of AID in B cells 
have been reported to increase IgH-cMyc translocations [201, 204] and mutations in some non-Ig 
targets [201, 203, 257]. 
Our data also suggests that there is very little turnover of cytoplasmic AID, with 
stabilization being the default pathway. Indeed, inhibiting the proteasome does not produce 
much polyubiquitinated AID in B cells while simultaneous inhibition of HSP90 and the 
proteasome results in massive accumulation of polyubiquitinated AID [523]. Furthermore, 
downregulation of the HSP90-associated E3 ubiquitin ligase CHIP does not impact the overall 
steady-state AID levels in a mouse B cell line (data not shown), suggesting that only a very 
small proportion of cytoplasmic AID is targeted for degradation under normal steady-state 
conditions. Conversely, nuclear AID is much less stable and seems to be constantly targeted to 
the proteasome by Ub-dependent and –independent pathways [331, 333]. It remains unclear 
whether AID nuclear degradation results from the loss of stabilizing interactions and/or an 
active program of destabilization. HSP90 is mostly found in the cytoplasm, where it constitutes 
1-2% of the total protein levels [375]. Nuclear AID could therefore loose this stabilizing 
interaction and be exposed to rapid degradation after import. However, there is still some 
HSP90 in the nucleus in normal and cancer cells [548, 549] and some evidence suggests that 
HSP90 can translocate into the nucleus in response to stress or other stimuli [550-553]. Since 
HSP90 does not have a nuclear localization sequence, its nuclear import may only occur by co-
transport with its clients. Indeed, HSP90 can be co-imported with the glucocorticoid receptor 
(GR) into the nucleus [554-556]. But whether HSP90 is localized in the nucleus in the context 
of B cell stimulation and whether nuclear AID is at any stage associated with this chaperone is 
unknown.   
A common feature of nuclear and cytoplasmic AID is the fact that they do not depend 
on internal lysines for polyubiquitination. AID with all lysine residues mutated to arginines 
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(Kzero) is still significantly polyubiquitinated in both the cytoplasm and the nucleus ([331] and 
chapter 4), suggesting either a N-terminal ligation or a non-canonical ubiquitination site. Our 
data indicates that AID degradation through N-terminal ligation is unlikely to occur in the 
cytoplasm, but further work is required to definitively exclude this possibility. Due to AID’s 
intrinsic instability, it is possible that the absence of available lysines in the Kzero mutant 
forces the Ub-proteasome pathway to use noncanonical residues for AID degradation. This 
could also have some unknown physiological relevance. 
 
5.3. Direct impact of AID stability in antibody diversification 
Because of the interdependence between AID subcellular localization and stability [315, 
325, 329, 331, 332], it has been difficult to evaluate the direct contribution of AID protein 
turnover in regulating antibody diversification. Here we could show that modulating AID 
stability, without visibly affecting its subcellular localization, influences the efficiency of 
antibody diversification in vitro (Chapter 4). AID intrinsic instability seems to depend at least 
on an N-degron and an internal PEST-like motif. The N-end rule, which depends on the Ub-
proteasome pathway for protein turnover, requires N-terminal proteolytic processing of its 
substrates [500]. While N-terminal methionine cleavage is an evolutionary conserved 
modification, affecting up to 70 % of the proteins in plant plastids [503], we have no direct 
evidence that AID is processed in such a way to reveal the destabilizing aspartic acid at 
position two. Analysis of purified AID by mass spectrometry or N-end sequencing of purified 
endogenous protein could reveal whether AID is post-translationally cleaved at its N-terminus. 
Similarly, it remains unclear whether the AID internal destabilizing motif we described 
(Chapter 4) is an actual PEST motif. These regions enriched in proline, aspartic/glutamic acid, 
serine and threonine, are generally found in short-lived proteins [508-511]. Interestingly, it has 
been hypothesized that PEST motifs confer increased susceptibility to proteolysis by recruiting 
both the Ub-dependent and -independent proteasomal degradation pathway [512]. It is possible 
that the AID PEST-like motif is recognized by REG-γ in the nucleus, thus targeting AID for 
Ub-independent proteasomal degradation but this has not been confirmed. Indeed, AID-REGγ 
interaction requires the first 140 amino acids of AID that encompass the PEST-like motif [484]. 
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Whether modulating AID’s instrinsic stability may affect antibody diversification in vivo also 
requires more investigation. But it is now clear that destabilizing motifs in AID directly 
contribute to its biological functions by modulating AID protein turnover and limiting its 
presence in the nucleus. 
 
5.4. Cytoplasmic pools of AID 
Differential AID stability between the cytoplasm and the nucleus is an additional way 
of restricting its access to the nucleus. Indeed, inhibiting HSP90 or DnaJa1 farnesylation 
(which prevents binding to AID), as well as DNAJA1 knockdown, do not affect cytoplasmic 
retention of AID [523, 524]. Both nuclear destabilization and cytoplasmic retention contribute 
to AID nuclear exclusion [315, 484, 522]. Cytoplasmic retention may involve the participation 
of the eEF1α translation factor, since it is stoichiometrically associated with AID in the 
cytoplasm and mutating the proposed AID cytoplasmic retention motif can disrupt this 
interaction [315, 325]. This step would logically be after AID is stabilized by and released from 
HSP90. AID would therefore coexist in different cytoplasmic pools [557]. We could envision 
that these regulatory mechanisms form a circuit (f.i. release from HSP90 is always followed by 
AID associated to cytoplasmic retention, which precedes nuclear import, etc; Figure 5.2A). 
Preliminary immunofluorescence experiments suggest that AID stabilization by HSP90 is a 
prerequisite for its nuclear import [523]. It is also likely that the transmission of AID from the 
meta-stable complex with HSP90 may require some maturation step such as post-translational 
modifications or oligomerization [327, 332]. This would therefore allow mechanisms with 
apparently the same effect to play distinct roles.  
 Alternatively, unstructured regions may confer to AID useful properties such as rapid 
and specific interaction potential without excessive binding strength [558]. In fact, unstructured 
proteins require the assistance of chaperones for interacting with other co-factors [559]. HSP90 
stabilization could therefore be a transitory state, where AID is subsequently transferred to 
several competing destinations (f.i. release from HSP90 could be followed by cytoplasmic 
retention or nuclear import or degradation; Figure 5.2B). This network model would prevent 
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AID from aggregating/or being targeted to the Ub-proteasome system while having the 
flexibility to bind multiple alternative partners. Of course, AID regulation may be a mixture of 
both models. Nevertheless, it remains unclear what dictates AID dissociation from HSP90 and 
what is the relative distribution of AID between the HSP90 stabilizing pool and the cytoplasmic 
retention pool. But altogether these mechanisms greatly contribute in determining the 
appropriate steady-state and nuclear levels of AID during antibody diversification. 
 
5.5. Pharmacological modulation of AID levels. 
Modulating AID stability seems to be one way of controlling AID expression levels 
and, thereby an important mechanism regulating antibody diversification. On the one hand, 
AID stabilization by the DnaJa1-HSP90 chaperoning pathway is important to obtain 
sufficiently high AID protein levels for efficient antibody diversification. On the other hand, 
AID pathological outcomes are restricted by both DnaJa1 levels and nuclear destabilization of 
AID, which limit the functional levels of this mutagenic enzyme. In fact, AID is oncogenic, 
which is likely a consequence of its capacity to mutate and generate DNA breaks, thus 
initiating chromosomal translocations and mutations in tumor suppressor genes and proto-
oncogenes [261-265]. Oncogenic AID lesions are directly correlated to AID protein levels as 
increased expression of AID in B cells leads to a large increase in IgH-cMyc translocations 
[201, 204] and increased mutations in some non-Ig targets [201, 203, 257]. Ectopic expression 
of AID in Ph+ CML promotes the progression into a fatal B lymphoid blast crisis as AID activity 
leads to the acquisition of mutations in BCR-ABL1 and the development of resistance to the 
therapeutic drug imatinib [129]. We have shown that HSP90 inhibitors such as geldanamycin 
derivates, which are already in clinical trials [444], could be exploited to indirectly target AID. 
Indeed, destabilization of AID with HSP90 inhibitors prevented AID-mediated mutations in 
BCR-ABL and the generation of resistance to imatinib in CML cells. Farnesyltransferase 
inhibitors, which prevent the binding of AID to DnaJa1, could also serve as a pharmacological 
tool to decrease 
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Figure 5.2.  Major post-translational regulation steps affecting AID levels. (A) Detailed 
schematic representation with each step participating in the stability and the subcellular 
localization regulation represented within a cycle. Only selected AID interacting factors are 
shown. After AID stabilization by the HSP90 molecular chaperoning pathway, some undefined 
maturation step or conformational change can allow AID to pass onto eEF1α and/or other 
cytoplasmic retention factors before active nuclear import. A number of factors could be 
implicated, alternatively or jointly, in AID nuclear import. Once inside the nucleus, AID is 
either exported by CRM1 or targeted to the Ig loci by interacting with a number of RNA 
processing factor, where it is phosphorylated by PKA. AID is (subsequently?) degraded in the 
nucleus either through Ub- or REGγ-dependent proteasomal degradation. (B) Simplified 
schematic representation of the same steps as in A but in the form of a network in which most 
pools of AID are interconnected. 
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AID protein levels. Whether increased expression of limiting factors of the HSP90 pathway, 
especially DnaJa1, could favour the development of AID-associated lymphomas/leukemias is 
unknown. Increased expression of members of the HSP90 pathway has been reported in solid 
tumors and haematological malignancies [408, 409], but little is known about DnaJa1 
expression profiles between healthy subjects and lymphoma/leukemia-affected patients. We 
also know very little about whether DnaJa1 levels correlate with AID levels in B cells and other 
relevant cell types/tissues.  
AID is also implicated in the onset of autoimmune diseases [242, 285-287] and could 
be an interesting target to treat pathologies such as rheumatoid arthristis and systemic lupus 
erythematosus, which are associated with exacerbated antibody diversification. Interestingly, 
several reports have shown a differential expression of DNAJA1 between healthy controls and 
patients affected with autoimmune diseases. DNAJA1 is overexpressed in synovial tissues of 
patients affected by rheumatoid arthritis [560]. Furthermore, differential expression of DNAJA1 
in peripheral blood of systemic lupus erythematosus patients has been reported and two single 
nucleotide polymorphisms in DNAJA1 are associated with the onset and the progression of this 
autoimmune disease [561, 562]. Mouse models recapitulating lupus and rheumatoid arthritis 
display increased levels of AID, which correlate with higher levels of autoantibodies [242, 285-
287]. Moreover, AID deficiency, or even haploinsufficiency, results in a more moderate disease 
[195, 242-244]. The challenge here, similar to AID involvement in cancer development, is to 
identify a disease and a mouse model where AID implication and onset can be predicted in 
order to target AID at the right time. In the absence of specific inhibitors of AID, exploiting 
HSP90 and farnesyltransferase inhibitors as described in this thesis (Chapter 2 and 3) proved to 
be a reasonable alternative to pharmacologically targeting AID. 
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CHAPTER 6: CONCLUSION 
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Our results show that AID is stabilized in the cytoplasm by the HSP90 molecular 
chaperoning pathway. This requires the participation of the HSP40 DnaJa1, which is a limiting 
step in AID stabilization. AID stability and protein levels directly modulate its biological 
functions. Increased AID stability, by introducing stabilizing mutations, or increased AID 
protein levels by overexpressing DnaJa1, result in a more efficient antibody diversification. 
Conversely, inhibiting HSP90 or farnesyltransferases as well as reducing DnaJa1 levels result 
in less antibody diversification and off-target mutations. 
We show this in particular for the BCR-ABL oncogene, in which HSP90 inhibitors 
prevent the emergence of an AID-dependent imatinib-resistant subpopulation of CML cells. 
Thus, pharmacological modulation of AID protein levels is an interesting possibility to treat 
AID-related cancers and/or pathologies associated with exacerbated antibody diversification. 
Mouse models, where AID has been directly implicated in the development of ALL or CML, 
are great tools to investigate whether this strategy could prevent or slow down the onset of 
these diseases. Preliminary work in patients affected by CML blast crisis suggested that the use 
of arsenic trioxide, a drug that downregulates AID mRNA and protein levels, combined to 
imatinib, could achieve better therapeutic effects by reducing drug resistance [563]. Similarly, 
disruption of Aicda in the mouse model of IBD reduces the incidence of colon cancer 
development [564], which could be another therapeutic opportunity. Downregulating AID 
protein levels could also minimize AID contribution to autoimmune diseases, as AID 
overexpression correlates with the production of autoantibodies and the onset of autoimmune 
diseases such as lupus and rheumatoid arthritis [242, 285-287]. Therefore, modulating AID 
levels, systematically or locally, could minimize its pathological contribution to both cancer 
and autoimmune diseases. Targeting the farnesylation of DnaJa1 by using farnesyltransferase 
inhibitors may reduce AID pathological outcomes as well and could serve as an alternative to 
HSP90 inhibitors. 
Our work raises the question of whether the HSP90 molecular chaperoning pathway 
could be a predisposing element in the development of AID-associated diseases. Since DnaJa1 
is a limiting factor in AID stabilization, one could hypothesize that upregulation of this co-
chaperones may result in higher steady-state AID levels, thus increasing the susceptibility to 
off-target mutations, chromosomal translocations, and antibody-associated autoimmune 
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diseases. It is also unclear whether AID is as dependent on HSP90 stabilization in normal 
versus transformed cells. Further experimental work is also needed to explore whether AID 
stabilization by the HSP90 molecular chaperoning pathway is as critical for its demethylation 
function as it is for antibody diversification.  
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